
<html lang="en"     class="pb-page"  data-request-id="5bd153a2-6f61-4685-977a-e806846a8ebd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-17;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c00500"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis" /></meta><meta name="dc.Creator" content="Hongyi  Zhao" /></meta><meta name="dc.Creator" content="Bin  Wang" /></meta><meta name="dc.Creator" content="Lei  Fu" /></meta><meta name="dc.Creator" content="Gang  Li" /></meta><meta name="dc.Creator" content="Haijia  Lu" /></meta><meta name="dc.Creator" content="Yuke  Liu" /></meta><meta name="dc.Creator" content="Li  Sheng" /></meta><meta name="dc.Creator" content="Yan  Li" /></meta><meta name="dc.Creator" content="Baoxi  Zhang" /></meta><meta name="dc.Creator" content="Yang  Lu" /></meta><meta name="dc.Creator" content="Chen  Ma" /></meta><meta name="dc.Creator" content="Haihong  Huang" /></meta><meta name="dc.Creator" content="Dongfeng  Zhang" /></meta><meta name="dc.Creator" content="Yu  Lu" /></meta><meta name="dc.Description" content="Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB. In this work, we..." /></meta><meta name="Description" content="Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB. In this work, we..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 15, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00500" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00500" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00500" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00500" /></link>
        
    
    

<title>Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00500" /></meta><meta property="og:title" content="Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0016.jpeg" /></meta><meta property="og:description" content="Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB. In this work, we discovered a conformationally constrained oxazolidinone 19c with improved anti-TB activity and safety profile through a focused lead optimization effort. Compound 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid. The druggability of compound 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P450 enzyme inhibition, and pharmacokinetics in animals. Compound 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity. In a 4 week repeated dose toxicology study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00500"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00500">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00500&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00500&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00500&amp;href=/doi/10.1021/acs.jmedchem.0c00500" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 9316-9339</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00451" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00522" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hongyi Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongyi Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongyi++Zhao">Hongyi Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing 101149, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Wang">Bin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Fu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Fu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing 101149, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Fu">Lei Fu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Li">Gang Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0924-7950" title="Orcid link">http://orcid.org/0000-0003-0924-7950</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haijia Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haijia Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haijia++Lu">Haijia Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuke Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuke Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuke++Liu">Yuke Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li Sheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Sheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Sheng">Li Sheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Li">Yan Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Baoxi Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Baoxi Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Baoxi++Zhang">Baoxi Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Lu">Yang Lu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2274-5703" title="Orcid link">http://orcid.org/0000-0002-2274-5703</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Polymorphic Drugs, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Ma">Chen Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haihong Huang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haihong Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#472d283e2422072e2a2a692624692429"><span class="__cf_email__" data-cfemail="cfa5a0b6acaa8fa6a2a2e1aeace1aca1">[email protected]</span></a>. Phone: +86-10-63165244.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haihong++Huang">Haihong Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongfeng Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongfeng Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#bdc7d9dbfdd4d0d093dcde93ded3"><span class="__cf_email__" data-cfemail="8df7e9ebcde4e0e0a3eceea3eee3">[email protected]</span></a>. Phone: +86-10-63165254.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongfeng++Zhang">Dongfeng Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0870-3782" title="Orcid link">http://orcid.org/0000-0003-0870-3782</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yu Lu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yu Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Department of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, 97 Ma Chang Street, Beijing 101149, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#036f767a76373b3435436b6c776e626a6f2d606c6e"><span class="__cf_email__" data-cfemail="e9859c909cddd1dedfa981869d84888085c78a8684">[email protected]</span></a>. Phone: +86-10-80505770.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Lu">Yu Lu</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00500&amp;href=/doi/10.1021%2Facs.jmedchem.0c00500" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 9316–9339</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 March 2020</li><li><span class="item_label"><b>Published</b> online</span>15 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00500" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00500</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9316%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHongyi%2BZhao%252C%2BBin%2BWang%252C%2BLei%2BFu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D17%26contentID%3Dacs.jmedchem.0c00500%26title%3DDiscovery%2Bof%2Ba%2BConformationally%2BConstrained%2BOxazolidinone%2Bwith%2BImproved%2BSafety%2Band%2BEfficacy%2BProfiles%2Bfor%2Bthe%2BTreatment%2Bof%2BMultidrug-Resistant%2BTuberculosis%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9339%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00500"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1390</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00500" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hongyi&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Fu&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Haijia&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Yuke&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Sheng&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Baoxi&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Haihong&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Dongfeng&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Lu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;9316-9339&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00500&quot;},&quot;abstract&quot;:&quot;Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB. In this work, we discovered a conformationally constrained oxazolidinone 19c with improved anti-TB activity and safety profile through a focused lead optimization effort. Compound 19c displayed superior in vivo efficacy in a mouse TB infection model compared to linezolid and sutezolid. The druggability of compound 19c was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P450 enzyme inhibition, and pharmacokinetics in animals. Compound 19c demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K+, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity. In a 4 week repeated dose toxicology study in rats, 19c appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00500&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00500" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00500&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00500" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00500&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00500" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00500&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00500&amp;href=/doi/10.1021/acs.jmedchem.0c00500" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00500" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00500" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00500%26sid%3Dliteratum%253Aachs%26pmid%3D32666789%26genre%3Darticle%26aulast%3DZhao%26date%3D2020%26atitle%3DDiscovery%2Bof%2Ba%2BConformationally%2BConstrained%2BOxazolidinone%2Bwith%2BImproved%2BSafety%2Band%2BEfficacy%2BProfiles%2Bfor%2Bthe%2BTreatment%2Bof%2BMultidrug-Resistant%2BTuberculosis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D17%26spage%3D9316%26epage%3D9339%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/jmcmar.2020.63.issue-17/20200910/jmcmar.2020.63.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Tuberculosis (TB) remains a serious public health challenge, and the research and development of new anti-TB drugs is an essential component of the global strategy to eradicate TB. In this work, we discovered a conformationally constrained oxazolidinone <b>19c</b> with improved anti-TB activity and safety profile through a focused lead optimization effort. Compound <b>19c</b> displayed superior <i>in vivo</i> efficacy in a mouse TB infection model compared to linezolid and sutezolid. The druggability of compound <b>19c</b> was demonstrated in a panel of assays including microsomal stability, cytotoxicity, cytochrome P450 enzyme inhibition, and pharmacokinetics in animals. Compound <b>19c</b> demonstrated an excellent safety profile in a battery of safety assays, including mitochondrial protein synthesis, hERG K<sup>+</sup>, hCav1.2, and Nav1.5 channels, monoamine oxidase, and genotoxicity. In a 4 week repeated dose toxicology study in rats, <b>19c</b> appeared to have less bone marrow suppression than linezolid, which has been a major liability of the oxazolidinone class.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tuberculosis (TB) is a major public health challenge, leading to about 1.2 million deaths in 2018. Multidrug-resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) have emerged rapidly and make the treatment and prevention of TB extremely difficult. Three countries with the largest share of the global MDR-TB burden were India (27%), China (14%), and the Russian Federation (9%).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> There is an urgent unmet medical need to develop new therapies with a novel mechanism of action for the treatment of MDR- and XDR-TB.</div><div class="NLM_p">Oxazolidinones are a relatively new class of antibacterial agents originally developed for the treatment of Gram-positive bacterial infections. This class of compounds inhibits bacterial protein synthesis by binding competitively to the 23S rRNA in the catalytic site of the bacterial 50S ribosomes.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Certain members of the oxazolidinone class have shown activity against <i>Mycobacterium tuberculosis</i> and are currently under clinical development for the treatment of MDR- and XDR-TB (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Linezolid (<b>1</b>) is the first oxazolidinone approved for commercialization (2000), and this compound has exhibited bacteriostatic activity against <i>M. tuberculosis</i> with a minimum inhibitory concentration (MIC) of about 1 μg/mL.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Linezolid is a key component of the Nix-TB regimen (bedaquiline, pretomanid, and linezolid) approved by the Food and Drug Administration in 2019 for the treatment of XDR-TB or treatment-intolerant/nonresponsive MDR-TB.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Sutezolid (<b>2</b>), originally discovered by Upjohn Company,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> is in phase II studies for TB. Sutezolid differs from linezolid by having a thiomorpholine substituent and has displayed a better anti-TB activity and improved safety profile compared to linezolid.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> In addition, delpazolid (<b>3</b>)<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and TBI-223 (<b>4</b>)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> are also under clinical development for the treatment of TB. The development of AZD5847 (<b>5</b>) by AstraZeneca for the treatment of Gram-positive infections and TB has been discontinued.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> The long duration required for the treatment of TB with linezolid has been associated with severe side effects such as anemia, thrombocytopenia, and optic and peripheral neuropathy. The toxicity of the oxazolidinone class is thought to be mediated by the inhibition of mitochondrial protein synthesis (MPS) and monoamine oxidase (MAO).<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> Therefore, discovery of new oxazolidinones with an improved safety and efficacy profile is extremely important for the treatment of TB.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of oxazolidinones as anti-TB agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A series of conformationally constrained tricyclic benzoxazinyl-oxazolidinones have been reported to have an excellent pharmacokinetic (PK) profile and potent antibacterial activity against Gram-positive bacteria.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> These reports promoted us to take this novel series as a lead to optimize for anti-TB activity. In our previous work, we have identified a novel series of conformationally constrained oxazolidinones, as exemplified by compound <b>6</b>, for the treatment of MDR-TB.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> These compounds contain a common 3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one core and exhibited an improved PK profile compared to linezolid. However, the <i>in vitro</i> anti-TB activity and MPS inhibitory activity of <b>6</b> were similar to those of linezolid (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In order to identify an oxazolidinone with improved anti-TB activity, reduced toxicity, and improved drug-like properties, we undertook a focused lead optimization effort based on the 3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one scaffold (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The stereochemistry of the core structure was first investigated, which indicated that the 3<i>S</i>,3<i>aS</i> configuration was optimal for anti-TB activity. Further optimization was centered around the (3<i>S</i>,3<i>aS</i>)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one core and focused on the variation of the R<sup>1</sup> group on the phenyl ring and the R<sup>2</sup> group on the oxazolidinone ring. Morpholine, 2-oxa-6-azaspiro[3.3]heptane, 4,4-difluoro-piperidine, and thiomorpholine were introduced to R<sup>1</sup> position. In addition, the known sulfoxide and sulfone metabolites of thiomorpholine were also prepared. To increase the metabolic stability of the thiomorpholine group, a bridge thiomorpholine was also prepared with the goal to increase steric hindrance. At the R<sup>2</sup> position, various substituents, including amides, heterocycles, carbamates, and sulfonamides, were introduced. Compound <b>19c</b> was identified through this effort as a promising development candidate for the treatment of MDR-/XDR-TB.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lead optimization strategy of 3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, the key epoxides <b>9a–d</b> were synthesized from but-2-ene-1,4-diol (<b>7a</b> and <b>7b</b>). <b>7a</b> was reacted with trityl chloride (TrCl) in the presence of triethylamine and 4-dimethylaminopyridine (DMAP) to afford compound <b>8a</b>. (<i>E</i>)-But-2-ene-1,4-diol (<b>7b</b>) reacted with TrCl in the presence of 2,4,6-collidine and tetrabutylammonium iodide (TBAI) to yield compound <b>8b</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compounds <b>8a</b> and <b>8b</b> were converted to the racemic epoxides <b>9a</b> and <b>9b</b> via oxidation reaction using 3-chloroperoxybenzoic acid (<i>m</i>-CPBA). A sharpless asymmetric epoxidation reaction was carried out to convert <b>8a</b> into epoxides <b>9c</b> and <b>9d</b>, respectively.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Nucleophilic substitution of <b>10a</b> and <b>10b</b> with different amines afforded compounds <b>11a–f</b>, followed by reduction of the nitro group using catalytic hydrogenation or zinc/acetic acid, and then, the aniline product was protected with benzyl chloroformate (CbzCl) to afford compounds <b>12a–f</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>9a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TrCl, Et<sub>3</sub>N, DMAP, DCM, 0 °C-rt for <b>8a</b>; TrCl, 2,4,6-collidine, TBAI, DCM, 0 °C-rt, for <b>8b</b>; (ii) <i>m</i>-CPBA, DCM, 30 °C; and (iii) TBHP, Ti(OiPr)<sub>4</sub>, 4 Å MS, DCM, −40 to −20 °C, <span class="smallcaps smallerCapital"><i>d</i></span>-(−)-DET for <b>9c</b>, <span class="smallcaps smallerCapital"><i>l</i></span>-(+)-DET for <b>9d</b>.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>12a–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine, <i>N</i>-methylmorpholine (NMM), MeCN, 80 °C; (ii) H<sub>2</sub>, Raney Ni, THF, 20–50 psi, rt for <b>12a</b>, <b>12c–e</b>; Zn, AcOH, THF, 30–40 °C for <b>12b</b> and <b>12f</b>; and (iii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O, 0 °C.</p></p></figure><div class="NLM_p">The synthesis of intermediates <b>15a–i</b> is depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Compound <b>12a</b> reacted with epoxides <b>9a–d</b> via Mitsunobu reaction to furnish compounds <b>13a–d</b>, respectively. Subsequently, treatment of compounds <b>13a–d</b> with <i>t</i>-BuOLi or <i>n</i>-BuLi afforded the key tricyclic intermediates <b>14a–d</b>. Cleavage of the trityl protective group yielded products <b>15a–d</b>. Compounds <b>12b–f</b> reacted with epoxide <b>9c</b> via Mitsunobu reaction to furnish compounds <b>13e–i</b>; subsequently, compounds <b>15e–i</b> were obtained via cyclization and deprotection.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ADDP, PPh<sub>3</sub>, THF or DCM, 0 °C-rt; (ii) <i>t</i>-BuOLi, THF, rt for <b>14a</b>, <b>14b</b> and <b>14d</b>; <i>n</i>-BuLi, THF, −78 °C-rt for <b>14c</b> and <b>14e–i</b>; and (iii) TFA, DCM, rt for <b>15a–f</b> and <b>15h</b>; TsOH·H<sub>2</sub>O, DCM, MeOH, rt for <b>15g</b> and <b>15i</b>.</p></p></figure><div class="NLM_p">The synthetic route of the target compounds <b>19a–l</b> is illustrated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Compounds <b>15a–d</b> reacted with 4-methylbenzenesulfonyl chloride to obtain compounds <b>16a–d</b>. Nucleophilic substitution of <b>16a–d</b> with potassium phthalimide afforded compounds <b>17a–d,</b> which reacted with methylamine in MeOH to yield <b>18a–d</b>. Finally, the target compounds <b>19a–d</b> were prepared from <b>18a–d</b> by acetylation. Compound <b>19e</b> was prepared by reaction of intermediate <b>15c</b> with acetyl chloride and Et<sub>3</sub>N in dichloromethane (DCM). The target compounds <b>19f–i</b> were synthesized by amidation of <b>18c</b> with different acyl chlorides. Compound <b>18c</b> was reacted with isonicotinic acid, pyrazine-2-carboxylic acid, and MeOH in the presence of 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride (EDCI)/1-hydroxybenzotriazole (HOBt) and 1,1′-carbonyldiimidazole (CDI) to afford the final products <b>19j–l</b>, respectively.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>19a–l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, Et<sub>3</sub>N, DMAP, DCM, 0 °C-rt; (ii) potassium phthalimide, DMF, 80 °C; (iii) MeNH<sub>2</sub>, MeOH, reflux; (iv) acetic anhydride, pyridine, DCM, 0 °C-rt; (v) acetyl chloride, Et<sub>3</sub>N, DCM, 0 °C-rt; and (vi) methylsulfonyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>19f</b>; acyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>19g–i</b>; isonicotinic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>19j</b>; pyrazine-2-carboxylic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>19k</b>; CDI, THF, rt, then MeOH, THF, rt for <b>19l</b>.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> displayed the synthesis of the target compounds <b>19m–o</b>. Intermediate <b>16c</b> was reacted with MeNH<sub>2</sub> in a sealed tube to furnish compound <b>19m</b>. Compound <b>19n</b> was obtained from the reaction of <b>16c</b> with <i>tert</i>-butyl isoxazol-3-yl-carbamate<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> in the presence of NaH, followed by removing the amino-protective group using HCl in ethyl acetate (EtOAc). Nucleophilic substitution of <b>16c</b> with sodium azide at 80 °C in <i>N</i>,<i>N</i>-dimethylforamide (DMF), followed by cycloaddition reaction with bicyclo[2.2.1]hepta-2,5-diene,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> gave compound <b>19o</b>.</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>19m–o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeNH<sub>2</sub>, MeOH, THF, sealed tube, 100 °C; (ii) <i>N</i>-Boc-3-aminoisoxazole, NaH, DMF, 0–70 °C; (iii) HCl, EtOAc rt then H<sub>2</sub>O, NaHCO<sub>3</sub>, rt; (iv) NaN<sub>3</sub>, DMF, 80 °C; and (v) bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><div class="NLM_p">The synthesis of compounds <b>19p–s</b> is outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. <b>19c</b> could be readily acetylated and methylated to afford compounds <b>19p</b> and <b>19q</b>, employing acetic anhydride/DMAP and MeI/NaH, respectively. The corresponding sulfoxide <b>19r</b> was prepared by treating <b>19c</b> with NaIO<sub>4</sub>, and sulfone <b>19s</b> was prepared by treating <b>19r</b> with NaIO<sub>4</sub> at higher temperature.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19p–s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) acetic anhydride, DMAP, 100 °C; (ii) MeI, NaH, THF, reflux; (iii) NaIO<sub>4</sub>, MeOH, H<sub>2</sub>O, rt; and (iv) NaIO<sub>4</sub>, MeOH, H<sub>2</sub>O, 60 °C.</p></p></figure><div class="NLM_p">The synthetic procedure of compounds <b>19t</b>, <b>20a–g</b> (containing bridge thiomorpholine<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>), <b>21</b>, <b>22</b>, and <b>23a–d</b> is shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Compounds <b>15e–h</b> were reacted with 4-methylbenzenesulfonyl chloride to obtain compounds <b>16e–h</b>. Nucleophilic substitution of <b>16e–h</b> with ammonium hydroxide afforded compounds <b>18e–h</b>. Compounds <b>19t</b>, <b>20a</b>, <b>21</b>, and <b>22</b> were prepared from <b>18e–h</b> by acetylation, respectively. The desired products <b>20b–g</b> were synthesized by the same sequence of steps as compounds <b>19g–l</b>. The hydroxyl of <b>15i</b> was reacted with methylsulfonyl chloride to obtain compound <b>16i</b>. Next, substitution of the sulfonate group in the presence of sodium azide afforded compound <b>18i</b>, followed by hydrogenation to afford the amine intermediate, and then, compounds <b>23a–c</b> were synthesized via condensation. Compound <b>18i</b> underwent cycloaddition to give compound <b>23d</b>. The target compounds <b>20h</b> and <b>20i</b> were synthesized utilizing the synthetic route shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>19t</b>, <b>20a–g</b>, <b>21</b>, <b>22</b>, and <b>23a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, Et<sub>3</sub>N, DMAP, DCM, rt; (ii) ammonium hydroxide, THF, sealed tube, 100 °C; (iii) acetic anhydride, pyridine, DCM, 0 °C-rt for <b>19t</b>, <b>20a</b>, <b>21</b> and <b>22</b>; CDI, THF, rt, then MeOH, THF, rt for <b>20b</b>; acyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>20c–e</b>; isonicotinic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>20f</b>; pyrazine-2-carboxylic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>20g</b>; (iv) MsCl, NMM, DCM, rt; (v) NaN<sub>3</sub>, DMF, 70 °C; (vi) H<sub>2</sub>, Pd/C, THF; (vii) acetic anhydride, pyridine, THF, 0 °C-rt for <b>23a</b>; acyl chloride, Et<sub>3</sub>N, THF, 0 °C for <b>23b–c</b>; and (viii) bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>20h</b> and <b>20i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>N</i>-boc-3-aminoisoxazole, NaH, DMF, 0–70 °C then HCl, EtOAc rt then H<sub>2</sub>O, NaHCO<sub>3</sub>, rt and (ii) NaN<sub>3</sub>, DMF, 80 °C then bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><div class="NLM_p">The absolute configuration of <b>19c</b> was confirmed by X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The lattice parameters were <i>a</i> = 12.150, <i>b</i> = 26.738, and <i>c</i> = 23.805 Å, and the lattice volume was 7713.78 Å<sup>3</sup>. There were eight molecules in one lattice. The configurations of chiral centers are (3<i>S</i>,3<i>aS</i>).</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystallographic structure of compound <b>19c</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77205" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77205" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All final compounds were evaluated for their inhibitory activity against <i>M. tuberculosis</i> H37Rv in microplate alamar blue assay (MABA) and cytotoxicity against the Vero cell line. Selected compounds were also tested for their MPS inhibitory activity.</div><div class="NLM_p">First, the impact of the stereochemistry of the 3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one core on the activity was investigated. Linezolid and other oxazolidinones currently under clinical development possess only one chiral center, and the 5-<i>S</i> configuration is known to be important for antibacterial activity.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Because of two chiral centers existing in this novel benzoxazinyl-oxazolidinone scaffold, it is essential to explore the relationship between the configurations and anti-TB activity. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds containing the racemate <i>trans</i> configuration (<b>15a</b>, <b>18a</b>, and <b>19a</b>) appeared significantly more potent than those with the racemate <i>cis</i> configuration (<b>15b</b>, <b>18b</b>, and <b>19b</b>) against <i>M. tuberculosis</i> H37Rv. It is anticipated that the (3<i>S</i>,3<i>aS</i>) isomer <b>19c</b> with <i>trans</i> configuration appeared much more potent than its isomer <b>19d</b> with (3<i>R</i>,3<i>aR</i>) configuration. This result is consistent with our previous finding that the (3<i>S</i>,3<i>aS</i>) configuration is essential for activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Antitubercular Activity of 3<i>a</i>,4-Dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-ones Containing Thiomorpholine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0013.gif" alt="" id="gr13" /></img><div></div></div><div class="NLM_p">Subsequently, further optimization was centered around the (3<i>S</i>,3<i>aS</i>)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one core. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, analogues with various R<sup>1</sup> and R<sup>2</sup> substitutions were prepared and evaluated for their anti-TB activity, cytotoxicity, and MPS activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Anti-TB Activity, Cytotoxicity, and MPS Inhibition of Target Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0014.gif" alt="" id="GRAPHIC-d7e1493-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>M. tuberculosis</i> H37Rv.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Vero cell lines.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">MPS inhibition.</p></div></div><div></div></div><div class="NLM_p">Among various R<sup>1</sup> substitutions explored, the thiomorpholine-substituted compound <b>19c</b> appeared to display the best anti-TB activity with an MIC of 0.03 μg/mL against the <i>M. tuberculosis</i> H37Rv strain. Deletion of the fluorine on the phenyl ring of <b>19c</b> to give compound <b>19t</b> resulted in a 25-fold loss of activity, indicating the importance of fluorine substitution on the activity. Compounds with other substitutions <b>21</b>, <b>22</b>, and <b>23a</b> appeared less active with MICs of 0.89, 0.91, and 3.92 μg/mL, respectively. The 3-thia-8-azabicyclo[3.2.1]octane-substituted analogues <b>20a–i</b> were designed with the intention to minimize the metabolism of the thiomorpholine group. However, these compounds were much less active against <i>M. tuberculosis</i> H37Rv strain with MIC ranging from 0.92 to >32 μg/mL.</div><div class="NLM_p">S-oxidation of sulfur-containing therapeutics is a well-known metabolic transformation catalyzed by cytochrome P450s or by flavin monooxygenases.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> PKs and metabolism study of sutezolid had shown that it is well absorbed orally but with significant first pass metabolism to sulfoxide and to a lesser extent of the sulfone metabolite.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Therefore, the potential metabolites of <b>19c</b> were prepared and evaluated for anti-TB activity against the H37Rv strain. We found that the sulfoxide <b>19r</b> and sulfone <b>19s</b> of <b>19c</b> maintained good anti-TB activity with MIC values of 0.44 and 0.93 μg/mL, respectively, but less potent than <b>19c</b>.</div><div class="NLM_p">Further optimization of the R<sup>2</sup> group around the thiomorpholine-substituted compound <b>19c</b> provided series derivatives <b>18c</b> and <b>19e–19q</b> with a variety of substitutions at the R<sup>2</sup> position. When R<sup>2</sup> was amino, compound <b>18c</b> showed potent activity and low MPS inhibition consistent with <b>19c</b>. Several compounds, including cyclopropanecarboxamido <b>19h</b>, cyclobutanecarboxamido <b>19i</b>, methyl carbamate <b>19l</b>, and isoxazolamino <b>19n</b>, all exhibited potent anti-TB activity with MICs similar to <b>19c</b> and better than sutezolid. However, compound <b>19p</b> with the diacetylamine group at R<sup>2</sup> had 10-fold decrease in antibacterial activity than <b>19c</b>, and when R<sup>2</sup> was the methylacetylamine or ester group, the related compounds <b>19q</b> and <b>19e</b> had almost no activity.</div><div class="NLM_p">The majority compounds with a variety of R<sup>1</sup> and R<sup>2</sup> groups exhibited low cytotoxicity against the Vero cell line (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The 50% inhibitory concentrations (IC<sub>50</sub>) for most compounds were >64 μg/mL. Compounds in the (3<i>S</i>,3<i>aS</i>)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one series appeared to have less MPS inhibition compared to both linezolid and sutezolid. The MPS IC<sub>50</sub> values for compound <b>19c</b> and many of its analogues were >100 μg/mL, compared to 7.98 μg/mL for linezolid and 8.17 μg/mL for sutezolid. These series compounds appeared to have a major advantage in minimizing toxicity caused by inhibition of MPS.</div><div class="NLM_p">Selective compounds with potent anti-TB activities were further evaluated for <i>in vitro</i> metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>19c</b> showed similar metabolic stability against mouse liver microsomes compared with sutezolid. Compound <b>18c</b> with an amino group at the R<sup>2</sup> position was less stable. Compounds <b>19g–l</b>, and <b>19n–o</b>, with a different R<sup>2</sup> substituent such as aliphatic amide, aryl amide, or heterocycles all displayed lower stability than <b>19c</b>. However, compound <b>19r</b>, the sulfoxide metabolite of <b>19c</b>, exhibited excellent metabolic stability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Microsome Stability of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">MLM<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center" char=".">remaining %<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">stability<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="char" char=".">48.7</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18c</b></td><td class="colsep0 rowsep0" align="char" char=".">15.8</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19g</b></td><td class="colsep0 rowsep0" align="char" char=".">6.02</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19h</b></td><td class="colsep0 rowsep0" align="char" char=".">15.0</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19i</b></td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19j</b></td><td class="colsep0 rowsep0" align="char" char=".">20.8</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19k</b></td><td class="colsep0 rowsep0" align="char" char=".">6.85</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19l</b></td><td class="colsep0 rowsep0" align="char" char=".">3.59</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19n</b></td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19o</b></td><td class="colsep0 rowsep0" align="char" char=".">21.7</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19r</b></td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="char" char=".">110.9</td><td class="colsep0 rowsep0" align="left">stable</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sutezolid</td><td class="colsep0 rowsep0" align="char" char=".">54.8</td><td class="colsep0 rowsep0" align="left">stable</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Mouse liver microsome.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Substrate concentrations were determined in incubations with NADPH after 30 min and normalized to concentrations at time zero.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Stability was determined without the NADPH cofactor.</p></div></div></div><div class="NLM_p">Based on its potent activity against <i>M. tuberculosis</i> H37Rv, low MPS inhibition, and good microsome stability, compound <b>19c</b> and its sulfoxide metabolite <b>19r</b> were further evaluated against drug-resistant TB strains (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) using linezolid and sutezolid as comparators. Compound <b>19c</b> displayed a better potency than linezolid and a similar potency to sutezolid against MDR-TB clinical isolated 12525 strain. Compound <b>19c</b> was more potent than compound <b>19r</b>, linezolid, and sutezolid against the linezolid-resistant (L-R) strain, with an MIC of 0.24 μg/mL. It is worth noting that there is about a 4- to 10-fold increase in the MIC value for L-R strain compared with that for H37Rv for all four compounds <b>19c</b>, <b>19r</b>, linezolid, and sutezolid, indicating that <b>19c</b> is likely having the same binding site as other oxazolidinones. Based on these results, compound <b>19c</b> was therefore identified as a potential development candidate for further investigation.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Activities of <b>19c</b> and <b>19r</b> against Drug-Resistant TB</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">MIC (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center" char=".">H37Rv</th><th class="colsep0 rowsep0" align="center">12525<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">L-R<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="left">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19r</b></td><td class="colsep0 rowsep0" align="char" char=".">0.67</td><td class="colsep0 rowsep0" align="left">0.46</td><td class="colsep0 rowsep0" align="char" char=".">6.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="char" char=".">0.32</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="char" char=".">3.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sutezolid</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INH</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RFP</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Resistance to INH and rifampicin (RFP).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Resistance to linezolid.</p></div></div></div><div class="NLM_p">To better understand the druggability of compound <b>19c</b>, a battery of <i>in vitro</i> ADME assays were performed. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, compound <b>19c</b> showed good membrane permeability and excellent metabolic stability against human liver microsomes. Compound <b>19c</b> also showed excellent metabolic stability in hepatocytes from different species. Compound <b>19c</b> was also tested against several isoforms of the cytochrome P450 (CYP450) enzymes, CYP1A2, CYP2D6, CYP2C9, CYP2C19, and CYP3A4. The IC<sub>50</sub> values against all these CYP450 isoforms were all >45 μM, indicating their low potential for drug–drug interactions.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. ADME Profiles of Compound <b>19c</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">metabolic stability of hepatocytes</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center">clint (mL/min/million cell)</th><th class="colsep0 rowsep0" align="center" char=".">caco-2 Papp × 10<sup>–6</sup> cm/s</th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>%<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CYP inhibition<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (IC<sub>50</sub>, μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left"><1.39</td><td class="colsep0 rowsep0" align="char" char=".">67.58</td><td class="colsep0 rowsep0" align="char" char=".">81.5</td><td class="colsep0 rowsep0" align="left">1A2 (>50)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">315</td><td class="colsep0 rowsep0" align="left">2.20</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">2C9 (>50)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">68.0</td><td class="colsep0 rowsep0" align="left">10.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">2C19 (48.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">6.90</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">2D6 (>50)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">76.2</td><td class="colsep0 rowsep0" align="left">9.10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left">3A4 (>50)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Human liver microsome; positive control: dextromethorphan (<i>T</i><sub>1/2</sub> 26.7 min), midazolam (<i>T</i><sub>1/2</sub> 3.65 min), phenacetin (<i>T</i><sub>1/2</sub> 53.3 min), diclofenac (<i>T</i><sub>1/2</sub> 6.1 min), and omeprazole (<i>T</i><sub>1/2</sub> 47.8 min).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Substrate concentrations were determined in incubations with NADPH after 30 min and normalized to concentrations at time zero.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Positive control, for 1A2, naphthoflavone (IC<sub>50</sub>): 0.018 μM; for 2C9, sulfaphenazole (IC<sub>50</sub>): 0.77 μM; for 2C19, tranylcypromine (IC<sub>50</sub>): 5.86 μM; for 2D6, quinidine (IC<sub>50</sub>): 0.044 μM; and for 3A4, ketoconazole (IC<sub>50</sub>): 0.069 μM.</p></div></div></div><div class="NLM_p">Subsequently, compound <b>19c</b> was further progressed into <i>in vivo</i> PK study (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>19c</b> was quickly absorbed after oral administration at 25 mg/kg dose in mice, with a <i>T</i><sub>max</sub> value of 0.25 h, <i>C</i><sub>max</sub> of 3 μg/mL, and half-life (<i>t</i><sub>1/2</sub>) of 14.7 h. The exposure of compound <b>19c</b> after oral administration was high with an area under the curve (AUC) value of >6000 ng·h/mL. As anticipated, sulfoxide <b>19r</b> and sulfone <b>19s</b> were identified as the metabolites of <b>19c</b> with oral exposure in the order <b>19r</b> > <b>19c</b> > <b>19s</b>. After intravenous administration, compound <b>19c</b> and its metabolite <b>19r</b> were detected in the whole blood samples, with <b>19c</b> > <b>19r</b> in the AUC. The concentration of metabolite <b>19s</b> was extremely low (<10 ng/mL). The oral bioavailability of compound <b>19c</b> reached 55.9%, supporting the further evaluation of its <i>in vivo</i> efficacy via oral administration.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mouse PK Properties of Compound <b>19c</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="left"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">po<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (25 mg/kg)</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">iv<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (2.5 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">parameters</th><th class="rowsep1 colsep0" align="center" char="."><b>19c</b></th><th class="rowsep1 colsep0" align="center" char="."><b>19r</b></th><th class="rowsep1 colsep0" align="center" char="."><b>19s</b></th><th class="rowsep1 colsep0" align="center" char="."><b>19c</b></th><th class="rowsep1 colsep0" align="center" char="."><b>19r</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2β</sub></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="char" char=".">14.7</td><td class="colsep0 rowsep0" align="char" char=".">6.28</td><td class="colsep0 rowsep0" align="char" char=".">7.64</td><td class="colsep0 rowsep0" align="char" char=".">0.923</td><td class="colsep0 rowsep0" align="char" char=".">3.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">ng/mL</td><td class="colsep0 rowsep0" align="char" char=".">3000</td><td class="colsep0 rowsep0" align="char" char=".">1518</td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char=".">4202</td><td class="colsep0 rowsep0" align="char" char=".">115</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–<i>t</i>)</sub></td><td class="colsep0 rowsep0" align="left">ng/mL h</td><td class="colsep0 rowsep0" align="char" char=".">6478</td><td class="colsep0 rowsep0" align="char" char=".">8752</td><td class="colsep0 rowsep0" align="char" char=".">1254</td><td class="colsep0 rowsep0" align="char" char=".">1159</td><td class="colsep0 rowsep0" align="char" char=".">443</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–∞)</sub></td><td class="colsep0 rowsep0" align="left">ng/mL h</td><td class="colsep0 rowsep0" align="char" char=".">7621</td><td class="colsep0 rowsep0" align="char" char=".">9021</td><td class="colsep0 rowsep0" align="char" char=".">1475</td><td class="colsep0 rowsep0" align="char" char=".">1194</td><td class="colsep0 rowsep0" align="char" char=".">592</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–<i>t</i>)</sub></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="char" char=".">7.59</td><td class="colsep0 rowsep0" align="char" char=".">9.83</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">0.540</td><td class="colsep0 rowsep0" align="char" char=".">3.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–∞)</sub></td><td class="colsep0 rowsep0" align="left">h</td><td class="colsep0 rowsep0" align="char" char=".">15.2</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">14.3</td><td class="colsep0 rowsep0" align="char" char=".">0.691</td><td class="colsep0 rowsep0" align="char" char=".">6.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL</td><td class="colsep0 rowsep0" align="left">mL/h/kg</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2189</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i></td><td class="colsep0 rowsep0" align="left">mL/kg</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2722</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> %</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">55.9</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Five mice for po.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Five mice for iv.</p></div></div></div><div class="NLM_p">The <i>in vivo</i> efficacy of compound <b>19c</b> was assessed in Balb/c mice in an acute TB infection model (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Compound <b>19c</b> was orally administered at 100 mg/kg/day, whereas the positive controls linezolid and isoniazid (INH) were given at 100 and 25 mg/kg/day, respectively. After 3 weeks of treatment, compound <b>19c</b> showed better efficacy than linezolid at the same dose level (<b>19c</b>, log<sub>10</sub> cfu/lung = 1.954, vs linezolid, log<sub>10</sub> cfu/lung = 4.136). Subsequently, a dose–response study was conducted in an acute TB model in Balb/c mice (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In this study, sutezolid was added as the positive control besides INH and linezolid, and the efficacy of linezolid dosed at 50 and 100 mg/kg/day, sutezolid at 25 and 50 mg/kg/day, and <b>19c</b> at 25, 50, and 100 mg/kg/day was evaluated. Colony-forming units (cfus) were enumerated in lungs following 3 weeks of treatment by oral gavage dosing 5 days of 1 week. We were pleased to find that <b>19c</b> exhibited better antitubercular activity than linezolid at all doses. Compound <b>19c</b> also showed better efficacy than sutezolid at the same dose levels.</div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy in the mouse model of acute <i>M. tuberculosis</i> infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vivo</i> Efficacy of Compound <b>19c</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">group</th><th class="colsep0 rowsep0" align="center">dosage (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">weight (g)</th><th class="colsep0 rowsep0" align="center" char="±">log<sub>10</sub> cfu/lung</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CMC</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="±">21.29 ± 0.84</td><td class="colsep0 rowsep0" align="char" char="±">7.102 ± 0.152</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char="±">21.25 ± 0.88</td><td class="colsep0 rowsep0" align="char" char="±">1.954 ± 0.159</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char="±">20.83 ± 0.43</td><td class="colsep0 rowsep0" align="char" char="±">4.136 ± 0.498</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INH</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="char" char="±">21.30 ± 0.66</td><td class="colsep0 rowsep0" align="char" char="±">1.929 ± 0.213</td></tr></tbody></table></div></div><div class="NLM_p">As a potential candidate, the preliminary toxicity of compound <b>19c</b> and its main metabolite <b>19r</b> was further evaluated, and the results are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. Both compounds were not cytotoxic with high IC<sub>50</sub> values > 64 μg/mL against the HepG2 cell line. Both compounds showed no inhibition of the hERG K<sup>+</sup>, hCav1.2, and Nav1.5 channels at the highest concentration tested (>30 μM), indicating that <b>19c</b> and <b>19r</b> had low potential for cardiotoxicity. As the main adverse effect of peripheral neuropathy related to inhibition of MAOs during the long-term use of oxazolidinone, the <i>in vitro</i> MAO-A and MAO-B inhibition activity was conducted to assess the risk of <b>19c</b> for peripheral neuropathy toxicity. The inhibitory activity of compound <b>19c</b> against MAOs was significantly lower, with a fourfold improvement over sutezolid, while the metabolite <b>19r</b> had an IC<sub>50</sub> of > 100 μM. These results suggested that <b>19c</b> might have an improved safety profile in terms of the risk for peripheral neuropathy. In addition, genotoxicity studies of compound <b>19c</b> and its metabolite <b>19r</b> were all negative.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Preliminary Toxicity Properties of Compounds <b>19c</b> and <b>19r</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="right" char="." /></col><col align="right" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char=".">cytotoxicity HepG2</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub>, μM</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>, μg/mL</th><th class="colsep0 rowsep0" align="center">mice bone marrow micronucleus<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">chromosome aberration<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">mini-ames<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">hERG K<sup>+</sup></th><th class="colsep0 rowsep0" align="center">hCav1.2</th><th class="colsep0 rowsep0" align="center">Nav1.5</th><th class="colsep0 rowsep0" align="center" char=".">MAO-A</th><th class="colsep0 rowsep0" align="center" char=".">MAO-B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19c</b></td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="right" char=".">44.8</td><td class="colsep0 rowsep0" align="right" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19r</b></td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">negative</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="right" char=".">>100</td><td class="colsep0 rowsep0" align="right" char=".">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>sutezolid</b></td><td class="colsep0 rowsep0" align="char" char=".">>64</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="right" char=".">13</td><td class="colsep0 rowsep0" align="right" char=".">0.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">ICR mice, at dose levels of 100, 200, 500, 1000, and 2000 mg/kg.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Compounds <b>19c</b> and <b>19r</b> were tested at concentrations from 20 to 150 μg/mL with or without metabolic activation (+/– S9) using the CHO-WBL cell.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Compounds <b>19c</b> and <b>19r</b> were tested at concentrations from 0.005 to 1000 μg/well with or without metabolic activation (+/– S9) using the two tester strains TA98 and TA100.</p></div></div></div><div class="NLM_p">To further assess the risk of compound <b>19c</b> for myelosuppression, a repeated dose toxicity study in SD rats (12 female and 12 male/group) was performed. Compound <b>19c</b> was administered orally once daily at doses of 50, 150, and 450 mg/kg/day for 4 weeks, followed by a 2 week recovery period. No mortality and significant body weight loss were observed in any of the compound <b>19c</b> groups. Compound <b>19c</b> had no significant effect on food consumption, eye examination, urine examination, and neuropsychic symptoms of SD rats. The histopathology revealed no changes in the main organs after 28 day administration and 14 day recovery period in any groups. More importantly, there were no bone marrow histopathological changes found in the highest 450 mg/kg/day dosing group. Furthermore, a hematologic analysis further confirmed that <b>19c</b> had a less myelosuppressive effect (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). No significant reductions in white blood cell (WBC) and red blood cell (RBC) counts were observed in any of the compound <b>19c</b> dosing groups compared to the vehicle control. Although the platelet (PLT) count in the 150 and 450 mg/kg/day female rat groups did not show statistically significant differences (<i>P</i> ≥ 0.05) compared to the control group, the drop in the mean value was observed. The decline of PLT count should be evaluated in good laboratory practice toxicity study. According to the reported data,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> there was a pronounced drop in WBC, RBC, and PLT counts in the 100 mg/kg/day rat group of linezolid in a repeated dose toxicity study. The results of MPS assay and repeated dose toxicity in rat demonstrated that compound <b>19c</b> displayed lower potential risk of myelosuppressive toxicity compared to linezolid.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Repeated Dose Toxicity of <b>19c</b>: Hematology Parameters in Rats<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char="±">group<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">50 mg/kg/day</th><th class="colsep0 rowsep0" align="center" char="±">150 mg/kg/day</th><th class="colsep0 rowsep0" align="center" char="±">450 mg/kg/day</th><th class="colsep0 rowsep0" align="center" char="±">vehicle</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WBC (10<sup>9</sup>/L)</td><td class="colsep0 rowsep0" align="left">F<a class="ref internalNav" href="#t9fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 1.44</td><td class="colsep0 rowsep0" align="char" char="±">3.04 ± 1.16</td><td class="colsep0 rowsep0" align="char" char="±">2.82 ± 1.40</td><td class="colsep0 rowsep0" align="char" char="±">3.61 ± 0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M<a class="ref internalNav" href="#t9fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">6.22 ± 2.17</td><td class="colsep0 rowsep0" align="char" char="±">6.11 ± 0.88</td><td class="colsep0 rowsep0" align="char" char="±">5.06 ± 0.86</td><td class="colsep0 rowsep0" align="char" char="±">6.12 ± 1.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RBC (10<sup>12</sup>/L)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">6.85 ± 0.58</td><td class="colsep0 rowsep0" align="char" char="±">6.61 ± 1.43</td><td class="colsep0 rowsep0" align="char" char="±">6.53 ± 1.20</td><td class="colsep0 rowsep0" align="char" char="±">7.32 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">7.29 ± 0.54</td><td class="colsep0 rowsep0" align="char" char="±">7.62 ± 0.44</td><td class="colsep0 rowsep0" align="char" char="±">7.46 ± 0.52</td><td class="colsep0 rowsep0" align="char" char="±">7.86 ± 0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PLT (10<sup>9</sup>/L)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">1094 ± 91</td><td class="colsep0 rowsep0" align="char" char="±">787 ± 411</td><td class="colsep0 rowsep0" align="char" char="±">735 ± 418</td><td class="colsep0 rowsep0" align="char" char="±">1051 ± 122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">955 ± 300</td><td class="colsep0 rowsep0" align="char" char="±">998 ± 57</td><td class="colsep0 rowsep0" align="char" char="±">1038 ± 45</td><td class="colsep0 rowsep0" align="char" char="±">1077 ± 117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MPV (fL)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">7.5 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCV (fL)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">56.5 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">56.6 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">56.5 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">56.1 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">59.7 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">58.5 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">58.7 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">57.5 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCH (pg)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">18.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">18.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">18.7 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">18.5 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">18.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">18.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">18.7 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">18.3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HGB (g/L)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">126 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">124 ± 27</td><td class="colsep0 rowsep0" align="char" char="±">122 ± 22</td><td class="colsep0 rowsep0" align="char" char="±">136 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">136 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">141 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">139 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">144 ± 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCT (%)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">38.7 ± 3.1</td><td class="colsep0 rowsep0" align="char" char="±">37.4 ± 8.0</td><td class="colsep0 rowsep0" align="char" char="±">36.9 ± 6.5</td><td class="colsep0 rowsep0" align="char" char="±">41.1 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">43.5 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">44.5 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">43.8 ± 2.7</td><td class="colsep0 rowsep0" align="char" char="±">45.2 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% retic (%)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">3.25 ± 0.72</td><td class="colsep0 rowsep0" align="char" char="±">2.89 ± 0.53</td><td class="colsep0 rowsep0" align="char" char="±">2.93 ± 0.73</td><td class="colsep0 rowsep0" align="char" char="±">2.85 ± 0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">2.97 ± 0.49</td><td class="colsep0 rowsep0" align="char" char="±">3.15 ± 0.49*</td><td class="colsep0 rowsep0" align="char" char="±">2.99 ± 0.40</td><td class="colsep0 rowsep0" align="char" char="±">2.48 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% neut (%)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">14.8 ± 4.5</td><td class="colsep0 rowsep0" align="char" char="±">12.2 ± 4.8</td><td class="colsep0 rowsep0" align="char" char="±">11.8 ± 3.6</td><td class="colsep0 rowsep0" align="char" char="±">18.5 ± 5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">13.0 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">17.0 ± 6.3</td><td class="colsep0 rowsep0" align="char" char="±">13.7 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">15.9 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">% lymph (%)</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">80.7 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">83.0 ± 6.0</td><td class="colsep0 rowsep0" align="char" char="±">83.7 ± 4.0*</td><td class="colsep0 rowsep0" align="char" char="±">76.9 ± 4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">M</td><td class="colsep0 rowsep0" align="char" char="±">82.0 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">77.3 ± 6.4</td><td class="colsep0 rowsep0" align="char" char="±">80.7 ± 5.3</td><td class="colsep0 rowsep0" align="char" char="±">77.4 ± 3.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">WBC, white blood cells; RBC, red blood cells; PLT, platelets; MPV, mean platelet volume; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; HGB, hemoglobin; HCT, hematocrit; % neut, neutrophils percentage; % lymph, lymphocytes percentage; % retic, reticulocytes percentage.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">Results are expressed as the mean ± SD (<i>n</i> = 12 for each group).</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">F, Female rat.</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">M, Male rat. *<i>P</i> < 0.05 versus vehicle.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28134" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28134" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A novel conformationally constrained oxazolidinone <b>19c</b> has been identified through a focused lead optimization effort. Compound <b>19c</b> displayed potent activity against susceptible <i>M. tuberculosis</i> H37Rv and drug-resistant MDR-TB isolated and linezolid-resistant strain. Further evaluation of compound <b>19c</b> revealed that this compound possesses favorable mouse and human microsomal stability, low cytotoxicity, low liability for drug–drug interactions, and an excellent PK profile. Compound <b>19c</b> exhibited better <i>in vivo</i> efficacy in a mouse TB model than linezolid and sutezolid. Compound <b>19c</b> exhibited an excellent safety profile in a panel of safety assessments, including inhibition of MPS, inhibition of hERG K<sup>+</sup>, hCav1.2, and Nav1.5 channels, inhibition of MAO-A and MAO-B enzymes, and genotoxicity assays. Compound <b>19c</b> showed reduced potential for myelosuppression in the 4 week repeated dose toxicity study. Compound <b>19c</b> was therefore selected as an anti-TB drug candidate and currently under preclinical development.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General</h4><div class="NLM_p last">All solvents used were of analytical grade. Inert atmosphere operations were conducted under argon in flame-dried glassware. All melting points were measured with a micro melting point apparatus (MP-J3, Yanaco) and were uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian 400 NMR or 500 NMR or 600 NMR spectrometer using CDCl<sub>3</sub> or DMSO-<i>d</i><sub>6</sub> as a solvent and tetramethylsilane as an internal standard. Chemical shift (δ) is reported in parts per million (ppm), and coupling constants (<i>J</i>) are reported in Hertz (Hz). Splitting patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; and brs, broad singlet. High-resolution mass spectrometry (HR-MS) spectra were obtained on a Thermo Fisher Exactive Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Optical rotations were measured with a Rudolph Research Analytical (Autopol IV-T). Reactions were monitored by thin-layer chromatography (TLC; silica gel GF254). Column chromatography was carried out using silica gel (200–300 mesh), and the solvent proportions were expressed on a volume: volume basis. The purity of all final compounds (≥95%) was established by high-performance liquid chromatography (HPLC), which was carried out on a Thermo Fisher Accela HPLC system (Thermo Fisher Scientific, Bremen, Germany) with an Agilent Zorbax SB-C18 column (5 μm, 2.1 × 50 mm), a column temperature of 40 °C, detection wavelength at 254 nm, flow rate = 0.3 mL/min, and a gradient of 5–95% MeCN in water (both containing 0.1 vol % of HCOOH) in 10 min.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Synthesis of Compounds <b>9a–d</b></h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (<i>Z</i>)-4-(Trityloxy)but-2-en-1-ol (<b>8a</b>)</h5><div class="NLM_p last">To a mixture of (<i>Z</i>)-1,4-butenediol <b>7a</b> (30 g, 340 mmol), Et<sub>3</sub>N (24 mL, 170 mmol), and DMAP (1 g) in DCM (250 mL) cooled with an ice-water bath was slowly added a solution of triphenylchloromethane (31 g, 113.6 mmol) in DCM (100 mL). The reaction mixture was stirred overnight at room temperature. The mixture was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and then, the filtrate was concentrated <i>in vacuo</i>. The residue was purified by column chromatography [10–25% EtOAc in petroleum ether (PE)] to give compound <b>8a</b> (27 g, 73.0%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.41 (m, 6H), 7.36–7.18 (m, 9H), 5.87–5.64 (m, 2H), 4.03 (d, <i>J</i> = 6.0 Hz, 2H), 3.71 (d, <i>J</i> = 5.6 Hz, 2H).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (<i>E</i>)-4-(Trityloxy)but-2-en-1-ol (<b>8b</b>)</h5><div class="NLM_p last">To a mixture of (<i>E</i>)-1,4-butenediol <b>7b</b> (0.88 g, 10 mmol), 2,4,6-collidine (0.4 mL, 3 mmol), and TBAI (50 mg) in DCM (10 mL) cooled with an ice-water bath was added triphenylchloromethane (0.56 g, 2 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was washed with 0.5 N HCl, water, and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and then, the filtrate was concentrated <i>in vacuo</i>. The residue was purified by column chromatography (15% EtOAc in PE) to give compound <b>8b</b> (0.32 g, 48.3%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.44 (m, 6H), 7.32–7.27 (m, 6H), 7.25–7.19 (m, 3H), 6.10–5.69 (m, 2H), 4.17 (d, <i>J</i> = 4.8 Hz, 2H), 3.71–3.56 (m, 2H), 1.34 (brs, 1H).</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> <i>cis</i>-(3-((Trityloxy)methyl)oxiran-2-yl)methanol (<b>9a</b>)</h5><div class="NLM_p last">To a solution of <b>8a</b> (10 g, 30.4 mmol) in DCM (80 mL) was added <i>m</i>-CPBA (6.4 g, 31.8 mmol). The reaction mixture was stirred overnight. After filtration, the filtrate was washed with saturated sodium bicarbonate solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. To the residue was added diethyl ether and stirred for 3 h. After filtration, the filter cake was washed with diethyl ether and dried to afford <b>9a</b> (7.3 g, 69.2%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.47–7.41 (m, 6H), 7.38–7.17 (m, 9H), 3.65–3.47 (m, 3H), 3.30–3.16 (m, 2H), 3.07 (dd, <i>J</i> = 10.4, 5.6 Hz, 1H) 1.87 (brs, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NaO<sub>3</sub>, 369.1461; found, 369.1445.</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>trans</i>-(3-((Trityloxy)methyl)oxiran-2-yl)methanol (<b>9b</b>)</h5><div class="NLM_p last">To a solution of <b>8b</b> (2.2 g, 6.7 mmol) in DCM (25 mL) was added <i>m</i>-CPBA (75%, 1.7 g, 7 mmol) portionwise. The reaction mixture was stirred overnight. After filtration, the filtrate was washed with saturated sodium bicarbonate solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. To the residue was added EtOAc/PE (1/5, 10 mL) and stirred for 2.5 h. After filtration, the filter cake was washed with the mixture solution and dried to afford <b>9b</b> (1.1 g, 47.4%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.42 (m, 6H), 7.34–7.28 (m, 6H), 7.26–7.21 (m, 3H), 3.94 (dd, <i>J</i> = 12.8, 2.4 Hz, 1H), 3.64 (dd, <i>J</i> = 12.4, 4.0 Hz, 1H), 3.38 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 3.25–3.15 (m, 2H), 3.12–3.11 (m, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NaO<sub>3</sub>, 369.1461; found, 369.1455.</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (2<i>R</i>,3<i>S</i>)-(3-((Trityloxy)methyl)oxiran-2-yl)methanol (<b>9c</b>)</h5><div class="NLM_p last">To a four-necked flask were added 4 Å molecular sieve (12 g) and anhydrous DCM (330 mL). The mixture was cooled to −40 °C under argon. <span class="smallcaps smallerCapital"><i>d</i></span>-(−)-Diethyl tartrate (13.6 mL, 79.2 mmol) was added, followed by titanium tetraisopropanolate (18.8 mL, 63.4 mmol), and the reaction mixture turned yellow. After stirring for 0.5 h, a solution of <b>8a</b> (26.1 g, 79.2 mmol) in DCM (120 mL) was added to the mixture and stirred for 0.5 h. A solution of <i>tert</i>-butyl hydroperoxide in toluene (3.8 M, 50 mL, 190 mmol) was added and stirred overnight at −20 °C. After the reaction was completely monitored by TLC, tartaric acid solution (10%, 200 mL) containing FeSO<sub>4</sub>·7H<sub>2</sub>O (30 g) was added and stirred at 0 °C for 1 h before layering. The organic layer was separated, and the water layer was extracted with DCM twice. The organic phase was combined and washed with brine twice, filtered, and evaporated to give a solid, which was stirred in <i>n</i>-hexane and filtered, followed by recrystallizing with PE/ethyl acetate to afford <b>9c</b> (15 g, 57.5%) as an off-white solid. The corresponding alcohol was analyzed by chiral HPLC (OD-H, 5 μm, 4.6 mm × 250 mmL; eluent: hexane/ethanol, 90/10; flow rate: 1 mL/min; λ = 215 nm; <i>T</i> = 20 °C): <i>t</i><sub>R</sub> = 6.46 min (96.49%) and <i>t</i><sub>R</sub> = 12.58 min (3.51%). The enantiomeric purity of <b>9c</b> was determined to be 92.98% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> +31.9 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48–7.41 (m, 6H), 7.35–7.19 (m, 9H), 3.64–3.50 (m, 3H), 3.30–3.15 (m, 2H), 3.07 (dd, <i>J</i> = 10.4, 5.6 Hz, 1H), 1.90 (brs, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NaO<sub>3</sub>, 369.1461; found, 369.1427.</div></div><div id="sec5_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (2<i>S</i>,3<i>R</i>)-(3-((Trityloxy)methyl)oxiran-2-yl)methanol (<b>9d</b>)</h5><div class="NLM_p last">Compound <b>9d</b> (6 g, 51.3%) was prepared from <b>8a</b> in the same manner as described for <b>9c</b> by replacing <span class="smallcaps smallerCapital"><i>d</i></span>-(−)-diethyl tartrate with <span class="smallcaps smallerCapital"><i>l</i></span>-(+)-diethyl tartrate. The enantiomeric purity of <b>9d</b> was determined to be 96.84% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> −31.1 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.20 (m, 15H) 3.65–3.50 (m, 3H), 3.28–3.17 (m, 2H), 3.06 (dd, <i>J</i> = 10.4, 5.6 Hz, 1H), 1.85 (t, <i>J</i> = 6.4 Hz, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + Na]<sup>+</sup> calcd for C<sub>23</sub>H<sub>22</sub>NaO<sub>3</sub>, 369.1461; found, 369.1448.</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Synthesis of Compounds <b>12a–f</b></h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 4-Fluoro-2-nitro-5-thiomorpholinophenol (<b>11a</b>)</h5><div class="NLM_p last">To a solution of 4,5-difluoro-2-nitrophenol <b>10a</b> (1.75 g, 10 mmol) in MeCN (20 mL) was added <i>N</i>-methylmorpholine (1.5 mL), followed by thiomorpholine (11 mL, 11 mmol). The reaction mixture was heated at 80 °C for 3 h. After cooling, water (20 mL) was added to form the precipitate which was filtered, washed with water, and dried to afford 2.53 g of <b>11a</b> as an orange solid (98.1%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.86 (s, 1H), 7.73 (d, <i>J</i> = 13.2 Hz, 1H), 6.42 (d, <i>J</i> = 7.6 Hz, 1H), 3.70–3.61 (m, 4H), 2.81–2.74 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>12</sub>FN<sub>2</sub>O<sub>3</sub>S, 259.0547; found, 259.0543.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Benzyl (5-Fluoro-2-hydroxy-4-thiomorpholinophenyl)carbamate (<b>12a</b>)</h5><div class="NLM_p last">To a suspension of <b>11a</b> (4 g, 15.5 mmol) in tetrahydrofuran (THF; 40 mL) was added Raney nickel (1 g). The mixture was hydrogenated at 20–50 psi for 2 h. The reaction mixture was filtered into a flask containing sodium bicarbonate (2.6 g, 31 mmol) and water (10 mL) in an ice bath under argon. CbzCl (2.0 mL, 14.4 mmol) was added dropwise, and the mixture was stirred for 20 min. The organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give a red solid. The crude product was purified by column chromatography eluted with PE/ethyl acetate = 7/3 to give <b>12a</b> (4.5 g, 80.4%) as a pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.51 (s, 1H), 8.45 (s, 1H), 7.37–7.28 (m, 6H), 6.48 (d, <i>J</i> = 8.8 Hz, 1H), 5.07 (s, 2H), 3.10 (t, <i>J</i> = 4.8 Hz, 4H), 2.68 (t, <i>J</i> = 4.8 Hz, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>3</sub>S, 363.1173; found, 363.1170.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 2-Nitro-5-thiomorpholinophenol (<b>11b</b>)</h5><div class="NLM_p last">Compound <b>11b</b> (13.1 g, 94.9%) was prepared from 5-fluoro-2-nitrophenol <b>10b</b> (9 g, 57.3 mmol) in the same manner as described for <b>11a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.24 (s, 1H), 7.96 (d, <i>J</i> = 10.0 Hz, 1H), 6.38 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 6.27 (d, <i>J</i> = 2.8 Hz, 1H), 4.00–3.72 (m, 4H), 2.82–2.56 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub>S, 241.0641; found, 241.0638.</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Benzyl (2-Hydroxy-4-thiomorpholinophenyl)carbamate (<b>12b</b>)</h5><div class="NLM_p last">To a suspension of <b>11b</b> (3.7 g, 15.5 mmol) in THF (80 mL) was added Zn dust (4 g, 62 mmol). AcOH (4.4 mL, 77.5 mmol) was added to the reaction mixture under argon and kept the inner temperature between 30 and 40 °C. After the reaction completed, the mixture was filtered into a flask containing sodium bicarbonate (3.9 g, 46.5 mmol) and water (40 mL) in an ice bath under argon. CbzCl (2.1 mL, 15.5 mmol) was added dropwise, and the mixture was stirred for 30 min. After removing the solvent, the residue was partitioned between ethyl ether and H<sub>2</sub>O and then extracted with ethyl ether. The organic solution was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by column chromatography eluted with DCM/MeOH = 99/1 to give <b>12b</b> (3.8 g, 74.6%) as a purple solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86 (s, 1H), 7.46–7.32 (m, 5H), 6.90 (d, <i>J</i> = 8.8 Hz, 1H), 6.63 (brs, 1H), 6.53 (d, <i>J</i> = 2.8 Hz, 1H), 6.41 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 5.22 (s, 2H), 3.64–3.39 (m, 4H), 2.81–2.64 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub>S, 345.1267; found, 345.1259.</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 5-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-4-fluoro-2-nitrophenol (<b>11c</b>)</h5><div class="NLM_p last">To a solution of 4,5-difluoro-2-nitrophenol <b>10a</b> (3.55 g, 20 mmol) in acetonitrile (40 mL) was added <i>N</i>-methylmorpholine (6.7 mL, 60 mmol) and 3-thio-8-azodicyclo[3.2.1]octane hydriodate (5.14 g, 20 mmol). The reaction mixture was stirred at 80 °C for 8 h before cooling. After adding water (30 mL), the solid was precipitated, which was filtered, washed with water, and dried to give <b>11c</b> (4.3 g, 75.7%) as an orange solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.05 (s, 1H), 7.74 (d, <i>J</i> = 14.8 Hz, 1H), 6.29 (d, <i>J</i> = 7.6 Hz, 1H), 4.72 (s, 2H), 3.28 (dd, <i>J</i> = 13.6, 2.0 Hz, 2H), 2.31–2.10 (m, 6H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>12</sub>H<sub>14</sub>FN<sub>2</sub>O<sub>3</sub>S, 285.0704; found, 285.0698.</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Benzyl (4-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-5-fluoro-2-hydroxyphenyl)carbamate (<b>12c</b>)</h5><div class="NLM_p last">Compound <b>12c</b> (4.2 g, 81.6%) was prepared from <b>11c</b> (4 g, 14.1 mmol) in the same manner as described for <b>12a</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.34 (s, 1H), 8.44 (s, 1H), 7.57–7.08 (m, 6H), 6.44 (d, <i>J</i> = 8.8 Hz, 1H), 5.11 (s, 2H), 4.26 (s, 2H), 3.13 (d, <i>J</i> = 12.8 Hz, 2H), 2.17–1.97 (m, 6H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>3</sub>S, 389.1330; found, 389.1327.</div></div><div id="sec5_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 4-Fluoro-5-morpholino-2-nitrophenol (<b>11d</b>)</h5><div class="NLM_p last">Compound <b>11d</b> (2.3 g, 56.1%) was prepared from 4,5-difluoro-2-nitrophenol <b>10a</b> (3 g, 17.1 mmol) in the same manner as described for <b>11a</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.86 (s, 1H), 7.74 (d, <i>J</i> = 13.2 Hz, 1H), 6.43 (d, <i>J</i> = 7.6 Hz, 1H), 4.00–3.70 (m, 4H), 3.49–3.21 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>12</sub>FN<sub>2</sub>O<sub>4</sub>, 243.0776; found, 243.0773.</div></div><div id="sec5_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Benzyl (5-Fluoro-2-hydroxy-4-morpholinophenyl)carbamate (<b>12d</b>)</h5><div class="NLM_p last">Compound <b>12d</b> (1.8 g, 62.7%) was prepared from <b>11d</b> (2 g, 8.3 mmol) in the same manner as described for <b>12a</b>. Red solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.52 (s, 1H), 8.49 (s, 1H), 7.62–7.16 (m, 6H), 6.49 (d, <i>J</i> = 8.4 Hz, 1H), 5.12 (s, 2H), 3.72 (t, <i>J</i> = 4.4 Hz, 4H), 2.90 (t, <i>J</i> = 4.4 Hz, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>, 347.1402; found, 347.1392.</div></div><div id="sec5_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 5-(4,4-Difluoropiperidin-1-yl)-4-fluoro-2-nitrophenol (<b>11e</b>)</h5><div class="NLM_p last">To a solution of 4,5-difluoro-2-nitrophenol <b>10a</b> (2.8 g, 16 mmol) in acetonitrile (15 mL) were added <i>N</i>-methylmorpholine (4 mL) and 4,4-difluoropiperidine hydrochloride (3.5 g, 22 mmol). The reaction mixture was heated at 80 °C for 4 h. After cooling, water was added (15 mL) and stayed overnight. The precipitate was filtered, and the filter cake was purified by column chromatography (PE/DCM = 80/20) to give <b>11e</b> (3 g, 68.2%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.83 (s, 1H), 7.75 (d, <i>J</i> = 13.2 Hz, 1H), 6.47 (d, <i>J</i> = 7.6 Hz, 1H), 3.47 (t, <i>J</i> = 6.0 Hz, 4H), 2.22–2.07 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>, 277.0795; found, 277.0791.</div></div><div id="sec5_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Benzyl (4-(4,4-Difluoropiperidin-1-yl)-5-fluoro-2-hydroxyphenyl)carbamate (<b>12e</b>)</h5><div class="NLM_p last">Compound <b>12e</b> (4.7 g, 77.0%) was prepared from <b>11e</b> (3 g, 10.87 mmol) in the same manner as described for <b>12a</b>. Light pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.49–7.30 (m, 5H), 7.01 (brs, 1H), 6.87–6.55 (m, 2H), 5.22 (s, 2H), 3.18 (brs, 4H), 2.17 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>, 381.1421; found, 381.1408.</div></div><div id="sec5_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 4-Fluoro-2-nitro-5-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenol (<b>11f</b>)</h5><div class="NLM_p last">To a solution of 4,5-difluoro-2-nitrophenol <b>10a</b> (4.0 g, 22.9 mmol) in acetonitrile (30 mL) was added <i>N</i>-methylmorpholine (4 mL, 45.8 mmol) and 2-oxa-6-azaspiro[3.3]heptane hemioxalate (4 g, 13.7 mmol). The reaction mixture was stirred at 80 °C for 5 h before cooling. After adding water (30 mL), the solid was precipitated, which was filtered, washed with water, and dried to give <b>11f</b> (5.0 g, 86.2%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 11.19 (s, 1H), 7.65 (d, <i>J</i> = 12.8 Hz, 1H), 5.83 (d, <i>J</i> = 7.6 Hz, 1H), 4.86 (s, 4H), 4.37 (d, <i>J</i> = 2.0 Hz, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>11</sub>H<sub>12</sub>FN<sub>2</sub>O<sub>4</sub>, 255.0776; found, 255.0765.</div></div><div id="sec5_1_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Benzyl (5-Fluoro-2-hydroxy-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl)carbamate (<b>12f</b>)</h5><div class="NLM_p last">Compound <b>12f</b> (1.24 g, 46.3%) was prepared from <b>11f</b> (1.9 g, 7.5 mmol) in the same manner as described for <b>12b</b>. Red solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.36 (s, 1H), 8.37 (s, 1H), 7.55–7.25 (m, 5H), 7.16 (s, 1H), 6.00 (d, <i>J</i> = 8.8 Hz, 1H), 5.09 (s, 2H), 4.69 (s, 4H), 3.97 (d, <i>J</i> = 2.0 Hz, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>, 359.1402; found, 359.1386.</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Synthesis of Compounds <b>15a–i</b></h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>cis</i>-Benzyl (5-Fluoro-4-thiomorpholino-2-((3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl) Carbamate (<b>13a</b>)</h5><div class="NLM_p last">To a 100 mL three-necked round bottom flask were added <b>12a</b> (1 g, 2.8 mmol), <b>9a</b> (1.1 g, 3.3 mmol), PPh<sub>3</sub> (1.47 g, 5.6 mmol), and anhydrous THF (20 mL), and then, ADDP (1.4 g, 5.6 mmol) was added in four batches at 0 °C. Then, the reaction was allowed to warm to room temperature and monitored by TLC. After the reaction completed, <i>n</i>-hexane was added for dilution and the mixture was filtered, and then, the filtrate was concentrated. The crude product was purified by column chromatography eluted with PE/ethyl acetate = 80/20 to give <b>13a</b> (1.3 g, 67.0%) as a pink foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 12.4 Hz, 1H), 7.47–7.21 (m, 20H), 7.13 (s, 1H), 6.44 (brs, 1H), 5.18 (s, 2H), 4.15 (dd, <i>J</i> = 11.2, 2.4 Hz, 1H), 3.81 (dd, <i>J</i> = 11.2, 6.4 Hz, 1H), 3.45 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 3.38–3.28 (m, 2H), 3.27–3.11 (m, 5H), 2.79 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>40</sub>FN<sub>2</sub>O<sub>5</sub>S, 691.2636; found, 691.2605.</div></div><div id="sec5_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>trans</i>-8-Fluoro-7-thiomorpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14a</b>)</h5><div class="NLM_p last">To a solution of <b>13a</b> (1 g, 1.45 mmol) in anhydrous THF (20 mL) was added <i>t</i>-BuOLi (0.17 g, 2.2 mmol). After the reaction completed, saturated NH<sub>4</sub>Cl aqueous (2 mL) was added to the reaction mixture and then evaporated. MeOH was added to the residue and stirred for 1 h. It was filtered, and the filter cake was washed with water and MeOH and dried to give <b>14a</b> (837 mg, 99.2%) as a pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 12.8 Hz, 1H), 7.44–7.25 (m, 15H), 6.55 (d, <i>J</i> = 7.6 Hz, 1H), 4.37 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.29–4.18 (m, 1H), 3.99–3.91 (m, 1H), 3.79 (t, <i>J</i> = 10.4 Hz, 1H), 3.53–3.45 (m, 2H), 3.34–3.19 (m, 4H), 2.85–2.74 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>4</sub>S, 583.2061; found, 583.2039.</div></div><div id="sec5_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>trans</i>-8-Fluoro-3-(hydroxymethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15a</b>)</h5><div class="NLM_p last">To a solution of <b>14a</b> (800 mg, 1.37 mmol) in DCM (18 mL) was added trifluoroacetic acid (1.8 mL, 23.3 mmol) under ice bath and stirred overnight at room temperature. The reaction mixture was adjusted to weak alkalinity with a solution of saturated NaHCO<sub>3</sub> and extracted with DCM. The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (DCM/MeOH = 98/2) to afford <b>15a</b> (360 mg, 77.3%) as a pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 13.2 Hz, 1H), 6.56 (d, <i>J</i> = 7.6 Hz, 1H), 4.46 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.40–4.31 (m, 1H), 4.19–4.09 (m, 1H), 4.07–3.98 (m, 1H), 3.94–3.80 (m, 2H), 3.36–3.20 (m, 4H), 2.88–2.76 (m, 4H), 2.05 (t, <i>J</i> = 6.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 153.6, 149.1 (d, <i>J</i> = 236.0 Hz), 140.5 (d, <i>J</i> = 2.0 Hz), 136.9 (d, <i>J</i> = 10.0 Hz), 117.5 (d, <i>J</i> = 11.0 Hz), 108.5 (d, <i>J</i> = 3.0 Hz), 106.0 (d, <i>J</i> = 28.0 Hz), 76.5, 65.9, 60.7, 52.94, 52.92, 51.6, 27.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S, 341.0966; found, 341.0953.</div></div><div id="sec5_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>trans</i>-Benzyl (5-Fluoro-4-thiomorpholino-2-((3-((trityloxy)methyl)oxiran-2-yl)methoxy) phenyl)carbamate (<b>13b</b>)</h5><div class="NLM_p last">Compound <b>13b</b> (304 mg, 45.9%) was prepared from <b>12a</b> (349 mg, 0.96 mmol) and <b>9b</b> (505 mg, 1.45 mmol) in the same manner as described for <b>13a</b>. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.94 (s, 1H), 7.58–7.16 (m, 21H), 6.63 (brs, 1H), 5.20 (s, 2H), 4.29 (d, <i>J</i> = 11.0 Hz, 1H), 3.90 (dd, <i>J</i> = 11.5, 6.0 Hz, 1H), 3.39–3.15 (m, 8H), 2.81 (s, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>40</sub>O<sub>5</sub>N<sub>2</sub>FS, 691.2636; found, 691.2610.</div></div><div id="sec5_1_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>cis</i>-8-Fluoro-7-thiomorpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14b</b>)</h5><div class="NLM_p last">Compound <b>14b</b> (81 mg, 46.3%) was prepared from <b>13b</b> (204 mg, 0.3 mmol) in the same manner as described for <b>14a</b>. Pale-pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.93 (d, <i>J</i> = 13.2 Hz, 1H), 7.43–7.20 (m, 15H), 6.69 (s, 1H), 4.87–4.74 (m, 1H), 4.35–4.24 (m, 2H), 3.91 (t, <i>J</i> = 10.4 Hz, 1H), 3.44 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 3.32 (brs, 4H), 3.17 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 2.86 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>4</sub>S, 583.2061; found, 583.2059.</div></div><div id="sec5_1_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>cis</i>-8-Fluoro-3-(hydroxymethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15b</b>)</h5><div class="NLM_p last">Compound <b>15b</b> (684 mg, 58.5%) was prepared from <b>14b</b> (2 g, 3.44 mmol) in the same manner as described for <b>15a</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 13.2 Hz, 1H), 6.73 (s, 1H), 4.84–4.80 (m, 1H), 4.52 (dd, <i>J</i> = 10.8, 2.8 Hz, 1H), 4.34–4.26 (m, 1H), 4.19 (t, <i>J</i> = 10.4 Hz, 1H), 3.96 (d, <i>J</i> = 13.6 Hz, 1H), 3.81 (d, <i>J</i> = 12.8 Hz, 1H), 3.39–3.26 (m, 4H), 2.86 (brs, 4H), 2.04 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 153.3, 150.3 (d, <i>J</i> = 236.0 Hz), 140.3 (d, <i>J</i> = 2.0 Hz), 136.7 (d, <i>J</i> = 11.0 Hz), 117.9 (d, <i>J</i> = 11.0 Hz), 108.5 (d, <i>J</i> = 3.0 Hz), 105.3 (d, <i>J</i> = 28.0 Hz), 75.2, 63.5, 59.0, 53.0, 52.0, 27.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S, 341.0958; found, 341.0966.</div></div><div id="sec5_1_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Benzyl (5-Fluoro-4-thiomorpholino-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13c</b>)</h5><div class="NLM_p last">To a 25 mL three-necked round bottom flask were added <b>12a</b> (3.0 g, 8.28 mmol), <b>9c</b> (3.7 g, 10.76 mmol), triphenylphosphine (4.3 g, 16.56 mmol), and anhydrous DCM (60 mL), and then, ADDP (4.2 g, 16.56 mmol) was added in portions at 0 °C. Then, the reaction was allowed to warm to room temperature and monitored by TLC. After the reaction completed, <i>n</i>-hexane was added for dilution and the mixture was filtered, and then, the filtrate was concentrated. The crude product was purified by column chromatography eluted with PE/DCM = 60/40 to give <b>13c</b> (4.2 g, 73.7%) as a red foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 12.4 Hz, 1H), 7.47–7.21 (m, 20H), 7.13 (s, 1H), 6.47 (brs, 1H), 5.18 (s, 2H), 4.16 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 3.81 (dd, <i>J</i> = 11.2, 6.8 Hz, 1H), 3.45 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 3.38–3.28 (m, 2H), 3.27–3.11 (m, 5H), 2.79 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>40</sub>O<sub>5</sub>N<sub>2</sub>FS, 691.2636; found, 691.2606.</div></div><div id="sec5_1_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-7-thiomorpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14c</b>)</h5><div class="NLM_p last">To a solution of <b>13c</b> (690 mg, 1 mmol) in anhydrous THF (11 mL) under argon at −78 °C was added <i>n</i>-BuLi (1.6 M in <i>n</i>-hexane, 0.69 mL, 1.1 mmol) dropwise. After addition, the resulting mixture was stirred for 1 h and then warmed to room temperature and stirred overnight. Saturated ammonium chloride was added to quench the reaction. The solvent was concentrated under reduced pressure, followed by adding ethyl acetate and water. The organic phase was separated, and the water phase was extracted with ethyl acetate again. The combined organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuum. The residue was purified by column chromatography eluted with PE/ethyl acetate = 75/25 to give <b>14c</b> (450 mg, 77.3%) as a pink solid. The product was analyzed by chiral HPLC (OZ-H, 5 μm, 4.6 mm × 250 mmL; eluent: hexane/isopropanol, 70/30; flow rate: 1 mL/min; λ = 240 nm; <i>T</i> = 20 °C): <i>t</i><sub>R</sub> = 11.12 min (2.43%) and <i>t</i><sub>R</sub> = 18.28 min (97.57%). The enantiomeric purity of <b>14c</b> was determined to be 95.14% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> −15.4 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 13.2 Hz, 1H), 7.46–7.39 (m, 6H), 7.37–7.23 (m, 9H), 6.57 (d, <i>J</i> = 8.0 Hz, 1H), 4.37 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.27–4.20 (m, 1H), 4.00–3.92 (m, 1H), 3.79 (t, <i>J</i> = 10.4 Hz, 1H), 3.54–3.43 (m, 2H), 3.34–3.19 (m, 4H), 2.85–2.75 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>4</sub>S, 583.2061; found, 583.2053.</div></div><div id="sec5_1_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-3-(hydroxymethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15c</b>)</h5><div class="NLM_p last">Compound <b>15c</b> (1.2 g, 98.4%) was prepared from <b>14c</b> (2.1 g, 3.6 mmol) in the same manner as described for <b>15a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.73 (d, <i>J</i> = 12.8 Hz, 1H), 6.61 (d, <i>J</i> = 6.4 Hz, 1H), 4.45 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.37–4.31 (m, 1H), 4.17–4.08 (m, 1H), 4.02 (dd, <i>J</i> = 12.4, 3.6 Hz, 1H), 3.92–3.81 (m, 2H), 3.33–3.22 (m, 4H), 2.85–2.76 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S, 341.0966; found, 341.0964.</div></div><div id="sec5_1_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Benzyl (5-Fluoro-4-thiomorpholino-2-(((2<i>S</i>,3<i>R</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13d</b>)</h5><div class="NLM_p last">Compound <b>13d</b> (5.9 g, 85.2%) was prepared from <b>12a</b> (3.1 g, 8.56 mmol) and <b>9d</b> (4 g, 11.56 mmol) in the same manner as described for <b>13c</b>. Red foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 12.4 Hz, 1H), 7.47–7.21 (m, 20H), 7.13 (brs, 1H), 6.45 (brs, 1H), 5.18 (s, 2H), 4.16 (dd, <i>J</i> = 11.2, 2.8 Hz, 1H), 3.81 (dd, <i>J</i> = 11.6, 6.8 Hz, 1H), 3.45 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 3.38–3.28 (m, 2H), 3.27–3.11 (m, 5H), 2.79 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>40</sub>FN<sub>2</sub>O<sub>5</sub>S, 691.2636; found, 691.2628.</div></div><div id="sec5_1_4_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (3<i>S</i>,3<i>aR</i>)-8-Fluoro-7-thiomorpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14d</b>)</h5><div class="NLM_p last">Compound <b>14d</b> (3.9 g, 93.1%) was prepared from <b>13d</b> (5.9 g, 8.55 mmol) in the same manner as described for <b>14a</b>. Pale pink solid. The enantiomeric purity of <b>14d</b> was determined to be 99.20% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> +15.4 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 12.8 Hz, 1H), 7.56–7.18 (m, 15H), 6.57 (d, <i>J</i> = 7.6 Hz, 1H), 4.37 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.27–4.19 (m, 1H), 4.00–3.92 (m, 1H), 3.79 (t, <i>J</i> = 10.4 Hz, 1H), 3.54–3.43 (m, 2H), 3.34–3.19 (m, 4H), 2.85–2.75 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>4</sub>S, 583.2061; found, 583.2048.</div></div><div id="sec5_1_4_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (3<i>S</i>,3<i>aR</i>)-8-Fluoro-3-(hydroxymethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15d</b>)</h5><div class="NLM_p last">Compound <b>15d</b> (2.1 g, 92.1%) was prepared from <b>14d</b> (3.9 g, 6.7 mmol) in the same manner as described for <b>15a</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 12.8 Hz, 1H), 6.58 (d, <i>J</i> = 7.8 Hz, 1H), 4.46 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.38–4.32 (m, 1H), 4.17–4.09 (m, 1H), 4.07–3.98 (m, 1H), 3.92–3.81 (m, 2H), 3.34–3.20 (m, 4H), 2.85–2.75 (m, 4H), 2.11 (t, <i>J</i> = 5.6 Hz, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S, 341.0966; found, 341.0956.</div></div><div id="sec5_1_4_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Benzyl (4-Thiomorpholino-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13e</b>)</h5><div class="NLM_p last">Compound <b>13e</b> (3.2 g, 71.0%) was prepared from <b>12b</b> (1.5 g, 4.36 mmol) and <b>9c</b> (2.26 g, 6.54 mmol) in the same manner as described for <b>13c</b>. Red oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95 (s, 1H), 7.59–7.18 (m, 20H), 7.17–6.89 (m, 1H), 6.67–6.19 (m, 2H), 5.17 (s, 2H), 4.13 (brs, 1H), 3.95–3.72 (m, 1H), 3.55–3.25 (m, 7H), 3.18 (brs, 1H), 2.72 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>41</sub>N<sub>2</sub>O<sub>5</sub>S, 673.2731; found, 673.2712.</div></div><div id="sec5_1_4_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (3<i>R</i>,3<i>aS</i>)-7-Thiomorpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14e</b>)</h5><div class="NLM_p last">Compound <b>14e</b> (2.97 g, 77.7%) was prepared from <b>13e</b> (2.7 g, 4 mmol) in the same manner as described for <b>14c</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87 (d, <i>J</i> = 8.4 Hz, 1H), 7.53–7.14 (m, 15H), 6.81–6.36 (m, 2H), 4.38 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.28–4.18 (m, 1H), 4.03–3.93 (m, 1H), 3.84 (t, <i>J</i> = 10.4 Hz, 1H), 3.60–3.42 (m, 6H), 2.74 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub>S, 565.2156; found, 565.2137.</div></div><div id="sec5_1_4_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (3<i>R</i>,3<i>aS</i>)-3-(Hydroxymethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15e</b>)</h5><div class="NLM_p last">Compound <b>15e</b> (626 mg, 68.5%) was prepared from <b>14e</b> (1.6 g, 2.84 mmol) in the same manner as described for <b>15a</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 6.61 (dd, <i>J</i> = 9.2, 2.8 Hz, 1H), 6.52 (d, <i>J</i> = 2.8 Hz, 1H), 4.54–4.44 (m, 1H), 4.43–4.36 (m, 1H), 4.08–3.86 (m, 2H), 3.78–3.61 (m, 2H), 3.49–3.41 (m, 4H), 2.69–2.61 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>S, 323.1060; found, 323.1050.</div></div><div id="sec5_1_4_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Benzyl (4-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-5-fluoro-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13f</b>)</h5><div class="NLM_p last">Compound <b>13f</b> (2.3 g, 33.3%) was prepared from <b>12c</b> (3.62 g, 10 mmol) and <b>9c</b> (4.5 g, 13 mmol) in the same manner as described for <b>13c</b>. Off-white foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.84 (d, <i>J</i> = 13.6 Hz, 1H), 7.47–7.19 (m, 20H), 7.03 (s, 1H), 6.34 (d, <i>J</i> = 7.6 Hz, 1H), 5.18 (s, 2H), 4.27 (brs, 2H), 4.18 (d, <i>J</i> = 11.6 Hz, 1H), 3.83–3.74 (m, 1H), 3.43 (dd, <i>J</i> = 10.8, 5.6 Hz, 1H), 3.36–3.23 (m, 4H), 3.14 (dd, <i>J</i> = 10.4, 4.8 Hz, 1H), 2.17–1.93 (m, 6H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>43</sub>H<sub>42</sub>FN<sub>2</sub>O<sub>5</sub>S, 717.2793; found, 717.2767.</div></div><div id="sec5_1_4_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (3<i>R</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14f</b>)</h5><div class="NLM_p last">Compound <b>14f</b> (1.7 g, 94.4%) was prepared from <b>13f</b> (2.1 g, 3 mmol) in the same manner as described for <b>14c</b>. Light purple solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.70 (d, <i>J</i> = 14.4 Hz, 1H), 7.47–7.41 (m, 6H), 7.36–7.23 (m, 9H), 6.40 (d, <i>J</i> = 8.0 Hz, 1H), 4.38–4.31 (m, 3H), 4.27–4.20 (m, 1H), 4.01–3.93 (m, 1H), 3.81 (t, <i>J</i> = 10.4 Hz, 1H), 3.54–3.43 (m, 2H), 3.38–3.28 (m, 2H), 2.21–1.99 (m, 6H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>36</sub>H<sub>34</sub>FN<sub>2</sub>O<sub>4</sub>S, 609.2218; found, 609.2198.</div></div><div id="sec5_1_4_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (3<i>R</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-3-(hydroxymethyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15f</b>)</h5><div class="NLM_p last">Compound <b>15f</b> (0.83 g, 84.0%) was prepared from <b>14f</b> (1.64 g, 2.7 mmol) in the same manner as described for <b>15a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.71 (d, <i>J</i> = 14.4 Hz, 1H), 6.43 (d, <i>J</i> = 8.0 Hz, 1H), 4.44 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.41–4.31 (m, 3H), 4.18–4.10 (m, 1H), 4.02 (dd, <i>J</i> = 12.4, 4.0 Hz, 1H), 3.93–3.82 (m, 2H), 3.41–3.31 (m, 2H), 2.22–2.02 (m, 7H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>S, 367.1122; found, 367.1118.</div></div><div id="sec5_1_4_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Benzyl (5-Fluoro-4-morpholino-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13g</b>)</h5><div class="NLM_p last">Compound <b>13g</b> (2.3 g, 74.2%) was prepared from <b>12d</b> (1.7 g, 4.59 mmol) and <b>9c</b> (2.3 g, 6.63 mmol) in the same manner as described for <b>13c</b>. Off-white foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.91 (d, <i>J</i> = 13.2 Hz, 1H), 7.51–7.19 (m, 20H), 7.12 (s, 1H), 6.43 (d, <i>J</i> = 7.2 Hz, 1H), 5.18 (s, 2H), 4.17 (dd, <i>J</i> = 11.2, 2.8 Hz, 1H), 3.95–3.68 (m, 5H), 3.45 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H), 3.39–3.23 (m, 2H), 3.16 (dd, <i>J</i> = 10.4, 4.8 Hz, 1H), 3.04–2.87 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>40</sub>FN<sub>2</sub>O<sub>6</sub>, 675.2865; found, 675.2858.</div></div><div id="sec5_1_4_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-7-morpholino-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14g</b>)</h5><div class="NLM_p last">Compound <b>14g</b> (1.78 g, 92.7%) was prepared from <b>13g</b> (2.3 g, 3.4 mmol) in the same manner as described for <b>14c</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 13.2 Hz, 1H), 7.57–7.14 (m, 15H), 6.53 (d, <i>J</i> = 7.6 Hz, 1H), 4.38 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 4.28–4.18 (m, 1H), 4.06–3.92 (m, 1H), 3.92–3.72 (m, 5H), 3.56–3.43 (m, 2H), 3.15–2.89 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>34</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>5</sub>, 567.2290; found, 567.2284.</div></div><div id="sec5_1_4_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-3-(hydroxymethyl)-7-morpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15g</b>)</h5><div class="NLM_p last">To a mixture of <b>14g</b> (1.7 g, 3 mmol), MeOH (1.3 mL), and DCM (9 mL) was added TsOH·H<sub>2</sub>O (1.14 g, 6 mmol). The resulting mixture was stirred overnight. Saturated NaHCO<sub>3</sub> aqueous was added to adjust to weak alkalinity and extracted with DCM. The combined organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. To the residue was added a mixture of DCM (20 mL) and PE (20 mL) and stirred for 1 h. The mixture was filtered, and the filter cake was dried to give <b>15g</b> (865 mg, 89.0%) as a purple solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 13.2 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 4.46 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.38–4.31 (m, 1H), 4.18–4.10 (m, 1H), 4.07–3.97 (m, 1H), 3.96–3.77 (m, 6H), 3.13–2.92 (m, 4H), 2.23 (brs, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>5</sub>, 325.1194; found, 325.1192.</div></div><div id="sec5_1_4_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Benzyl (4-(4,4-Difluoropiperidin-1-yl)-5-fluoro-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13h</b>)</h5><div class="NLM_p last">Compound <b>13h</b> (2.2 g, 76.3%) was prepared from <b>12e</b> (1.6 g, 4.2 mmol) and <b>9c</b> (1.87 g, 5.4 mmol) in the same manner as described for <b>13c</b>. Pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.92 (d, <i>J</i> = 13.2 Hz, 1H), 7.51–7.19 (m, 20H), 7.13 (s, 1H), 6.44 (d, <i>J</i> = 7.6 Hz, 1H), 5.18 (s, 2H), 4.17 (dd, <i>J</i> = 11.2, 2.0 Hz, 1H), 3.81 (dd, <i>J</i> = 11.2, 6.4 Hz, 1H), 3.46 (dd, <i>J</i> = 10.4, 4.8 Hz, 1H), 3.37–3.29 (m, 2H), 3.16 (dd, <i>J</i> = 10.4, 4.8 Hz, 1H), 3.05 (t, <i>J</i> = 5.6 Hz, 4H), 2.22–2.01 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>42</sub>H<sub>40</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>, 709.2884; found, 709.2866.</div></div><div id="sec5_1_4_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (3<i>R</i>,3<i>aS</i>)-7-(4,4-Difluoropiperidin-1-yl)-8-fluoro-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14h</b>)</h5><div class="NLM_p last">Compound <b>14h</b> (2.97 g, 77.7%) was prepared from <b>13h</b> (4.5 g, 6.36 mmol) in the same manner as described for <b>14c</b>. Light pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 13.2 Hz, 1H), 7.54–7.18 (m, 15H), 6.55 (d, <i>J</i> = 7.6 Hz, 1H), 4.37 (dd, <i>J</i> = 10.4, 2.4 Hz, 1H), 4.29–4.17 (m, 1H), 4.02–3.90 (m, 1H), 3.78 (t, <i>J</i> = 10.4 Hz, 1H), 3.59–3.41 (m, 2H), 3.23–3.03 (m, 4H), 2.28–2.00 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>32</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>, 601.2309; found, 601.2305.</div></div><div id="sec5_1_4_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (3<i>R</i>,3<i>aS</i>)-7-(4,4-Difluoropiperidin-1-yl)-8-fluoro-3-(hydroxymethyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15h</b>)</h5><div class="NLM_p last">Compound <b>15h</b> (2.97 g, 77.7%) was prepared from <b>14h</b> (2.9 g, 4.83 mmol) in the same manner as described for <b>15a</b>. Light pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.78 (d, <i>J</i> = 13.2 Hz, 1H), 6.75 (d, <i>J</i> = 7.6 Hz, 1H), 4.47 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.39–4.32 (m, 1H), 4.18–4.11 (m, 1H), 4.03 (dd, <i>J</i> = 12.4, 4.0 Hz, 1H), 3.92–3.83 (m, 2H), 3.28–3.13 (m, 4H), 2.28–2.14 (m, 5H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>, 359.1213; found, 359.1208.</div></div><div id="sec5_1_4_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Benzyl (5-Fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-2-(((2<i>R</i>,3<i>S</i>)-3-((trityloxy)methyl)oxiran-2-yl)methoxy)phenyl)carbamate (<b>13i</b>)</h5><div class="NLM_p last">Compound <b>13i</b> (488 mg, 71.1%) was prepared from <b>12f</b> (358 mg, 1 mmol) and <b>9c</b> (467 mg, 1.35 mmol) in the same manner as described for <b>13c</b>. Yellow semisolid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 12.0 Hz, 1H), 7.49–7.18 (m, 20H), 7.00 (s, 1H), 5.93 (d, <i>J</i> = 8.0 Hz, 1H), 5.17 (s, 2H), 4.81 (s, 4H), 4.13 (dd, <i>J</i> = 11.2, 2.8 Hz, 1H), 4.05–3.93 (m, 4H), 3.81 (dd, <i>J</i> = 11.6, 6.8 Hz, 1H), 3.44 (dd, <i>J</i> = 10.8, 5.6 Hz, 1H), 3.36–3.25 (m, 2H), 3.17 (dd, <i>J</i> = 10.4, 4.8 Hz, 1H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>42</sub>H<sub>40</sub>FN<sub>2</sub>O<sub>6</sub>, 687.2865; found, 687.2842.</div></div><div id="sec5_1_4_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3-((trityloxy)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>14i</b>)</h5><div class="NLM_p last">Compound <b>14i</b> (425 mg, 56.6%) was prepared from <b>13i</b> (0.9 g, 1.3 mmol) in the same manner as described for <b>14c</b>. White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 12.8 Hz, 1H), 7.48–7.18 (m, 15H), 6.03 (d, <i>J</i> = 8.0 Hz, 1H), 4.82 (s, 4H), 4.35 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.26–4.17 (m, 1H), 4.05 (d, <i>J</i> = 2.0 Hz, 4H), 3.98–3.89 (m, 1H), 3.78 (t, <i>J</i> = 10.0 Hz, 1H), 3.53–3.41 (m, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>32</sub>FN<sub>2</sub>O<sub>5</sub>, 579.2290; found, 579.2297.</div></div><div id="sec5_1_4_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (3<i>R</i>,3<i>aS</i>)-8-Fluoro-3-(hydroxymethyl)-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>15i</b>)</h5><div class="NLM_p last">Compound <b>15i</b> (60 mg, 95.2%) was prepared from <b>14i</b> (107 mg, 0.19 mmol) in the same manner as described for <b>15g</b>. Semisolid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.47 (d, <i>J</i> = 13.6 Hz, 1H), 6.15 (d, <i>J</i> = 8.8 Hz, 1H), 4.69 (s, 4H), 4.57–4.31 (m, 2H), 4.08–3.84 (m, 6H), 3.78–3.58 (m, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>5</sub>, 337.1194; found, 337.1189.</div></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Synthesis of the Target Compounds <b>19a–t</b></h4><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> <i>trans</i>-(8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16a</b>)</h5><div class="NLM_p last">To a mixture of <b>15a</b> (172 mg, 0.51 mmol), triethylamine (0.11 mL, 0.77 mmol), and DMAP (5 mg) in DCM (7 mL) was added <i>p</i>-methylbenzenesulfonyl chloride (116 mg, 0.61 mmol) portionwise at 0 °C. The reaction mixture was stirred for 1.5 h and diluted with DCM. The organic phase was washed sequentially with water, 10% citric acid solution, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give <b>16a</b> (197 mg, 67.1%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 7.5 Hz, 2H), 7.67 (d, <i>J</i> = 13.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 6.62 (brs, 1H), 4.51–4.40 (m, 2H), 4.37–4.21 (m, 2H), 4.08–3.98 (m, 1H), 3.82 (t, <i>J</i> = 10.5 Hz, 1H), 3.37–3.20 (m, 4H), 2.82 (brs, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 495.1054; found, 495.1032.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> <i>trans</i>-2-((8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isoindoline-1,3-dione (<b>17a</b>)</h5><div class="NLM_p last">To a solution of <b>16a</b> (572 mg, 1.16 mmol) in DMF (6 mL) was added potassium phthalimide (429 mg, 2.32 mmol). The reaction mixture was stirred at 80 °C for 2 h and cooled to room temperature. Water (8 mL) was added. The precipitate was formed and filtered. The filter cake was washed with water and dried to afford <b>17a</b> (471 mg, 86.6%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (dd, <i>J</i> = 5.5, 3.0 Hz, 2H), 7.78 (dd, <i>J</i> = 5.0, 3.0 Hz, 2H), 7.71 (d, <i>J</i> = 12.5 Hz, 1H), 6.64 (brs, 1H), 4.65–4.61 (m, 1H), 4.42 (dd, <i>J</i> = 10.5, 3.0 Hz, 1H), 4.22 (dd, <i>J</i> = 14.0, 6.5 Hz, 1H), 4.10–3.98 (m, 2H), 3.83 (t, <i>J</i> = 10.0 Hz, 1H), 3.37–3.22 (m, 4H), 2.83 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>S, 470.1180; found, 470.1182.</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> <i>trans</i>-3-(Aminomethyl)-8-fluoro-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18a</b>)</h5><div class="NLM_p last">To a suspension of <b>17a</b> (441 mg, 0.94 mmol) in MeOH (6 mL) was added a solution of methylamine in methanol (33%, 3 mL). The reaction mixture was refluxed for 2.5 h and cooled to room temperature. After cooling, water was added for dilution, and the mixture was extracted three times with EtOAc. The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH/ammonium hydroxide = 100/2/1) to afford <b>18a</b> (281 mg, 88.1%) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 13.0 Hz, 1H), 6.55 (d, <i>J</i> = 7.5 Hz, 1H), 4.45 (dd, <i>J</i> = 10.5, 3.0 Hz, 1H), 4.30–4.22 (m, 1H), 4.08–3.98 (m, 1H), 3.86 (t, <i>J</i> = 10.0 Hz, 1H), 3.34–3.20 (m, 4H), 3.15 (dd, <i>J</i> = 13.5, 4.5 Hz, 1H), 3.08 (dd, <i>J</i> = 14.0, 5.5 Hz, 1H), 2.80 (t, <i>J</i> = 4.5 Hz, 4H), 1.30 (brs, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 153.5, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.8 (d, <i>J</i> = 11.0 Hz), 117.2 (d, <i>J</i> = 11.0 Hz), 108.2 (d, <i>J</i> = 4.0 Hz), 107.2 (d, <i>J</i> = 24.0 Hz), 77.1, 66.9, 53.4, 53.30, 53.28, 44.1, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>O<sub>3</sub>N<sub>3</sub>FS, 340.1126; found, 340.1116.</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> <i>trans</i>-<i>N</i>-((-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19a</b>)</h5><div class="NLM_p last">To a mixture of <b>18a</b> (123 mg, 0.36 mmol) and pyridine (0.044 mL, 0.54 mmol) in DCM (5 mL) in an ice bath was added acetic anhydride (0.044 mL, 0.47 mmol). The reaction was stirred for 1.5 h and diluted with DCM. The organic phase was washed sequentially with water, diluted hydrochloric acid, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (DCM/MeOH = 99/1) to give <b>19a</b> (112 mg, 81.8%) as an off-white solid. mp 220–222 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.71 (d, <i>J</i> = 13.0 Hz, 1H), 6.58 (d, <i>J</i> = 7.5 Hz, 1H), 6.06 (t, <i>J</i> = 5.5 Hz, 1H), 4.50 (dd, <i>J</i> = 10.5, 2.5 Hz, 1H), 4.43–4.34 (m, 1H), 3.96–3.87 (m, 1H), 3.83 (t, <i>J</i> = 10.0 Hz, 1H), 3.78–3.63 (m, 2H), 3.34–3.20 (m, 4H), 2.81 (t, <i>J</i> = 4.5 Hz, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.9, 153.1, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 3.0 Hz), 138.0 (d, <i>J</i> = 10.0 Hz), 116.8 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 3.0 Hz), 107.0 (d, <i>J</i> = 28.0 Hz), 75.2, 66.4, 53.28, 53.25, 53.0, 41.2, 27.9, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>4</sub>S, 382.1231; found, 382.1220.</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> <i>cis</i>-(8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16b</b>)</h5><div class="NLM_p last">Compound <b>16b</b> (887 mg, 72.4%) was prepared from <b>15b</b> (842 mg, 2.48 mmol) in the same manner as described for <b>16a</b>. Pale-orange foam solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.85–7.74 (m, 3H), 7.39 (d, <i>J</i> = 6.0 Hz, 2H), 6.76 (s, 1H), 5.00–4.89 (m, 1H), 4.53 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 4.31 (t, <i>J</i> = 6.8 Hz, 1H), 4.18–4.12 (m, 2H), 3.94 (t, <i>J</i> = 8.4 Hz, 1H), 3.41–3.25 (m, 4H), 2.86 (brs, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 495.1040; found, 495.1054.</div></div><div id="sec5_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> <i>cis</i>-2-((8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isoindoline-1,3-dione (<b>17b</b>)</h5><div class="NLM_p last">Compound <b>17b</b> (675 mg, 85.7%) was prepared from <b>16b</b> (830 mg, 1.68 mmol) in the same manner as described for <b>17a</b>. White solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.95–7.82 (m, 3H), 7.82–7.74 (m, 2H), 7.05 (s, 1H), 5.30–5.17 (m, 1H), 4.59 (d, <i>J</i> = 9.5 Hz, 1H), 4.33 (t, <i>J</i> = 8.5 Hz, 1H), 4.15–4.00 (m, 2H), 3.75 (dd, <i>J</i> = 14.0, 3.5 Hz, 1H), 3.42 (s, 4H), 2.96 (s, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>S, 470.1170; found, 470.1180.</div></div><div id="sec5_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> <i>cis</i>-3-(Aminomethyl)-8-fluoro-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18b</b>)</h5><div class="NLM_p last">Compound <b>18b</b> (330 mg, 76.0%) was prepared from <b>17b</b> (600 mg, 1.28 mmol) in the same manner as described for <b>18a</b>. White solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 12.8 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 4.82–4.71 (m, 1H), 4.50 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.30–4.17 (m, 1H), 4.07 (t, <i>J</i> = 10.4 Hz, 1H), 3.35–3.18 (m, 4H), 3.08–2.91 (m, 2H), 2.87–2.74 (m, 4H), 1.25 (brs, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 153.5, 150.3 (d, <i>J</i> = 238.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.7 (d, <i>J</i> = 10.0 Hz), 117.6 (d, <i>J</i> = 12.0 Hz), 108.2 (d, <i>J</i> = 3.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 76.2, 63.8, 53.30, 53.27, 52.9, 41.4, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>O<sub>3</sub>N<sub>3</sub>FS, 340.1118; found, 340.1126.</div></div><div id="sec5_1_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <i>cis</i>-<i>N</i>-((-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19b</b>)</h5><div class="NLM_p last">Compound <b>19b</b> (82 mg, 74.2%) was prepared from <b>18b</b> (100 mg, 0.29 mmol) in the same manner as described for <b>19a</b>. White solid. mp 253–255 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.79 (d, <i>J</i> = 13.0 Hz, 1H), 6.91 (s, 1H), 6.03 (s, 1H), 4.90 (t, <i>J</i> = 8.5 Hz, 1H), 4.52 (d, <i>J</i> = 10.5 Hz, 1H), 4.27 (t, <i>J</i> = 9.0 Hz, 1H), 3.90 (t, <i>J</i> = 10.5 Hz, 2H), 3.38 (s, 4H), 3.23–3.07 (m, 1H), 2.92 (s, 4H), 2.04 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.4, 152.9, 150.3 (d, <i>J</i> = 240.0 Hz), 140.3 (d, <i>J</i> = 2.0 Hz), 138.0, 117.2 (d, <i>J</i> = 9.0 Hz), 108.4 (d, <i>J</i> = 2.0 Hz), 107.1 (d, <i>J</i> = 28.0 Hz), 74.0, 63.3, 53.30, 53.27, 52.5, 39.0, 27.9, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>O<sub>4</sub>N<sub>3</sub>FS, 382.1221; found, 382.1231.</div></div><div id="sec5_1_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> ((3<i>R</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16c</b>)</h5><div class="NLM_p last">Compound <b>16c</b> (1.59 g, 85.0%) was prepared from <b>15c</b> (1.2 g, 3.53 mmol) in the same manner as described for <b>16a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.88–7.73 (m, 2H), 7.67 (d, <i>J</i> = 12.8 Hz, 1H), 7.46–7.33 (m, 2H), 6.62 (d, <i>J</i> = 7.0 Hz, 1H), 4.50–4.40 (m, 2H), 4.33 (dd, <i>J</i> = 11.2, 4.4 Hz, 1H), 4.26 (dd, <i>J</i> = 11.2, 6.0 Hz, 1H), 4.07–3.99 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.33–3.23 (m, 4H), 2.86–2.78 (m, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 495.1054; found, 495.1056.</div></div><div id="sec5_1_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 2-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isoindoline-1,3-dione (<b>17c</b>)</h5><div class="NLM_p last">Compound <b>17c</b> (243 mg, 88.0%) was prepared from <b>16c</b> (0.29 g, 0.59 mmol) in the same manner as described for <b>17a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94–7.87 (m, 2H), 7.83–7.72 (m, 3H), 6.91 (brs, 1H), 4.67–4.60 (m, 1H), 4.44 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.22 (dd, <i>J</i> = 14.4, 6.8 Hz, 1H), 4.10–4.01 (m, 2H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.38 (brs, 4H), 2.92 (brs, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>O<sub>5</sub>N<sub>3</sub>FS, 470.1180; found, 470.1181.</div></div><div id="sec5_1_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (3<i>S</i>,3<i>aS</i>)-3-(Aminomethyl)-8-fluoro-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18c</b>)</h5><div class="NLM_p last">Compound <b>18c</b> (130 mg, 89.2%) was prepared from <b>17c</b> (200 mg, 0.43 mmol) in the same manner as described for <b>18a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 12.8 Hz, 1H), 6.55 (d, <i>J</i> = 7.6 Hz, 1H), 4.45 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.29–4.23 (m, 1H), 4.07–4.00 (m, 1H), 3.86 (t, <i>J</i> = 10.4 Hz, 1H), 3.32–3.20 (m, 4H), 3.19–3.04 (m, 2H), 2.83–2.76 (m, 4H), 1.41 (brs, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 153.5, 150.3 (d, <i>J</i> = 238.0 Hz), 140.4 (d, <i>J</i> = 3.0 Hz), 137.8 (d, <i>J</i> = 11.0 Hz), 117.2 (d, <i>J</i> = 11.0 Hz), 108.2 (d, <i>J</i> = 3.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 77.1, 66.9, 53.4, 53.33, 53.31, 44.2, 28.0. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>3</sub>S, 340.1126; found, 340.1111.</div></div><div id="sec5_1_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19c</b>)</h5><div class="NLM_p last">Compound <b>19c</b> (128 mg, 63.4%) was prepared from <b>18c</b> (0.18 g, 0.53 mmol) in the same manner as described for <b>19a</b>. Off-white solid. mp 190–192 °C. The corresponding product was analyzed by chiral HPLC (IC, 5 μm, 4.6 mm × 250 mmL; eluent: hexane/ethanol, 65/35; flow rate: 1 mL/min; λ <b>=</b> 254 nm; <i>T</i> = 20 °C): <i>t</i><sub>R</sub> = 17.40 min (0.09%) and <i>t</i><sub>R</sub> = 24.44 min (99.91%). The enantiomeric purity of <b>19c</b> was determined to be 99.82% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> −18.3 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 12.5 Hz, 1H), 6.59 (d, <i>J</i> = 6.0 Hz, 1H), 6.28 (t, <i>J</i> = 5.5 Hz, 1H), 4.51 (dd, <i>J</i> = 10.0, 2.5 Hz, 1H), 4.43–4.37 (m, 1H), 3.95–3.88 (m, 1H), 3.85 (t, <i>J</i> = 10.5 Hz, 1H), 3.79–3.63 (m, 2H), 3.35–3.20 (m, 4H), 2.81 (brs, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 171.1, 153.2, 150.2 (d, <i>J</i> = 238.8 Hz), 140.4, 137.9 (d, <i>J</i> = 10.0 Hz), 116.8 (d, <i>J</i> = 11.2 Hz), 108.4, 106.9 (d, <i>J</i> = 27.5 Hz), 75.3, 66.4, 53.2, 53.0, 41.1, 27.8, 23.0. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>4</sub>S, 382.1231; found, 382.1222.</div></div><div id="sec5_1_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> ((3<i>S</i>,3<i>aR</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16d</b>)</h5><div class="NLM_p last">Compound <b>16d</b> (2.9 g, 100.0%) was prepared from <b>15d</b> (2 g, 5.88 mmol) in the same manner as described for <b>16a</b>. Pink solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.66 (d, <i>J</i> = 12.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 6.57 (d, <i>J</i> = 7.6 Hz, 1H), 4.50–4.40 (m, 2H), 4.37–4.22 (m, 2H), 4.07–3.99 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.35–3.20 (m, 4H), 2.86–2.78 (m, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 495.1054; found, 495.1041.</div></div><div id="sec5_1_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 2-(((3<i>R</i>,3<i>aR</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isoindoline-1,3-dione (<b>17d</b>)</h5><div class="NLM_p last">Compound <b>17d</b> (2.55 g, 92.7%) was prepared from <b>16d</b> (2.9 g, 5.86 mmol) in the same manner as described for <b>17a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94–7.87 (m, 2H), 7.83–7.72 (m, 2H), 6.69 (d, <i>J</i> = 12.8 Hz, 1H), 6.54 (d, <i>J</i> = 8.0 Hz, 1H), 4.67–4.60 (m, 1H), 4.42 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.22 (dd, <i>J</i> = 14.0, 6.8 Hz, 1H), 4.10–4.01 (m, 2H), 3.83 (t, <i>J</i> = 10.4 Hz, 1H), 3.33–3.18 (m, 4H), 2.87–2.72 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>21</sub>O<sub>5</sub>N<sub>3</sub>FS, 470.1180; found, 470.1174.</div></div><div id="sec5_1_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> (3<i>R</i>,3<i>aR</i>)-3-(Aminomethyl)-8-fluoro-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18d</b>)</h5><div class="NLM_p last">Compound <b>18d</b> (1.64 g, 90.6%) was prepared from <b>17d</b> (2.5 g, 5.33 mmol) in the same manner as described for <b>18a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 13.0 Hz, 1H), 6.55 (d, <i>J</i> = 7.8 Hz, 1H), 4.45 (dd, <i>J</i> = 10.4, 3.0 Hz, 1H), 4.29–4.23 (m, 1H), 4.07–4.00 (m, 1H), 3.86 (t, <i>J</i> = 10.2 Hz, 1H), 3.32–3.20 (m, 4H), 3.19–3.04 (m, 2H), 2.83–2.76 (m, 4H), 1.35 (brs, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 153.5, 150.3 (d, <i>J</i> = 238.0 Hz), 140.4 (d, <i>J</i> = 3.0 Hz), 137.8 (d, <i>J</i> = 11.0 Hz), 117.2 (d, <i>J</i> = 11.0 Hz), 108.2 (d, <i>J</i> = 3.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 77.1, 66.9, 53.4, 53.31, 53.28, 44.1, 28.0. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>3</sub>S, 340.1126; found, 340.1115.</div></div><div id="sec5_1_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> <i>N</i>-(((3<i>R</i>,3<i>aR</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19d</b>)</h5><div class="NLM_p last">Compound <b>19d</b> (1.44 g, 80.1%) was prepared from <b>18d</b> (1.6 g, 4.72 mmol) in the same manner as described for <b>19a</b>. Off-white solid. mp 210–212 °C. The enantiomeric purity of 1<b>9d</b> was determined to be 100% ee. [α]<sub class="stack">D</sub><sup class="stack">24</sup> +15.1 (<i>c</i> 1, CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.68 (d, <i>J</i> = 13.2 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 6.38 (t, <i>J</i> = 6.0 Hz, 1H), 4.50 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.45–4.37 (m, 1H), 3.97–3.88 (m, 1H), 3.83 (t, <i>J</i> = 10.0 Hz, 1H), 3.71 (t, <i>J</i> = 4.0 Hz, 2H), 3.32–3.19 (m, 4H), 2.86–2.72 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.1, 153.2, 150.2 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 3.0 Hz), 138.0 (d, <i>J</i> = 12.0 Hz), 116.8 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 5.0 Hz), 106.9 (d, <i>J</i> = 28.0 Hz), 75.3, 66.4, 53.3, 53.2, 53.0, 41.2, 27.9, 23.0. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>4</sub>S, 382.1231; found, 382.1230.</div></div><div id="sec5_1_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (3<i>R</i>,3<i>aS</i>)-8-(Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl Acetate (<b>19e</b>)</h5><div class="NLM_p last">To a solution of <b>15c</b> (340 mg, 1 mmol) in DCM (6 mL) was added Et<sub>3</sub>N (0.21 mL, 1.5 mmol) in an ice bath. Acetyl chloride (0.086 mL, 1.2 mmol) was added and stirred for 0.5 h at room temperature. The reaction mixture was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was stirred in a solution of EtOAc (4 mL) and PE (2 mL) to give <b>19e</b> (308 mg, 80.6%) as a white solid. mp 195–197 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 12.5 Hz, 1H), 6.58 (d, <i>J</i> = 7.0 Hz, 1H), 4.52–4.32 (m, 4H), 4.05–3.95 (m, 1H), 3.87 (t, <i>J</i> = 10.0 Hz, 1H), 3.36–3.20 (m, 4H), 2.81 (brs, 4H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.3, 152.9, 150.3 (d, <i>J</i> = 239.0 Hz), 140.3 (d, <i>J</i> = 2.0 Hz), 138.0 (d, <i>J</i> = 10.0 Hz), 116.9 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 3.0 Hz), 107.3 (d, <i>J</i> = 28.0 Hz), 73.2, 66.5, 63.2, 53.28, 53.25, 52.8, 27.9, 20.6. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>5</sub>S, 383.1071; found, 383.1058.</div></div><div id="sec5_1_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)methanesulfonamide (<b>19f</b>)</h5><div class="NLM_p last">Compound <b>19f</b> (43 mg, 51.8%) was prepared from <b>18c</b> (70 mg, 0.175 mmol) and methylsulfonyl chloride (0.016 mL, 0.21 mmol) in the same manner as described for <b>19e</b>. Off-white solid. mp 234–235 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.61–7.51 (m, 2H), 6.68 (d, <i>J</i> = 8.4 Hz, 1H), 4.55–4.47 (m, 2H), 4.04–3.94 (m, 2H), 3.50–3.35 (m, 2H), 3.24–3.12 (m, 4H), 2.97 (s, 3H), 2.77–2.69 (m, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 153.1, 149.1 (d, <i>J</i> = 237.0 Hz), 140.5 (d, <i>J</i> = 1.5 Hz), 137.0 (d, <i>J</i> = 10.5 Hz), 117.3 (d, <i>J</i> = 10.5 Hz), 108.5 (d, <i>J</i> = 3.0 Hz), 105.9 (d, <i>J</i> = 27.0 Hz), 74.6, 65.7, 52.9, 52.5, 44.1, 40.0, 27.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>S<sub>2</sub>, 418.0901; found, 418.0894.</div></div><div id="sec5_1_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isobutyramide (<b>19g</b>)</h5><div class="NLM_p last">Compound <b>19g</b> (38 mg, 58.5%) was prepared from <b>18c</b> (55 mg, 0.16 mmol) and isobutyryl chloride (0.020 mL, 0.18 mmol) in the same manner as described for <b>19e</b>. Off-white solid. mp 193–195 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 13.2 Hz, 1H), 7.01 (brs, 1H), 6.06 (t, <i>J</i> = 5.6 Hz, 1H), 4.51 (dd, <i>J</i> = 10.0, 2.4 Hz, 1H), 4.45–4.36 (m, 1H), 4.00–3.87 (m, 1H), 3.86–3.62 (m, 3H), 3.50–3.33 (m, 4H), 2.94 (brs, 4H), 2.49–2.36 (m, 1H), 1.17 (d, <i>J</i> = 4.0 Hz, 3H), 1.16 (d, <i>J</i> = 4.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 177.9, 153.2, 150.3 (d, <i>J</i> = 239.0 Hz), 140.5 (d, <i>J</i> = 2.0 Hz), 137.9, 117.0, 108.4 (d, <i>J</i> = 1.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 75.3, 66.4, 53.3, 53.1, 41.3, 35.5, 27.9, 19.6, 19.4. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>25</sub>FN<sub>3</sub>O<sub>4</sub>S, 410.1544; found, 410.1528.</div></div><div id="sec5_1_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclopropanecarboxamide (<b>19h</b>)</h5><div class="NLM_p last">Compound <b>19h</b> (86 mg, 70.5%) was prepared from <b>18c</b> (0.10 g, 0.30 mmol) and cyclopropanecarbonyl chloride (0.035 mL, 0.39 mmol) in the same manner as described for <b>19e</b>. Off-white solid. mp 209–211 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 13.2 Hz, 1H), 6.60 (d, <i>J</i> = 7.6 Hz, 1H), 6.16 (t, <i>J</i> = 6.0 Hz, 1H), 4.48 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.43–4.36 (m, 1H), 3.95–3.88 (m, 1H), 3.82 (t, <i>J</i> = 10.0 Hz, 1H), 3.79–3.65 (m, 2H), 3.32–3.23 (m, 4H), 2.86–2.76 (m, 4H), 1.45–1.36 (m, 1H), 1.01–0.94 (m, 2H), 0.85–0.77 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 174.8, 153.3, 150.3 (d, <i>J</i> = 240.0 Hz), 140.5 (d, <i>J</i> = 3.0 Hz), 137.8 (d, <i>J</i> = 12.0 Hz), 117.1 (d, <i>J</i> = 9.0 Hz), 108.5 (d, <i>J</i> = 2.0 Hz), 107.0 (d, <i>J</i> = 28.0 Hz), 75.5, 66.5, 53.4, 53.3, 53.1, 41.3, 27.9, 14.6, 7.8. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>4</sub>S, 408.1388; found, 408.1379.</div></div><div id="sec5_1_5_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclobutanecarboxamide (<b>19i</b>)</h5><div class="NLM_p last">Compound <b>19i</b> (30 mg, 24.8%) was prepared from <b>18c</b> (98 mg, 0.29 mmol) and cyclobutanecarbonyl chloride (0.037 mL, 0.37 mmol) in the same manner as described for <b>19e</b>. Off-white solid. mp 176–178 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.71 (d, <i>J</i> = 12.8 Hz, 1H), 6.63 (d, <i>J</i> = 7.2 Hz, 1H), 5.83 (t, <i>J</i> = 6.4 Hz, 1H), 4.50 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.42–4.36 (m, 1H), 3.94–3.86 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.78–3.71 (m, 1H), 3.71–3.62 (m, 1H), 3.36–3.22 (m, 4H), 3.11–2.97 (m, 1H), 2.89–2.76 (m, 4H), 2.34–2.11 (m, 4H), 2.07–1.81 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 175.9, 153.2, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 3.0 Hz), 138.0 (d, <i>J</i> = 10.0 Hz), 116.8 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 3.0 Hz), 107.1 (d, <i>J</i> = 28.0 Hz), 75.3, 66.4, 53.29, 53.26, 53.1, 41.2, 39.6, 27.9, 25.3, 18.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>25</sub>FN<sub>3</sub>O<sub>4</sub>S, 422.1544; found, 422.1534.</div></div><div id="sec5_1_5_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isonicotinamide (<b>19j</b>)</h5><div class="NLM_p last"><b>18c</b> (60 mg, 0.18 mmol), isonicotinic acid (26 mg, 0.21 mmol), EDCI (40 mg, 0.21 mmol), HOBt (28 mg, 0.21 mmol), and triethylamine (0.050 mL, 0.35 mmol) were added to a 5 mL flask. DMF (2 mL) was added and stirred overnight at room temperature. The solid can be precipitated by adding ice water and filtered. The obtained solid was purified by column chromatography (DCM/EtOAc/MeOH = 50/50/1) to afford <b>19j</b> (46 mg, 59.0%) as a white solid. mp 135–137 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.77 (d, <i>J</i> = 4.4 Hz, 2H), 7.69 (d, <i>J</i> = 5.6 Hz, 2H), 7.65 (d, <i>J</i> = 12.8 Hz, 1H), 7.35 (t, <i>J</i> = 6.0 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 4.61–4.49 (m, 2H), 4.03–3.93 (m, 2H), 3.92–3.80 (m, 2H), 3.33–3.18 (m, 4H), 2.86–2.75 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.4, 153.2, 150.6, 150.2 (d, <i>J</i> = 240.0 Hz), 140.5 (d, <i>J</i> = 3.0 Hz), 138.2 (d, <i>J</i> = 11.0 Hz), 121.1, 116.6 (d, <i>J</i> = 9.0 Hz), 108.4 (d, <i>J</i> = 3.0 Hz), 107.0 (d, <i>J</i> = 28.0 Hz), 75.2, 66.4, 53.3, 53.2, 42.0, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>FN<sub>4</sub>O<sub>4</sub>S, 445.1340; found, 445.1324.</div></div><div id="sec5_1_5_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)pyrazine-2-carboxamide (<b>19k</b>)</h5><div class="NLM_p last">Compound <b>19k</b> (41 mg, 51.9%) was prepared from <b>18c</b> (60 mg, 0.18 mmol) and pyrazine-2-carboxylic acid (25 mg, 0.21 mmol) in the same manner as described for <b>19j</b>. Pale-yellow solid. mp 212–214 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.38 (d, <i>J</i> = 1.6 Hz, 1H), 8.80 (d, <i>J</i> = 2.0 Hz, 1H), 8.57 (dd, <i>J</i> = 2.4, 1.6 Hz, 1H), 8.27 (t, <i>J</i> = 6.0 Hz, 1H), 7.73 (d, <i>J</i> = 12.8 Hz, 1H), 6.68 (brs, 1H), 4.60–4.46 (m, 2H), 4.08–3.81 (m, 4H), 3.37–3.22 (m, 4H), 2.83 (brs, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.0, 153.0, 150.3 (d, <i>J</i> = 239.0 Hz), 147.9, 144.4, 143.4, 142.8, 140.4 (d, <i>J</i> = 2.0 Hz), 137.8 (d, <i>J</i> = 10.0 Hz), 116.9 (d, <i>J</i> = 11.0 Hz), 108.4 (d, <i>J</i> = 3.0 Hz), 107.1 (d, <i>J</i> = 28.0 Hz), 75.0, 66.4, 53.29, 53.26, 53.2, 41.2, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>4</sub>S, 446.1298; found, 446.1276.</div></div><div id="sec5_1_5_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> Methyl (((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)carbamate (<b>19l</b>)</h5><div class="NLM_p last">To a solution of <b>18c</b> (0.10 g, 0.29 mmol) in THF (9 mL) was added CDI (0.49 g, 3 mmol) and stirred at room temperature for 50 min. Anhydrous methanol (3 mL) was added and stirred overnight at room temperature. The solvent was evaporated, and then, the residue was diluted with DCM. The resulting mixture was washed with saturated ammonium chloride solution and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by column chromatography (PE/EtOAc = 60/40) to afford <b>19l</b> (77 mg, 64.7%) as a white solid. mp 155–156 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.72 (d, <i>J</i> = 12.8 Hz, 1H), 6.56 (d, <i>J</i> = 7.6 Hz, 1H), 5.24 (brs, 1H), 4.49 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.41–4.35 (m, 1H), 3.99–3.91 (m, 1H), 3.84 (t, <i>J</i> = 10.4 Hz, 1H), 3.70 (s, 3H), 3.67–3.58 (m, 2H), 3.36–3.24 (m, 4H), 2.80 (t, <i>J</i> = 5.2 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 157.4, 153.1, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.8 (d, <i>J</i> = 8.0 Hz), 117.1 (d, <i>J</i> = 8.0 Hz), 108.5 (d, <i>J</i> = 2.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 75.2, 66.5, 53.39, 53.37, 52.9, 52.7, 43.0, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>S, 398.1180; found, 398.1172.</div></div><div id="sec5_1_5_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> (3<i>S</i>,3<i>aS</i>)-8-Fluoro-3-((methylamino)methyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>19m</b>)</h5><div class="NLM_p last">A solution of <b>16c</b> (0.090 g, 0.17 mmol) and methylamine methanol solution (3 mL) in THF (3 mL) was heated at 100 °C for 1 h in a sealed tube. The reaction solution was concentrated and purified by column chromatography (DCM/MeOH/ammonium hydroxide = 100/2/1) to afford <b>19m</b> (30 mg, 50.0%) as an off-white solid. mp 155–156 °C. <sup>1</sup>H NM<i>R</i> (400 MHz, CDCl<sub>3</sub>): δ 7.75 (d, <i>J</i> = 12.8 Hz, 1H), 6.54 (d, <i>J</i> = 8.0 Hz, 1H), 4.44 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.39–4.31 (m, 1H), 4.08–3.98 (m, 1H), 3.84 (t, <i>J</i> = 10.4 Hz, 1H), 3.33–3.20 (m, 4H), 3.04–2.91 (m, 2H), 2.83–2.75 (m, 4H), 2.51 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 153.4, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.8 (d, <i>J</i> = 11.0 Hz), 117.2 (d, <i>J</i> = 11.0 Hz), 108.2 (d, <i>J</i> = 3.0 Hz), 107.2 (d, <i>J</i> = 28.0 Hz), 75.5, 66.9, 53.9, 53.8, 53.33, 53.31, 36.7, 28.0. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>3</sub>S, 354.1282; found, 354.1275.</div></div><div id="sec5_1_5_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> (3<i>S</i>,3<i>aS</i>)-8-Fluoro-3-((isoxazol-3-ylamino)methyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>19n</b>)</h5><div class="NLM_p last">To a solution of <i>N</i>-boc-3-aminoisoxazole (0.074 g, 0.4 mmol) in anhydrous DMF (2 mL) cooled in an ice-water bath was added NaH (60%, 17 mg, 0.44 mmol). After stirring for 5 min, <b>16c</b> (197 mg, 0.4 mmol) was added. The reaction mixture was heated at 70 °C for 2 h, and then, water was added, the mixture was extracted with DCM, and the organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (PE/EtOAc = 85/15) to give 181 mg of oil with a yield of 89.4%. To a solution of the abovementioned product (141 mg, 0.28 mmol) in EtOAc (2 mL) was added a solution of HCl in methanol (5 N, 4 mL), and the resulting solution was stirred at room temperature for 0.5 h. The solvent was evaporated, and water (3 mL) was added to the residue. Saturated sodium bicarbonate was used to adjust the pH to alkalinity. The precipitate was filtered. The filter cake was washed with water and dried to afford <b>19n</b> (94 mg, 82.7%) as a white solid. mp 148–150 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.08 (d, <i>J</i> = 2.0 Hz, 1H), 7.73 (d, <i>J</i> = 13.2 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 5.88 (d, <i>J</i> = 1.6 Hz, 1H), 4.61–4.54 (m, 1H), 4.51 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.35 (t, <i>J</i> = 6.4 Hz, 1H), 4.05–3.98 (m, 1H), 3.86 (t, <i>J</i> = 10.0 Hz, 1H), 3.82–3.74 (m, 1H), 3.74–3.65 (m, 1H), 3.31–3.20 (m, 4H), 2.79 (t, <i>J</i> = 5.2 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.3, 158.6, 153.2, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 138.0 (d, <i>J</i> = 10.0 Hz), 116.9 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 3.0 Hz), 107.1 (d, <i>J</i> = 28.0 Hz), 96.3, 74.6, 66.6, 53.27, 53.25, 45.9, 27.9. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>20</sub>FN<sub>4</sub>O<sub>4</sub>S, 407.1184; found, 407.1174.</div></div><div id="sec5_1_5_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> (3<i>S</i>,3<i>aS</i>)-3-((1<i>H</i>-1,2,3-Triazol-1-yl)methyl)-8-fluoro-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>19o</b>)</h5><div class="NLM_p last">To a solution of <b>16c</b> (494 mg, 1 mmol) in DMF (10 mL) was added sodium azide (130 mg, 2 mmol). The reaction mixture was heated at 80 °C for 2.5 h and cooled to room temperature. Ice water (10 mL) was added. The precipitate was filtered, washed with water, and dried to give 343 mg of the azide product as an off-white solid with a yield of 87.7%. A solution of the azide product (0.11 g, 0.3 mmol) and bicyclo[2.2.1]hepta-2,5-diene (0.31 mL, 3 mmol) in 1,4-dioxane (3 mL) was refluxed for 5 h. Then, the reaction was cooled to room temperature and concentrated under reduced pressure. The crude residue was purified by column chromatography (DCM/MeOH = 99/1) to give <b>19o</b> (83 mg, 70.9%) as an off-white solid. mp 223–225 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80–7.77 (m, 2H), 7.64 (d, <i>J</i> = 12.8 Hz, 1H), 6.64 (d, <i>J</i> = 6.8 Hz, 1H), 4.84 (d, <i>J</i> = 4.8 Hz, 2H), 4.72–4.66 (m, 1H), 4.46 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.08–4.00 (m, 1H), 3.84 (t, <i>J</i> = 10.4 Hz, 1H), 3.35–3.23 (m, 4H), 2.83 (t, <i>J</i> = 4.4 Hz, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 152.2, 150.3 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.4 (<i>J</i> = 2.0 Hz), 134.7, 125.1, 117.2, 108.9, 107.4 (d, <i>J</i> = 28.0 Hz), 73.5, 66.2, 53.52, 53.50, 53.1, 51.3, 27.7. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>19</sub>FN<sub>5</sub>O<sub>3</sub>S, 392.1187; found, 392.1178.</div></div><div id="sec5_1_5_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> <i>N</i>-Acetyl-<i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19p</b>)</h5><div class="NLM_p last">To a solution of <b>19c</b> (381 mg, 1 mmol) in acetic anhydride (3 mL) was added DMAP (122 mg, 1 mmol). The mixture was heated at 100 °C for 17 h. Saturated NaHCO<sub>3</sub> aqueous was added to adjust the pH to alkalinity. The mixture was extracted with EtOAc twice. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by preparative TLC (DCM/EtOAc = 80/20) to give <b>19p</b> (93 mg, 22.0%) as a pale yellow solid. mp 176–178 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 12.8 Hz, 1H), 6.58 (d, <i>J</i> = 8.0 Hz, 1H), 4.59 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.47–4.39 (m, 1H), 4.23 (dd, <i>J</i> = 15.2, 2.0 Hz, 1H), 4.03–3.87 (m, 2H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.37–3.15 (m, 4H), 2.86–2.72 (m, 4H), 2.50 (s, 6H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): δ 173.3, 152.4, 150.3 (d, <i>J</i> = 240.0 Hz), 140.3 (d, <i>J</i> = 1.5 Hz), 138.0 (d, <i>J</i> = 10.5 Hz), 116.7 (d, <i>J</i> = 10.5 Hz), 108.4 (d, <i>J</i> = 1.5 Hz), 106.9 (d, <i>J</i> = 28.5 Hz), 75.5, 66.4, 54.1, 53.27, 53.25, 47.9, 27.9, 26.4. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>5</sub>S, 424.1337; found, 424.1322.</div></div><div id="sec5_1_5_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)-<i>N</i>-methylacetamide (<b>19q</b>)</h5><div class="NLM_p last">To a solution of <b>19c</b> (381 mg, 1 mmol) in anhydrous THF (6 mL) cooled in an ice-water bath was added NaH (60%, 148 mg, 1.2 mmol). After stirring for 5 min, MeI (0.075 mL, 1.2 mmol) was added. The reaction mixture was refluxed for 1.5 h, and the solvent was evaporated. The resulting residue was purified by column chromatography (DCM/MeOH = 99/2) to give an oil which was purified by recrystallization (MeOH) to give <b>19q</b> (220 mg, 55.7%) as a white solid. mp 197–199 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.74 (d, <i>J</i> = 12.8 Hz, 1H), 6.58 (d, <i>J</i> = 8.0 Hz, 1H), 4.53 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.50–4.44 (m, 1H), 4.00–3.86 (m, 2H), 3.81 (t, <i>J</i> = 10.0 Hz, 1H), 3.58 (dd, <i>J</i> = 14.4, 6.4 Hz, 1H), 3.33–3.23 (m, 4H), 3.20 (s, 3H), 2.84–2.74 (m, 4H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.8, 153.0, 150.2 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 137.8 (d, <i>J</i> = 11.0 Hz), 117.0 (d, <i>J</i> = 11.0 Hz), 108.3 (d, <i>J</i> = 4.0 Hz), 106.8 (d, <i>J</i> = 26.0 Hz), 76.0, 66.4, 53.5, 53.3, 53.2, 50.2, 38.5, 27.9, 21.6. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>4</sub>S, 396.1388; found, 396.1383.</div></div><div id="sec5_1_5_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-7-(1-oxidothiomorpholino)-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19r</b>)</h5><div class="NLM_p last">To a mixture of <b>19c</b> (0.1 g, 0.26 mmol) and sodium periodate (0.11 g, 0.52 mmol) were added methanol (4 mL) and water (1.5 mL), and the reaction mixture was stirred overnight at room temperature. The solvent was removed under reduced pressure, and methanol was added to the residue. The mixture was filtered to remove the solid, and the filtrate was purified by column chromatography (EtOAc/MeOH = 96/4) to afford <b>19r</b> (74 mg, 71.8%) as a white solid. mp 214–216 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 12.8 Hz, 1H), 6.68 (d, <i>J</i> = 8.0 Hz, 1H), 6.04 (t, <i>J</i> = 6.0 Hz, 1H), 4.52 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.43–4.37 (m, 1H), 3.96–3.89 (m, 1H), 3.83 (t, <i>J</i> = 10.4 Hz, 1H), 3.79–3.63 (m, 4H), 3.31–3.20 (m, 2H), 3.06–2.93 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.0, 153.1, 150.2 (d, <i>J</i> = 239.0 Hz), 140.6 (d, <i>J</i> = 2.0 Hz), 135.8 (d, <i>J</i> = 11.0 Hz), 118.1 (d, <i>J</i> = 11.0 Hz), 108.7 (d, <i>J</i> = 3.0 Hz), 107.3 (d, <i>J</i> = 27.0 Hz), 75.3, 66.4, 53.0, 46.0, 42.4, 42.3, 41.3, 23.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>S, 398.1180; found, 398.1162.</div></div><div id="sec5_1_5_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(1,1-Dioxidothiomorpholino)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19s</b>)</h5><div class="NLM_p last">To a mixture of <b>19r</b> (1 g, 2.5 mmol) and sodium periodate (1.35 g, 6.3 mmol) were added methanol (9 mL) and water (5 mL). The mixture was stirred at 60 °C for 10 h. After cooling, water (20 mL) was added to form a solid precipitate which was filtered, washed with water, and dried to afford <b>19s</b> (535 mg, 51.9%) as a pink solid. mp 226–228 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 12.8 Hz, 1H), 6.59 (d, <i>J</i> = 8.0 Hz, 1H), 6.07 (t, <i>J</i> = 6.4 Hz, 1H), 4.52 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.44–4.37 (m, 1H), 3.96–3.89 (m, 1H), 3.83 (t, <i>J</i> = 10.0 Hz, 1H), 3.79–3.63 (m, 2H), 3.59–3.52 (m, 4H), 3.23–3.16 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.0, 153.1, 150.0 (d, <i>J</i> = 239.0 Hz), 140.5 (d, <i>J</i> = 3.0 Hz), 135.2 (d, <i>J</i> = 12.0 Hz), 118.1 (d, <i>J</i> = 11.0 Hz), 109.0 (d, <i>J</i> = 2.0 Hz), 107.4 (d, <i>J</i> = 27.0 Hz), 75.3, 66.4, 53.0, 51.9, 49.54, 49.51, 41.2, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>6</sub>S, 414.1130; found, 414.1126.</div></div><div id="sec5_1_5_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> ((3<i>R</i>,3<i>aS</i>)-1-Oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16e</b>)</h5><div class="NLM_p last">Compound <b>16e</b> (0.81 g, 89.6%) was prepared from <b>15e</b> (0.61 g, 1.9 mmol) in the same manner as described for <b>16a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.76 (d, <i>J</i> = 9.2 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 6.57 (d, <i>J</i> = 7.6 Hz,1H), 6.48 (s, 1H), 4.49-4.38 (m, 2 H), 4.33 (dd, <i>J</i> = 10.8, 4.0 Hz, 1H), 4.25 (dd, <i>J</i> = 11.2, 6.0 Hz, 1H), 4.05-3.97 (m, 1H), 3.86 (t, <i>J</i> = 10.4 Hz, 1H), 3.50 (t, <i>J</i> = 4.8 Hz, 4H), 2.73 (brs, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 477.1149; found, 477.1133.</div></div><div id="sec5_1_5_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> (3<i>S</i>,3<i>aS</i>)-3-(Aminomethyl)-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18e</b>)</h5><div class="NLM_p last">To a suspension of <b>16e</b> (0.66 g, 1.39 mmol) in THF (10 mL) in a sealed tube was added ammonium hydroxide (5 mL). The reaction mixture was heated at 100 °C for 7 h. After cooling, THF was evaporated, and the aqueous phase was extracted with EtOAc three times. The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (DCM/MeOH/ammonium hydroxide = 98/2/1) to give <b>18e</b> (240 mg, 53.8%) as a light red solid.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.84 (d, <i>J</i> = 8.4 Hz, 1H), 6.56 (dd, <i>J</i> = 8.8, 2.8 Hz, 1H), 6.46 (d, <i>J</i> = 2.4 Hz, 1H), 4.43 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.24 (dd, <i>J</i> = 11.6, 5.2 Hz, 1H), 4.04–3.96 (m, 1H), 3.90 (t, <i>J</i> = 10.0 Hz, 1H), 3.55–3.42 (m, 4H), 3.18–3.01 (m, 2H), 2.81–2.65 (m, 4H), 1.32 (s, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>S, 322.1220; found, 322.1210.</div></div><div id="sec5_1_5_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-1-Oxo-7-thiomorpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>19t</b>)</h5><div class="NLM_p last">Compound <b>19t</b> (30 mg, 33.0%) was prepared from <b>18e</b> (80 mg, 0.25 mmol) in the same manner as described for <b>19a</b>. White solid. mp 152–154 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.8 Hz, 1H), 6.57 (d, <i>J</i> = 6.8 Hz, 1H), 6.48 (s, 1H), 6.10 (brs, 1H), 4.49 (d, <i>J</i> = 8.0 Hz, 1H), 4.42–4.32 (m, 1H), 3.97–3.82 (m, 2H), 3.80–3.60 (m, 2H), 3.50 (t, <i>J</i> = 4.8 Hz, 4H), 2.73 (brs, 4H), 2.04 (s, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): δ 170.8, 153.4, 145.1, 120.1, 111.2, 105.2, 74.9, 66.7, 53.2, 52.2, 41.5, 26.6, 23.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub>S, 364.1326; found, 364.1337.</div></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Synthesis of the Target Compounds <b>20a–i</b></h4><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> ((3<i>R</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16f</b>)</h5><div class="NLM_p last">Compound <b>16f</b> (1.07 g, 95.5%) was prepared from <b>15f</b> (0.79 g, 2.16 mmol) in the same manner as described for <b>16a</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (dd, <i>J</i> = 6.8, 1.6 Hz, 2H), 7.62 (d, <i>J</i> = 14.4 Hz, 1H), 7.40 (dd, <i>J</i> = 8.0, 0.4 Hz, 2H), 6.41 (d, <i>J</i> = 8.0 Hz, 1H), 4.48–4.30 (m, 5H), 4.26 (dd, <i>J</i> = 10.8, 5.6 Hz, 1H), 4.06–4.00 (m, 1H), 3.84 (t, <i>J</i> = 10.4 Hz, 1H), 3.34 (t, <i>J</i> = 11.6 Hz, 2H), 2.48 (s, 3H), 2.21–1.99 (m, 6H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>2</sub>O<sub>6</sub>S<sub>2</sub>, 521.1211; found, 521.1204.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> (3<i>S</i>,3<i>aS</i>)-3-(Aminomethyl)-7-(3-thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18f</b>)</h5><div class="NLM_p last">Compound <b>18f</b> (464 mg, 82.5%) was prepared from <b>16f</b> (0.8 g, 1.54 mmol) in the same manner as described for <b>18e</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.70 (d, <i>J</i> = 14.0 Hz, 1H), 6.41 (d, <i>J</i> = 8.0 Hz, 1H), 4.43 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.39–4.31 (m, 2H), 4.29–4.22 (m, 1H), 4.07–3.99 (m, 1H), 3.87 (t, <i>J</i> = 10.4 Hz, 1H), 3.38–3.28 (m, 2H), 3.19–3.04 (m, 2H), 2.23–2.00 (m, 6H), 1.29 (brs, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>3</sub>S, 366.1282; found, 366.1265.</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>20a</b>)</h5><div class="NLM_p last">Compound <b>20a</b> (43 mg, 62.3%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) in the same manner as described for <b>19a</b>. White solid. mp 235–236 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (d, <i>J</i> = 14.4 Hz, 1H), 6.42 (d, <i>J</i> = 8.4 Hz, 1H), 6.14 (t, <i>J</i> = 6.0 Hz, 1H), 4.48 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.43–4.31 (m, 3H), 3.95–3.88 (m, 1H), 3.84 (t, <i>J</i> = 10.0 Hz, 1H), 3.78–3.63 (m, 2H), 3.39–3.29 (m, 2H), 2.21–1.99 (m, 9H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.0, 153.2, 147.6 (d, <i>J</i> = 237.0 Hz), 140.8, 132.8 (d, <i>J</i> = 10.0 Hz), 113.8 (d, <i>J</i> = 11.0 Hz), 107.8 (d, <i>J</i> = 29.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.2, 66.6, 57.4, 57.2, 53.1, 41.3, 30.2, 30.0, 28.34, 28.31, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>4</sub>S, 408.1388; found, 408.1368.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> Methyl-(((3<i>S</i>,3<i>aS</i>)-7-(3-thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)carbamate (<b>20b</b>)</h5><div class="NLM_p last">Compound <b>20b</b> (25 mg, 34.7%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) in the same manner as described for <b>19l</b>. Off-white solid. mp 149–151 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 14.0 Hz, 1H), 6.41 (d, <i>J</i> = 7.6 Hz, 1H), 5.19 (s, 1H), 4.47 (dd, <i>J</i> = 10.4, 2.8 Hz, 1H), 4.43–4.31 (m, 3H), 3.95 (brs, 1H), 3.85 (t, <i>J</i> = 10.4 Hz, 1H), 3.71 (s, 3H), 3.67–3.56 (m, 2H), 3.33 (t, <i>J</i> = 11.2 Hz, 2H), 2.22–2.00 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 157.4, 153.1, 147.7 (d, <i>J</i> = 237.0 Hz), 140.8 (d, <i>J</i> = 1.0 Hz), 132.6 (d, <i>J</i> = 10.0 Hz), 114.0 (d, <i>J</i> = 11.0 Hz), 107.9 (d, <i>J</i> = 28.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.1, 66.6, 57.5, 57.3, 52.9, 52.7, 43.1, 30.2, 30.1, 28.33, 28.30. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>5</sub>S, 424.1337; found, 424.1326.</div></div><div id="sec5_1_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isobutyramide (<b>20c</b>)</h5><div class="NLM_p last">Compound <b>20c</b> (54 mg, 73.0%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) and isobutyryl chloride (0.022 mL, 0.21 mmol) in the same manner as described for <b>19g</b>. White solid. mp 164–165 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 13.2 Hz, 1H), 6.41 (brs, 1H), 6.06 (t, <i>J</i> = 6.0 Hz, 1H), 4.47 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.43–4.28 (m, 3H), 3.97–3.79 (m, 2H), 3.79–3.61 (m, 2H), 3.34 (t, <i>J</i> = 11.6 Hz, 2H), 2.49–2.36 (m, 1H), 2.21–1.99 (m, 6H), 1.17 (d, <i>J</i> = 2.8 Hz, 3H), 1.16 (d, <i>J</i> = 2.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 178.0, 153.3, 147.6 (d, <i>J</i> = 236.0 Hz), 140.9, 132.8 (d, <i>J</i> = 10.0 Hz), 113.8 (d, <i>J</i> = 11.0 Hz), 107.9 (d, <i>J</i> = 29.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.2, 66.6, 57.4, 57.1, 53.1, 41.3, 35.5, 30.2, 30.0, 28.4, 28.3, 19.6, 19.4. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>4</sub>S, 436.1701; found, 436.1680.</div></div><div id="sec5_1_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclopropanecarboxamide (<b>20d</b>)</h5><div class="NLM_p last">Compound <b>20d</b> (57 mg, 77.0%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) and cyclopropanecarbonyl chloride (0.019 mL, 0.21 mmol) in the same manner as described for <b>19h</b>. Off-white solid. mp 169–171 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 14.4 Hz, 1H), 6.41 (d, <i>J</i> = 8.0 Hz, 1H), 6.23 (t, <i>J</i> = 6.0 Hz, 1H), 4.46 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.43–4.28 (m, 3H), 3.96–3.63 (m, 4H), 3.39–3.25 (m, 2H), 2.23–1.95 (m, 6H), 1.47–1.35 (m, 1H), 1.02–0.92 (m, 2H), 0.84–0.74 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 174.6, 153.2, 147.8 (d, <i>J</i> = 236.0 Hz), 140.8 (d, <i>J</i> = 1.0 Hz), 132.8 (d, <i>J</i> = 10.0 Hz), 113.9 (d, <i>J</i> = 11.0 Hz), 107.7 (d, <i>J</i> = 29.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.4, 66.6, 57.4, 57.1, 53.1, 41.4, 30.2, 30.0, 28.4, 28.3, 14.6, 7.81, 7.80. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>25</sub>FN<sub>3</sub>O<sub>4</sub>S, 434.1544; found, 434.1525.</div></div><div id="sec5_1_6_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclobutanecarboxamide (<b>20e</b>)</h5><div class="NLM_p last">Compound <b>20e</b> (65 mg, 85.5%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) and cyclobutanecarbonyl chloride (0.020 mL, 0.21 mmol) in the same manner as described for <b>19i</b>. White solid. mp 195–196 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 14.0 Hz, 1H), 6.41 (d, <i>J</i> = 7.6 Hz, 1H), 5.87 (t, <i>J</i> = 6.0 Hz, 1H), 4.47 (dd, <i>J</i> = 10.0, 2.4 Hz, 1H), 4.43–4.28 (m, 3H), 3.97–3.79 (m, 2H), 3.79–3.61 (m, 2H), 3.34 (t, <i>J</i> = 10.8 Hz, 2H), 3.14–2.95 (m, 1H), 2.35–1.80 (m, 12H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 175.9, 153.2, 147.6 (d, <i>J</i> = 236.0 Hz), 140.9, 132.8 (d, <i>J</i> = 10.0 Hz), 113.8 (d, <i>J</i> = 11.0 Hz), 107.8 (d, <i>J</i> = 29.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.2, 66.6, 57.4, 57.2, 53.1, 41.3, 39.6, 30.2, 30.0, 28.4, 28.3, 25.4, 25.3, 18.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>4</sub>S, 448.1701; found, 448.1683.</div></div><div id="sec5_1_6_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)isonicotinamide (<b>20f</b>)</h5><div class="NLM_p last">Compound <b>20f</b> (54 mg, 67.5%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) and isonicotinic acid (25 mg, 0.2 mmol) in the same manner as described for <b>19j</b>. White solid. mp 149–150 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.78 (dd, <i>J</i> = 4.8, 1.6 Hz, 2H), 7.68 (dd, <i>J</i> = 4.8, 1.6 Hz, 2H), 7.63 (d, <i>J</i> = 14.4 Hz, 1H), 7.17 (d, <i>J</i> = 6.0 Hz, 1H), 6.41 (d, <i>J</i> = 8.0 Hz, 1H), 4.58–4.48 (m, 2H), 4.35 (brs, 2H), 4.04–3.95 (m, 2H), 3.94–3.82 (m, 2H), 3.36–3.27 (m, 2H), 2.21–2.00 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.4, 153.2, 150.7, 147.5 (d, <i>J</i> = 236.0 Hz), 140.9 (d, <i>J</i> = 1.0 Hz), 140.4, 133.0 (d, <i>J</i> = 11.0 Hz), 121.0, 113.5 (d, <i>J</i> = 11.0 Hz), 107.7 (d, <i>J</i> = 29.0 Hz), 105.9 (d, <i>J</i> = 5.0 Hz), 75.1, 66.5, 57.2, 57.1, 53.3, 42.1, 30.1, 30.0, 28.4, 28.3. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>4</sub>O<sub>4</sub>S, 471.1497; found, 471.1479.</div></div><div id="sec5_1_6_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)pyrazine-2-carboxamide (<b>20g</b>)</h5><div class="NLM_p last">Compound <b>20g</b> (64 mg, 80.0%) was prepared from <b>18f</b> (62 mg, 0.17 mmol) and pyrazine-2-carboxylic acid (25 mg, 0.2 mmol) in the same manner as described for <b>19k</b>. Pale yellow solid. mp >250 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.39 (s, 1H), 8.80 (d, <i>J</i> = 2.4 Hz, 1H), 8.58–8.55 (m, 1H), 8.28 (t, <i>J</i> = 6.0 Hz, 1H), 7.67 (d, <i>J</i> = 14.0 Hz, 1H), 6.41 (d, <i>J</i> = 7.2 Hz, 1H), 4.56–4.46 (m, 2H), 4.34 (brs, 2H), 4.05–3.83 (m, 4H), 3.38–3.26 (m, 2H), 2.20–1.99 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 164.0, 153.0, 147.9, 147.6 (d, <i>J</i> = 236.0 Hz), 144.5, 143.5, 142.8, 140.8 (d, <i>J</i> = 1.0 Hz), 132.9 (d, <i>J</i> = 10.0 Hz), 113.7 (d, <i>J</i> = 11.0 Hz), 107.8 (d, <i>J</i> = 29.0 Hz), 105.8 (d, <i>J</i> = 5.0 Hz), 74.9, 66.6, 57.3, 57.1, 53.2, 41.3, 30.1, 30.0, 28.3. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>4</sub>S, 472.1449; found, 472.1430.</div></div><div id="sec5_1_6_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> (3<i>S</i>,3<i>aS</i>)-7-(3-Thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-3-((isoxazol-3-ylamino)methyl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>20h</b>)</h5><div class="NLM_p last">Compound <b>20h</b> (65 mg, 68.4%) was prepared from <b>16f</b> (0.11 g, 0.22 mmol) and <i>N</i>-boc-3-aminoisoxazole (0.041 g, 0.22 mmol) in the same manner as described for <b>19n</b>. Pale pink solid. mp 180–182 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.08 (s, 1H), 7.70 (d, <i>J</i> = 14.0 Hz, 1H), 6.45 (d, <i>J</i> = 8.0 Hz, 1H), 5.89 (s, 1H), 4.58 (brs, 1H), 4.53–4.46 (m, 1H), 4.42–4.31 (m, 2H), 4.06–3.98 (m, 1H), 3.87 (t, <i>J</i> = 10.0 Hz, 1H), 3.81–3.65 (m, 2H), 3.44–3.34 (m, 2H), 2.22–2.02 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.3, 158.6, 153.2, 147.7 (d, <i>J</i> = 236.0 Hz), 140.8, 132.2 (d, <i>J</i> = 10.0 Hz), 114.5 (d, <i>J</i> = 12.0 Hz), 107.9 (d, <i>J</i> = 29.0 Hz), 106.1 (d, <i>J</i> = 3.0 Hz), 96.4, 74.5, 66.8, 57.8, 57.5, 53.3, 46.0, 30.3, 30.1, 28.29, 28.25. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>22</sub>FN<sub>4</sub>O<sub>4</sub>S, 433.1340; found, 433.1321.</div></div><div id="sec5_1_6_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> (3<i>S</i>,3<i>aS</i>)-3-((1<i>H</i>-1,2,3-Triazol-1-yl)methyl)-7-(3-thia-8-azabicyclo[3.2.1]octan-8-yl)-8-fluoro-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>20i</b>)</h5><div class="NLM_p last">Compound <b>20i</b> (70 mg, 65.4%) was prepared from <b>16f</b> (135 mg, 0.26 mmol) in the same manner as described for <b>19o</b>. Off-white solid. mp 225–227 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79 (d, <i>J</i> = 0.8 Hz, 1H), 7.78 (d, <i>J</i> = 1.2 Hz, 1H), 7.58 (d, <i>J</i> = 14.0 Hz, 1H), 6.39 (d, <i>J</i> = 8.0 Hz, 1H), 4.86–4.81 (m, 2H), 4.72–4.66 (m, 1H), 4.44 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.39–4.30 (m, 2H), 4.07–3.99 (m, 1H), 3.86 (t, <i>J</i> = 10.4 Hz, 1H), 3.37–3.26 (m, 2H), 2.20–2.00 (m, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 152.3, 147.6 (d, <i>J</i> = 236.0 Hz), 140.8 (d, <i>J</i> = 2.0 Hz), 134.7, 133.1 (d, <i>J</i> = 10.0 Hz), 125.1, 113.2 (d, <i>J</i> = 11.0 Hz), 107.9 (d, <i>J</i> = 29.0 Hz), 105.8 (d, <i>J</i> = 5.0 Hz), 73.5, 66.3, 57.3, 57.1, 53.2, 51.4, 30.1, 30.0, 28.34, 28.30. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>3</sub>S, 418.1344; found, 418.1324.</div></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Synthesis of the Target Compound <b>21</b></h4><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> ((3<i>R</i>,3<i>aS</i>)-8-Fluoro-7-morpholino-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16g</b>)</h5><div class="NLM_p last">Compound <b>16g</b> (1.06 g, 88.3%) was prepared from <b>15g</b> (0.8 g, 2.5 mmol) in the same manner as described for <b>16a</b>. Pale purple solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.4 Hz, 2H), 7.67 (d, <i>J</i> = 13.2 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 6.55 (d, <i>J</i> = 7.6 Hz, 1H), 4.51–4.40 (m, 2H), 4.37–4.22 (m, 2H), 4.07–4.00 (m, 1H), 3.94–3.72 (m, 5H), 3.10–2.91 (m, 4H), 2.47 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>FN<sub>2</sub>O<sub>7</sub>S, 479.1283; found, 479.1277.</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> (3<i>S</i>,3<i>aS</i>)-3-(Aminomethyl)-8-fluoro-7-morpholino-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18g</b>)</h5><div class="NLM_p last">Compound <b>18g</b> (418 mg, 61.6%) was prepared from <b>16g</b> (1.0 g, 2.09 mmol) in the same manner as described for <b>18e</b>. Off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 13.2 Hz, 1H), 6.53 (d, <i>J</i> = 7.6 Hz, 1H), 4.46 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.30–4.22 (m, 1H), 4.09–3.99 (m, 1H), 3.95–3.75 (m, 5H), 3.28–2.87 (m, 6H), 1.28 (s, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>4</sub>, 324.1354; found, 324.1345.</div></div><div id="sec5_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-7-morpholino-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>21</b>)</h5><div class="NLM_p last">Compound <b>21</b> (81 mg, 72.1%) was prepared from <b>18g</b> (100 mg, 0.31 mmol) in the same manner as described for <b>19a</b>. Off-white solid. mp 179–181 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.73 (d, <i>J</i> = 13.2 Hz, 1H), 6.57 (d, <i>J</i> = 8.0 Hz, 1H), 6.10 (brs, 1H), 4.51 (dd, <i>J</i> = 10.0, 1.6 Hz, 1H), 4.44–4.36 (m, 1H), 3.99–3.80 (m, 6H), 3.79–3.61 (m, 2H), 3.19–2.93 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.9, 153.1, 150.1 (d, <i>J</i> = 239 Hz), 140.5 (d, <i>J</i> = 2.0 Hz), 137.0 (d, <i>J</i> = 10.0 Hz), 116.6 (d, <i>J</i> = 11.0 Hz), 107.14 (d, <i>J</i> = 28.0 Hz), 107.10 (d, <i>J</i> = 4.0 Hz), 75.2, 66.9, 66.4, 53.0, 51.0, 50.9, 41.3, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>, 366.1460; found, 366.1457.</div></div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Synthesis of the Target Compound <b>22</b></h4><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> ((3<i>R</i>,3<i>aS</i>)-7-(4,4-Difluoropiperidin-1-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl 4-Methylbenzenesulfonate (<b>16h</b>)</h5><div class="NLM_p last">Compound <b>16h</b> (1.07 g, 95.5%) was prepared from <b>15h</b> (0.4 g, 1.12 mmol) in the same manner as described for <b>16a</b>. Off-white foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.0 Hz, 2H), 7.68 (d, <i>J</i> = 12.8 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 6.61 (d, <i>J</i> = 7.6 Hz, 1H), 4.51–4.39 (m, 2H), 4.33 (dd, <i>J</i> = 10.8, 4.0 Hz, 1H), 4.26 (dd, <i>J</i> = 10.8, 5.6 Hz, 1H), 4.08–4.00 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.23–3.08 (m, 4H), 2.47 (s, 3H), 2.25–2.08 (m, 4H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub>S, 513.1302; found, 513.1300.</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> (3<i>S</i>,3<i>aS</i>)-3-(Aminomethyl)-7-(4,4-difluoropiperidin-1-yl)-8-fluoro-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18h</b>)</h5><div class="NLM_p last">Compound <b>18h</b> (330 mg, 86.4%) was prepared from <b>16h</b> (1.07 g, 2.09 mmol) in the same manner as described for <b>18e</b>. Off-white foam solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.76 (d, <i>J</i> = 13.2 Hz, 1H), 6.55 (d, <i>J</i> = 8.0 Hz, 1H), 4.45 (dd, <i>J</i> = 10.8, 3.2 Hz, 1H), 4.31–4.23 (m, 1H), 4.10–4.00 (m, 1H), 3.86 (t, <i>J</i> = 10.4 Hz, 1H), 3.26–2.97 (m, 6H), 2.22–2.05 (m, 4H), 1.34 (brs, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>19</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 358.1373; found, 358.1368.</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-7-(4,4-Difluoropiperidin-1-yl)-8-fluoro-1-oxo-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>22</b>)</h5><div class="NLM_p last">Compound <b>22</b> (95 mg, 76.6%) was prepared from <b>18h</b> (112 mg, 0.31 mmol) in the same manner as described for <b>19a</b>. Pale yellow solid. mp 230–232 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.71 (d, <i>J</i> = 13.2 Hz, 1H), 6.56 (d, <i>J</i> = 8.0 Hz, 1H), 6.25 (t, <i>J</i> = 6.0 Hz, 1H), 4.51 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.45–4.35 (m, 1H), 3.97–3.88 (m, 1H), 3.83 (t, <i>J</i> = 10.0 Hz, 1H), 3.78–3.62 (m, 2H), 3.20–3.04 (m, 4H), 2.22–2.08 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 171.0, 153.2, 150.1 (d, <i>J</i> = 239.0 Hz), 140.4 (d, <i>J</i> = 2.0 Hz), 136.4 (d, <i>J</i> = 11.0 Hz), 121.4 (t, <i>J</i> = 240.0 Hz), 116.9 (d, <i>J</i> = 10.0 Hz), 108.0 (d, <i>J</i> = 3.0 Hz), 107.1 (d, <i>J</i> = 28.0 Hz), 75.3, 66.4, 53.0, 47.9 (q, <i>J</i> = 6.0 Hz), 41.2, 34.1 (q, <i>J</i> = 23.0 Hz), 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>21</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>, 400.1479; found, 400.1458.</div></div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Synthesis of the Target Compounds <b>23a–d</b></h4><div id="sec5_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> ((3<i>R</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl Methanesulfonate (<b>16i</b>)</h5><div class="NLM_p last">To a solution of <b>15i</b> (0.4 g, 1.2 mmol) in DCM (10 mL) cooled to 0 °C with an ice-water bath was added <i>N</i>-methylmorpholine (0.26 mL, 2.4 mmol), and then, methanesulfonyl chloride (0.11 mL, 1.4 mmol) was added. The reaction mixture was stirred for 5.5 h at room temperature and concentrated to give a solid. The residue was stirred with water and filtered to give <b>16i</b> (0.49 g, 99.4%) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.47 (d, <i>J</i> = 13.2 Hz, 1H), 6.16 (d, <i>J</i> = 8.4 Hz, 1H), 4.78–4.66 (m, 4H), 4.64–4.49 (m, 3H), 4.06–3.89 (m, 6H), 3.27 (s, 3H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>7</sub>S, 415.0970; found, 415.0961.</div></div><div id="sec5_1_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> (3<i>S</i>,3<i>aS</i>)-3-(Azidomethyl)-8-fluoro-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>18i</b>)</h5><div class="NLM_p last">To a solution of compound <b>16i</b> (384 mg, 0.93 mmol) in DMF (10 mL) was added sodium azide (120 mg, 1.86 mmol). The reaction mixture was heated at 70 °C for 3 h and cooled to room temperature. Water (10 mL) was added to the mixture, and the resulting solid was filtered, washed with water, and dried to give <b>18i</b> (285 mg, 84.8%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 12.8 Hz, 1H), 6.06 (d, <i>J</i> = 8.4 Hz, 1H), 4.82 (s, 4H), 4.42 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.37–4.29 (m, 1H), 4.07 (d, <i>J</i> = 2.0 Hz, 4H), 4.02–3.94 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H), 3.78–3.63 (m, 2H). HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>4</sub>, 362.1259; found, 362.1243.</div></div><div id="sec5_1_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)acetamide (<b>23a</b>)</h5><div class="NLM_p last">To a solution of compound <b>18i</b> (70 mg, 0.19 mmol) in THF (5 mL) was added Pd/C (10%, 10 mg). The resulting mixture was stirred in a hydrogen atmosphere for 2 h and then filtered. To the filtrate was added pyridine (0.031 mL, 0.38 mmol) at 0 °C, and then, acetic anhydride (0.029 mL, 0.3 mmol) was added dropwise. The mixture was warmed to room temperature and stirred overnight. The mixture was diluted with DCM. The organic phase was washed sequentially with 0.5 N hydrochloric acid and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (DCM/methanol = 98/2) to give compound <b>23a</b> (42 mg, 58.3%) as an off-white solid. mp 105–107 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.63 (d, <i>J</i> = 12.8 Hz, 1H), 6.05 (d, <i>J</i> = 8.0 Hz, 1H), 5.96 (t, <i>J</i> = 6.0 Hz, 1H), 4.82 (s, 4H), 4.50–4.43 (m, 1H), 4.39–4.33 (m, 1H), 4.06 (d, <i>J</i> = 2.0 Hz, 4H), 3.92–3.77 (m, 2H), 3.76–3.61 (m, 2H), 2.04 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 170.9, 153.2, 147.0 (d, <i>J</i> = 236 Hz), 140.8 (d, <i>J</i> = 2.0 Hz), 136.4 (d, <i>J</i> = 12.0 Hz), 113.5 (d, <i>J</i> = 10.0 Hz), 107.0 (d, <i>J</i> = 26.0 Hz), 102.3 (d, <i>J</i> = 4.0 Hz), 81.0, 75.0, 66.5, 62.9, 62.8, 53.0, 41.3, 39.72, 39.69, 23.1. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>21</sub>FN<sub>3</sub>O<sub>5</sub>, 378.1460; found, 378.1449.</div></div><div id="sec5_1_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclopropanecarboxamide (<b>23b</b>)</h5><div class="NLM_p last">To a solution of compound <b>18i</b> (70 mg, 0.19 mmol) in THF (5 mL) was added Pd/C (10%, 10 mg). The resulting mixture was stirred in a hydrogen atmosphere for 3 h and then filtered. To the filtrate was added triethylamine (0.054 mL, 0.38 mmol) at 0 °C, and then, cyclopropanecarbonyl chloride (0.025 mL, 0.27 mmol) was added dropwise. The mixture was warmed to room temperature and stirred for 1 h. The solvent was evaporated, and the residue was purified by column chromatography (DCM/methanol = 99/1) to give compound <b>23b</b> (45 mg, 58.4%) as an off-white solid. mp 181–183 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 12.8 Hz, 1H), 6.10 (t, <i>J</i> = 6.0 Hz, 1H), 6.04 (d, <i>J</i> = 8.4 Hz, 1H), 4.82 (s, 4H), 4.45 (dd, <i>J</i> = 10.0, 2.8 Hz, 1H), 4.40–4.34 (m, 1H), 4.05 (d, <i>J</i> = 2.0 Hz, 4H), 3.93–3.72 (m, 3H), 3.72–3.63 (m, 1H), 1.45–1.35 (m, 1H), 1.02–0.95 (m, 2H), 0.84–0.76 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 174.6, 153.2, 147.0 (d, <i>J</i> = 236.0 Hz), 140.8 (d, <i>J</i> = 2.0 Hz), 136.4 (d, <i>J</i> = 13.0 Hz), 113.6 (d, <i>J</i> = 10.0 Hz), 107.0 (d, <i>J</i> = 26.0 Hz), 102.4 (d, <i>J</i> = 5.0 Hz), 81.0, 75.3, 66.6, 62.87, 62.86, 53.0, 41.4, 39.72, 39.70, 14.6, 7.8. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>5</sub>, 404.1616; found, 404.1608.</div></div><div id="sec5_1_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> <i>N</i>-(((3<i>S</i>,3<i>aS</i>)-8-Fluoro-1-oxo-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-3-yl)methyl)cyclobutanecarboxamide (<b>23c</b>)</h5><div class="NLM_p last">Compound <b>23c</b> (44 mg, 55.7%) was prepared from <b>18i</b> (70 mg, 0.19 mmol) in the same manner as described for <b>23b</b>. Off-white solid. mp 118–120 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.60 (d, <i>J</i> = 12.8 Hz, 1H), 6.03 (d, <i>J</i> = 8.4 Hz, 1H), 5.82 (t, <i>J</i> = 6.0 Hz, 1H), 4.81 (s, 4H), 4.45 (dd, <i>J</i> = 10.0, 2.4 Hz, 1H), 4.38–4.32 (m, 1H), 4.05 (d, <i>J</i> = 2.0 Hz, 4H), 3.91–3.68 (m, 3H), 3.67–3.59 (m, 1H), 3.08–2.95 (m, 1H), 2.32–2.10 (m, 4H), 2.05–1.78 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 175.9, 153.3, 147.0 (d, <i>J</i> = 235 Hz), 140.8 (d, <i>J</i> = 2.0 Hz), 136.4 (d, <i>J</i> = 13.0 Hz), 113.5 (d, <i>J</i> = 11.0 Hz), 107.1 (d, <i>J</i> = 25.0 Hz), 102.4 (d, <i>J</i> = 4.0 Hz), 81.0, 75.2, 66.5, 62.87, 62.85, 53.1, 41.3, 39.72, 39.70, 39.6, 25.33, 25.31, 18.2. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>25</sub>FN<sub>3</sub>O<sub>5</sub>, 418.1773; found, 418.1762.</div></div><div id="sec5_1_9_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> (3<i>S</i>,3<i>aS</i>)-3-((1<i>H</i>-1,2,3-Triazol-1-yl)methyl)-8-fluoro-7-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one (<b>23d</b>)</h5><div class="NLM_p last">Compound <b>23d</b> (42 mg, 56.8%) was prepared from <b>18i</b> (70 mg, 0.19 mmol) in the same manner as described for <b>19o</b>. Off-white solid. mp 219–221 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79 (d, <i>J</i> = 0.8 Hz, 1H), 7.78 (d, <i>J</i> = 0.8 Hz, 1H), 7.53 (d, <i>J</i> = 12.8 Hz, 1H), 6.03 (d, <i>J</i> = 8.4 Hz, 1H), 4.85–4.80 (m, 6H), 4.69–4.63 (m, 1H), 4.42 (dd, <i>J</i> = 10.4, 3.2 Hz, 1H), 4.05 (d, <i>J</i> = 2.0 Hz, 4H), 4.04–3.97 (m, 1H), 3.82 (t, <i>J</i> = 10.4 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 152.3, 147.0 (d, <i>J</i> = 235 Hz), 140.7 (d, <i>J</i> = 3.0 Hz), 136.6 (d, <i>J</i> = 2.0 Hz), 134.6, 125.0, 113.0 (d, <i>J</i> = 11.0 Hz), 107.2 (d, <i>J</i> = 26.0 Hz), 102.3 (d, <i>J</i> = 5.0 Hz), 81.0, 73.3, 66.3, 62.83, 62.81, 53.1, 51.4, 39.71, 39.68. HR-MS (ESI): <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>19</sub>FN<sub>5</sub>O<sub>4</sub>, 388.1416; found, 388.1405.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Minimum Inhibitory Concentration</h3><div class="NLM_p last">MIC values of compounds against <i>M. tuberculosis</i> (H37Rv and DR-TB strains) were determined by the MABA, according to the published protocol.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Cytotoxicity</h3><div class="NLM_p last">The potential cytotoxicity of the tested compounds on Vero cells or HepG2 cells was evaluated using MTT assay as previously reported.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> Mitochondrial Protein Synthesis Inhibition</h3><div class="NLM_p last">MPS was measured on the cardiac (H9C2) cell line that was obtained from National Platform of Experimental Cell Resources for Sci-Tech. The H9C2 cells were kept in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) with 10% fetal bovine serum (FBS; Hyclone) and 1× glutamine and NEAA at 37 °C, 5% CO<sub>2</sub>. The cell monolayer was washed with prewarmed phosphate-buffered saline (PBS) and detached using trypsin. After centrifugation (1000 rpm for 5 min at rt), the cells were resuspended with the cell culture medium and seeded at 1500 cells/well into a 384-well plate. After 18 h, the target compound<b>s</b> with final concentrations of 200, 66.67, 22.22, 7.41, 2.47, 0.82, 0.27, 0.09, and 0.03 μM were added to the appropriate well and then incubated at 37 °C, 5% CO<sub>2</sub> for 5 days. A negative control with 0.5% dimethyl sulfoxide (DMSO) was for every compound. MPS inhibition was evaluated by MitoBiogenesis In-Cell ELISA. IC<sub>50</sub> calculation was performed using Graph Pad Prim 5 software.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Caco-2 Permeability Assay</h3><div class="NLM_p last">The Caco-2 cell line is derived from a human colon adenocarcinoma. The cells were seeded in Transwells (Millipore, 0.4 μm pore size) and formed a confluent monolayer after 21 days of culture. On day 21, the target compound (50 μM) was added into the apical side of the membrane, and the concentration of the compound across the Caco-2 cell monolayer was quantified by ultraperformance liquid chromatography after 1 h incubation at 37 °C. Transepithelial electrical resistance should be determined before and after transport experiments and should be over 500Ω·cm<sup>2</sup>. The apparent permeability coefficient (<i>P</i><sub>app</sub>) for the compound is calculated from the following equation: <i>P</i><sub>app</sub> = (d<i>Q</i>/d<i>t</i>)/(<i>C</i><sub>0</sub> × <i>A</i>), where d<i>Q</i>/d<i>t</i> is the rate of permeation of the drug across the cells, <i>C</i><sub>0</sub> is the initial concentration, and <i>A</i> is the area of the cell monolayer.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> Liver Microsome Stability</h3><div class="NLM_p last">The assay was performed with liver microsomes from male CD-1 mice (Gibco) and pooled humans (Xenotech). Compounds of interest were tested at 1 μM with a final concentration of microsomal protein of 1 mg/mL. The reaction was initiated by the addition of nicotinamide adenine dinucleotide phosphate (NADPH; 1 mM), and samples were incubated for up to 60 min at 37 °C in a shaking incubator. The reaction was terminated at 0, 5, 15, and 30 min by the addition of ice-cold ACN/MeOH (50:50) spiked with the internal standard. An aliquot of the reaction mixture was removed at 0, 5, 15, 30, and 60 min, followed by the addition of ice-cold ACN/MeOH (50:50) spiked with the internal standard. Samples were centrifuged at 4000 rpm for 15 min, and the supernatants were analyzed by liquid chromatography with tandem mass spectrometry (LC–MS/MS). The assay evaluated the metabolic stability of compounds by measuring the amount of parent remaining to test compounds with or without the NADPH cofactor.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> Hepatocyte Stability</h3><div class="NLM_p last">The assay was performed with hepatocytes from male CD-1 mice (BioreclamationIVT), male SD rats (BioreclamationIVT), male beagle dogs (BioreclamationIVT), male cynomolgus monkeys (RILD), and pooled humans (BioreclamationIVT). Compounds of interest were tested at 1 μM with a final hepatocyte concentration of 1 million cells/mL. The reaction was initiated by the addition of prewarmed hepatocyte working solution (2 million cells/mL) to the compound working solution (2 μM). Reaction mixtures were incubated for up to 120 min at 37 °C in a CO<sub>2</sub> incubator. At the predetermined time points (0, 15, 30, 60, 90, and 120 min), 30 μL of the reaction mixtures was removed, and reaction was terminated by the addition of 200 mL of methanol/ACN (1:1, v/v) with 0.1% formic acid with the internal standard. Samples were mixed well and then were centrifuged at 4000 rpm at 4 °C for 15 min. Supernatants (100 μL) were removed to a 96-well plate for LC–MS/MS analysis. The assay evaluated the metabolic stability of compounds in hepatocytes by measuring the amount of parent remaining in the test compounds.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> CYP Inhibition</h3><div class="NLM_p last">Compounds were incubated with human liver microsome (0.2 mg/mL) containing phosphate buffer for 20 min. The compound was tested in a range of concentrations (0.1–50 μM), alongside a relevant positive control. The positive controls, which are CYP isoform-specific (1A2, 2C9, 2C19, 2D6, and 3A4) substrates, were also incubated with human liver microsomes in a range of the tested compound concentrations. At the end of incubation, the amount of parent remaining to each substrate is monitored by LC–MS/MS at each of the tested compound concentrations. IC<sub>50</sub> was calculated using Sigma-plot software.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i143" class="anchor-spacer"></div><h3 class="article-section__title" id="_i143"> PK Studies</h3><div class="NLM_p last">All animal protocols were approved by Institute Animal Care and Welfare Committee. The selected compound <b>19c</b> was subjected to PK studies in Balb/c mice (female) weighing 20–25 g with five mice in the oral administration group and five mice in the intravenous injection group. The tested compound was given orally (p.o.) at a dose of 25 mg/kg and intravenously (i.v.) at a dose of 2.5 mg/kg. The tested compound was formulated with 0.5% carboxymethyl cellulose for p.o. administration and with 10% DMSO/physiological saline for i.v. administration. Blood samples were collected at 5, 15, 30 min, 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 h after oral dosing and 2, 5, 15, 30 min, 1, 2, 4, 6, 8, 12, 24, 36, and 48 h after i.v. administration. Analyte quantitation was performed using an LC–MS/MS Quantum Access mass spectrometer (Applied Biosystems). Chromatographic separation was performed on a Zobax SB-C18 column (50 mm × 2.1 mm, 3.5 μm) with an isocratic mobile phase of methanol/water at 0.3 mL/min flow rate. Compound detection on the mass spectrometer was performed in the electrospray positive ionization mode. The PK parameters were calculated using WinNonlin software version 6.3 based on noncompartmental analysis (Pharsight Corporation, Mountain View, USA). The oral bioavailability was calculated as the ratio between the AUC following intravenous administration corrected for dose (<i>F</i> = (AUC<sub>p.o.</sub> × dose<sub>i.v.</sub>)/(AUC<sub>i.v.</sub> × dose<sub>p.o.</sub>) × 100%).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> <i>In Vivo</i> TB Infection Assay</h3><div class="NLM_p last">All animal protocols were approved by Institute Animal Care and Welfare Committee. SPF Balb/c mice (female) were used in this study. Each treated group was composed of six mice. Mice were infected via aerosol with a suspension of 5 × 10<sup>6</sup> cfu/mL <i>M. tuberculosis</i> (H37Rv) using a Glas-Col inhalation system to deposit 50–100 bacilli into the lungs of each animal. The course of infection was followed by plating homogenates of harvested organs [<i>n</i> = 3] on 7H11 agar plates [7H11 plates containing 10% oleic acid-albumin-dextrose-catalase enrichment, 50 mg/mL cycloheximide, 200 U/mL polymyxin B, 50 μg/mL carbenicillin, and 20 μg/mL trimethoprim] and determining cfu on days 3, 10, and 30 post infection. INH, linezolid, sutezolid, and compound <b>19c</b> were suspended in 0.5% CMC and administered by oral gavage. The control group received only 0.5% CMC. Mice were treated on day 10 post infection and five times per week. The treatment period was 3 weeks. Mice were sacrificed the day after the last day of treatment, lungs removed, homogenized, and serially diluted in 10-fold steps in Hanks balanced salt solution (HBSS). A total of 100 μL was spread on 7H11 agar in duplicate. The plates were incubated at 37 °C for 3 weeks. Data are expressed as the log<sub>10</sub> (and as log<sub>10</sub> reduction) provided by a given dose of the compound against the growth of the organism in the untreated control group. Mean log<sub>10</sub> values were calculated from bacterial burden counts. Student’s <i>t</i>-test was used to compare means between the test and control groups. A <i>P</i> value of ≤ 0.05 was considered significant.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i145" class="anchor-spacer"></div><h3 class="article-section__title" id="_i145"> Mice Bone Marrow Micronucleus Assay</h3><div class="NLM_p last">An animal care and use application for the study was approved by Pharmaron Institutional Animal Care and Use Committee (IACUC). Compounds <b>19c</b> and <b>19r</b> were subjected to the assay in CD-1 (ICR) mice (male, <i>n</i> = 42) weighing 28.3–33.3 g. The mice were randomly divided into seven groups (solvent control, positive control, <b>19c</b> or <b>19r</b> at dose levels of 100, 200, 500, 1000, and 2000 mg/kg) with three mice per group. Animals were fed ad libitum with rodent diet, and water was provided ad libitum via water bottles. Animals were dosed 2 consecutive days via oral gavage with the vehicle control and the test article. The second dose occurred 24 h (±30 min) after the first dose. At 18–24 h post the last dose, animals were sacrificed for bone marrow harvest. The bone marrow from each animal was examined microscopically to determine micronucleus frequency and the proportion of polychromatic erythrocytes to total erythrocytes. Three concentrations of compounds <b>19c</b> and <b>19r</b> were analyzed for micronucleus formation, that is, 500, 1000, and 2000 mg/kg. The top dose level analyzed was the limit dose recommended by ICH S2R1. The results indicated that compounds <b>19c</b> and <b>19r</b> did not induce statistically significant increases in bone marrow micronucleus formation at dose levels of up to 2000 mg/kg.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i146" class="anchor-spacer"></div><h3 class="article-section__title" id="_i146"> Chromosome Aberration Test</h3><div class="NLM_p last">Chinese hamster ovary (CHO) cells, clone WBL, were cultured in a humidified atmosphere of 5% CO<sub>2</sub> in air at 37 °C in McCoy’s 5A medium, supplemented with 10% FBS, 2 mM GlutaMAX, 100 units/mL penicillin, and 100 μg/mL streptomycin. Cells were seeded 20–24 h before treatment in a 0.4 × 10<sup>6</sup>/5 mL/25 cm<sup>2</sup> flask. Cultures treated with the metabolic activation system were refed with serum-free S-9 mix just before treatment. Compounds were dissolved in DMSO and added to cultures, and the cultures were incubated at 37 °C. Treatments were for either 3 or 20 h, and aberrations were scored in cells harvested for 20 h from the beginning of treatment. At the termination of the 3 h treatments, the cultures were washed twice with HBSS and refed with a fresh complete medium. Cultures were incubated for a further 17 h. Colcemid (0.1 μg/mL) was added 2 h before monolayers were harvested by trypsinization. A cell sample was counted using the Coulter counter to determine the cell number as an indicator of cytotoxicity. The viable cells were verified by checking samples for trypan blue dye exclusion. The cells were treated with hypotonic KCl (75 mM) for 3 min at room temperature, washed twice with a fixative (methanol/glacial acetic acid, 3:1, v/v), dropped onto slides, air-dried, and stained with Giemsa stain. A total of 300 metaphase cells from each concentration (150 per duplicate flask) were examined and scored for chromosome aberrations. Compound <b>19c</b> was tested for the chromosome analysis at the concentrations of 20, 60, and 150 μg/mL in groups A and B and 20, 60, and 135 μg/mL in group C. Compound <b>19r</b> was tested at concentrations of 90, 180, and 397.1 μg/mL for the chromosome analysis. Statistical analysis of chromosome aberration data was performed using SAS 9.2 software.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Mini-Ames Assay</h3><div class="NLM_p last">Two strains of <i>Salmonella typhimurium</i> bacteria (TA98 and TA100) were used in the study and were originally obtained from Molecular Toxicology (Boone, NC), USA. DMSO was used as the solvent/vehicle control, and the highest concentration tested was 1000 μg/well, which was equal to an OECD limit concentration of 5000 μg/plate in standard Ames assay. Bacteria, test compound or vehicle/positive control formulation, and 10% S9 mixture or PBS buffer were added to molten agar at 45 °C, mixed rapidly, and poured onto a six-well plate containing minimal agar media. After the agar was solidified, the plates were inverted and incubated at 37 °C for 48–72 h. Revertant colonies were counted manually, and the background lawn was inspected for signs of cytotoxicity. The results were considered to be positive for mutagenic potential if the increase in mean revertants at the peak of the dose response was equal to or greater than twofold the mean solvent/vehicle control value, and the increase should be dose-related. The results indicated that compounds <b>19c</b> and <b>19r</b> were not cytotoxic to the tester strains and were not mutagenic at concentrations of up to 1000 μg/well.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i148" class="anchor-spacer"></div><h3 class="article-section__title" id="_i148"> Inhibition Evaluation on the hERG K<sup>+</sup> Channel</h3><div class="NLM_p last">HEK 293 cells were stably transfected with a human ether-à-go-go related gene (hERG) channel. The voltage-gated hERG potassium channel current was recorded at room temperature (25 °C) from randomly selected transfected cells under whole-cell manual patch clamp systems equipped with an EPC10 USB (HEKA) or Multiclamp 700B amplifier (Molecular Devices), while electrical data were digitalized using Digidata1440A with sampling frequency at 10 kHz using Patchmaster or pClamp10, respectively. hERG current inhibition in the presence of five concentrations, including 30, 10, 3.0, 1.0, and 0.3 μM, was tested for IC<sub>50</sub> determination. Dofetilide was also included as a positive control to ensure the accuracy and sensitivity of the test system. All experiments were performed in duplicate for IC<sub>50</sub> determination. The compound with IC<sub>50</sub> > 30 μM was generally considered to have a lower potential for hERG K<sup>+</sup> channel inhibition.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i149" class="anchor-spacer"></div><h3 class="article-section__title" id="_i149"> HEK-293 Cell-Line/hCav1.2 Assay</h3><div class="NLM_p">HEK-293 cells stably expressing the human Cav1.2 L-type Ca channel (α1c, α2/δ, and β2a subunits) along with the inward rectifier potassium channel Kir2.3 were grown in media containing 90% DMEM culture media supplemented with 10% (v/v) FBS, 100 U/mL penicillin -streptomycin, 40 μg/mL zeocin, 100 μg/mL hygromycin B, and 100 μg/mL G418 (geneticin). Before the experiment, the cells were inoculated to 1.2 × 10<sup>4</sup> cells per well and incubated overnight in a 384-well cell culture plate, each well containing 10 μL of DMEM supplemented with 1% FBS and 100 U/mL penicillin–streptomycin. To each well of the cell plate, 10 μL of 2× fluorochrome containing 5 mM probenecid, 4 μM fluo-4 AM, and 1 mM brilliant black was added. Then, the cells were incubated at 37 °C for 60 min in a 5% CO<sub>2</sub> atmosphere. Duplicate per dose was measured with test compounds at concentrations of 1.52, 4.57, 13.72, 41.15, 123.46, 370.37, 1111.11, 3333.33, 10,000.00, and 30,000.00 nM on FLIPR<sup>Tetra</sup>. Fluorescence was read at an excitation of 470–495 nm and an emission of 515–575 nm. The calcium channel inhibition rate was calculated using the following equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_m001.gif" alt="" id="_i150" /></img></span><i>U</i>: fluorescence signal intensity of the test compound; <i>C</i><sub>p</sub>: fluorescence signal intensity of positive control (EC80 of the calcium channel activator KCl); <i>C</i><sub>n</sub>: fluorescence signal intensity of the solvent control.</div><div class="NLM_p last">IC<sub>50</sub> was performed using XLfit software.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> CHO Cell-Line/Nav1.5 Assay</h3><div class="NLM_p">CHO cells expressing the Nav1.5 channel were maintained in 90% F12K supplemented with 10% (v/v) FBS, 100 U/mL penicillin–streptomycin, 20 mM HEPES, and 700 μg/mL G418 (geneticin) in a humidified incubator with an atmosphere of 5% CO<sub>2</sub> at 37 °C. For electrophysiological recordings, the cells were superfused by extracellular saline containing 132 mM NaCl, 4 mM KCl, 3 mM CaCl<sub>2</sub>, 0.5 mM MgCl<sub>2</sub>, 11.1 mM glucose, and 10 mM HEPES (pH 7.35). Compounds for testing were dissolved in DMSO at concentrations of 30, 10, 3, 1, and 0.3 mM and then diluted in extracellular saline to 30, 10, 3.0, 1.0, and 0.3 μM, respectively. The glass electrodes for whole-cell patch-clamp recording were filled with intracellular saline containing 140 mM KCl, 2 mM MgCl<sub>2</sub>, 10 mM EGTA, 10 mM HEPES, and 5 mM MgATP (pH 7.35). Cells were clamped to a holding potential of −80 mV and then depolarized to −10 mV using a 20 ms-long voltage followed by a repolarization to −80 mV. The current-induced interval was 15 s. The sampling frequency was 50 kHz, and filter frequency was 10 kHz. The instantaneous peak current under depolarization was indicated as Nav1.5 channel current. The inhibition rate was calculated using the following equation<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_m002.gif" alt="" id="_i152" /></img></span></div><div class="NLM_p last">IC<sub>50</sub> was performed using Graphpad Prism 6.0 software.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i153" class="anchor-spacer"></div><h3 class="article-section__title" id="_i153"> MAO Inhibition</h3><div class="NLM_p">Stock solution of the test article was prepared in DMSO at 50 mM concentration and stored frozen at −20 °C. Serial dilutions of the stock solution were prepared in acetonitrile/DMSO (8:2) for testing. The test article was incubated at seven increasing concentrations (0.1–100 μM) in duplicate with human, recombinant MAO-A or MAO-B (50 μg/mL) in 100 mM potassium phosphate (pH 7.4) containing 5 mM magnesium chloride and a probe substrate, kynuramine (50 μM for MAO-A and 25 μM for MAO-B). Human MAO-A and human MAO-B were purchased from Corning (catalog numbers 456,283 and 456,284, respectively).</div><div class="NLM_p last">The control MAO inhibitor (tranylcypromine) was screened alongside the test article as a positive control for each isoform. After 20 min of incubation, the reactions were terminated by the addition of methanol containing propranolol as an analytical internal standard for quantification. The quenched samples were incubated at 4 °C for 10 min and then centrifuged at 4 °C for 10 min. The supernatant was removed, and the formed probe metabolite (4-hydroxyquinoline) was analyzed by LC–MS/MS. A decrease in the formation of the probe metabolite compared to the vehicle control was used to calculate the IC<sub>50</sub> value.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i154" class="anchor-spacer"></div><h3 class="article-section__title" id="_i154"> Repeated Dose Toxicity Study</h3><div class="NLM_p">All animal protocols were approved by Institute Animal Care and Welfare Committee. SD rats (6–7 weeks) were used in this study. A total of 96 rats were divided into four dose groups: vehicle control group, low, medium, and high dose groups. Each group was composed of 24 rats (♀12 and ♂12). Compound <b>19c</b> was administered orally once daily at doses of 50, 150, and 450 mg/kg/day for 4 weeks, followed by a 2 week recovery period.</div><div class="NLM_p">After the last administration, eight male and eight female animals were dissected in each group. After 14 days of recovery period, the remaining four male and four female animals were dissected in each group. The clinical symptoms of the animals were observed before administration, after administration, and in the afternoon during the experiment. Neurological symptoms were inspected at the day before the end of administration and the day before the end of the recovery period. Weight of rats was weighed once a week, and the dosage volume was adjusted according to the latest rat weight. Food consumption was weighed once a week. Ophthalmic examination was conducted during quarantine domestication, the end of drug administration, and the end of the recovery period within 7 days; urine examination was conducted within 7 days before the end of administration and recovery period. Blood samples were collected at the end of administration for hematological and serum biochemical examination, weighing of the organ, bone marrow smear, and pathological examination of tissue samples.</div><div class="NLM_p last">The Bartlett test was used to test for variance homogeneity. If the result showed no significance (<i>P</i> ≥ 0.05), one-way analysis of variance (ANOVA) was used. If ANOVA showed significance (<i>P</i> < 0.05), Dunnett’s test (parameter method) was used for multiple comparisons to identify statistically significant differences between the control group and each test article group.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i155"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00500" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00500?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00500</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra of all compounds and chiral HPLC of compounds <b>9a</b>, <b>9c–d</b>, <b>14a</b>, <b>14c–d</b>, <b>19a</b>, and <b>19c–d</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">X-ray crystal structure data of compound <b>19c</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_002.cif" class="ext-link">CIF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_001.pdf">jm0c00500_si_001.pdf (7.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_002.cif">jm0c00500_si_002.cif (3.96 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_003.csv">jm0c00500_si_003.csv (7.7 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00500" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haihong Huang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation,
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cba1a4b2a8ae8ba2a6a6e5aaa8e5a8a5"><span class="__cf_email__" data-cfemail="8ae0e5f3e9efcae3e7e7a4ebe9a4e9e4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongfeng Zhang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation,
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0870-3782" title="Orcid link">http://orcid.org/0000-0003-0870-3782</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#463c2220062f2b2b682725682528"><span class="__cf_email__" data-cfemail="e8928c8ea8818585c6898bc68b86">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Lu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing Chest Hospital, Capital
Medical University, 97
Ma Chang Street, Beijing 101149, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4428313d31707c7372042c2b3029252d286a272b29"><span class="__cf_email__" data-cfemail="4e223b373b7a7679780e26213a232f2722602d2123">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongyi Zhao</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation,
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Wang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing Chest Hospital, Capital
Medical University, 97
Ma Chang Street, Beijing 101149, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Fu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Drug Resistance Tuberculosis Research, Department
of Pharmacology, Beijing Tuberculosis and Thoracic Tumor Research
Institute, Beijing Chest Hospital, Capital
Medical University, 97
Ma Chang Street, Beijing 101149, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Li</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation,
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0924-7950" title="Orcid link">http://orcid.org/0000-0003-0924-7950</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haijia Lu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Active Substance Discovery and Druggability Evaluation,
Chinese Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuke Liu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Sheng</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Li</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese
Academy of Medical Sciences Key Laboratory of Anti-DR TB Innovative
Drug Research, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baoxi Zhang</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of
Medical Sciences, 1 Xian
Nong Tan Street, Beijing 100050, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Lu</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of
Medical Sciences, 1 Xian
Nong Tan Street, Beijing 100050, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2274-5703" title="Orcid link">http://orcid.org/0000-0002-2274-5703</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Ma</span> - <span class="hlFld-Affiliation affiliation">Beijing
Key Laboratory of Polymorphic Drugs, Chinese Academy of Medical Sciences
Key Laboratory of Anti-DR TB Innovative Drug Research, Institute of
Materia Medica, Peking Union Medical College
and Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Beijing 100050, P. R.
China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i156">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00804" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00804" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (grant 81502917), the National Science & Technology Major Project of China (grant 2015ZX09102007-013), and the CAMS Innovation Fund for Medical Sciences (grant 2017-I2M-1-011). We thank the technical support from Global Alliance for TB Drug Development. We thank Dr. Zhenkun Ma for his advice and help in preparation of this manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">TB</td><td class="NLM_def"><p class="first last">tuberculosis</p></td></tr><tr><td class="NLM_term">MDR-TB</td><td class="NLM_def"><p class="first last">multidrug-resistant TB</p></td></tr><tr><td class="NLM_term">XDR-TB</td><td class="NLM_def"><p class="first last">extensively drug resistant TB</p></td></tr><tr><td class="NLM_term">MPS</td><td class="NLM_def"><p class="first last">mitochondrial protein synthesis</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">TrCl</td><td class="NLM_def"><p class="first last">trityl chloride</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term"><i>m</i>-CPBA</td><td class="NLM_def"><p class="first last">3-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">CbzCl</td><td class="NLM_def"><p class="first last">benzyl chloroformate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylforamide</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TBHP</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl hydroperoxide</p></td></tr><tr><td class="NLM_term"><span class="smallcaps smallerCapital"><i>d</i></span>-(−)-DET</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital"><i>d</i></span>-(−)-diethyl tartrate</p></td></tr><tr><td class="NLM_term"><span class="smallcaps smallerCapital"><i>l</i></span>-(+)-DET</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital"><i>l</i></span>-(−)-diethyl tartrate</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">Mini-Ames</td><td class="NLM_def"><p class="first last">bacterial reverse mutation</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i158">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 31 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Global Tuberculosis Report
2019</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report%0A2019%3B+World+Health%0AOrganization%3A+Geneva%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%250A2019%26pub%3DWorld%2520Health%250AOrganization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0lhnQ_Ann4krSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0lhnQ_Ann4krSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhameliya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4379</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151106125759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.2174%2F0929867323666151106125759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26549430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=4379-4397&author=P.+Jadhavarauthor=M.+Vajaauthor=T.+Dhameliyaauthor=A.+Chakraborti&title=Oxazolidinones+as+anti-tubercular+agents%3A+discovery%2C+development+and+future+perspectives&doi=10.2174%2F0929867323666151106125759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives</span></div><div class="casAuthors">Jadhavar, Pradeep S.; Vaja, Maulikkumar D.; Dhameliya, Tejas M.; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4379-4397</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">TB drug development pipeline represents varied structural classes of mols.  Oxazolidinones represent synthetic anti-bacterial agents with unique mechanism of action having wide spectrum of activity, oral bioavailability and well established SAR.  They act by inhibiting translation at the initiation phase of protein synthesis.  Linezolid was the first oxazolidinone to reach the market in the year 2000 for the treatment of methicillin-resistant staphylococcal and vancomycin-resistant enterococcal infections.  Oxazolidinones have shown very good anti-mycobacterial activities.  Several oxazolidinones are currently in development for their possible use in TB therapy.  Oxazolidinones are classified on the basis of C-ring modifications.  DuP-721 was the first oxazolidinone having good anti-TB activity.  Linezolid, sutezolid and AZD5847 are in clin. development.  Several other C-ring modifications have shown promising results.  The usefulness of these oxazolidinones in the drug resistant TB is already established.  Toxicity, esp. myelosuppression, has been an important limiting factor for their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe0zxDblkvjLVg90H21EOLACvtfcHk0lhnQ_Ann4krSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D&md5=82f05591b2efaa98e30416bcecfc5749</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151106125759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151106125759%26sid%3Dliteratum%253Aachs%26aulast%3DJadhavar%26aufirst%3DP.%26aulast%3DVaja%26aufirst%3DM.%26aulast%3DDhameliya%26aufirst%3DT.%26aulast%3DChakraborti%26aufirst%3DA.%26atitle%3DOxazolidinones%2520as%2520anti-tubercular%2520agents%253A%2520discovery%252C%2520development%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D4379%26epage%3D4397%26doi%3D10.2174%2F0929867323666151106125759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0lgXQAMzQypKzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.-C.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2227</span>, <span class="refDoi"> DOI: 10.1128/aac.00414-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00414-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=18391030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2226-2227&author=T.-S.+Huangauthor=Y.-C.+Liuauthor=C.-L.+Syauthor=Y.-S.+Chenauthor=H.-Z.+Tuauthor=B.-C.+Chen&title=In+vitro+activities+of+linezolid+against+clinical+isolates+of+Mycobacterium+tuberculosis+complex+isolated+in+Taiwan+over+10+years&doi=10.1128%2Faac.00414-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span></div><div class="casAuthors">Huang, Tsi-Shu; Liu, Yung-Ching; Sy, Cheng-Len; Chen, Yao-Shen; Tu, Hui-Zin; Chen, Bao-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2226-2227</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Significant increases in the MIC90s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 μg/mL) and 2004 (2 μg/mL).  The MICs were 4 μg/mL in three strains.  Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoueJqnCpdKkrVg90H21EOLACvtfcHk0lgXQAMzQypKzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D&md5=444b842f9b0931bc13cb0f6d231e3a5e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FAAC.00414-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00414-07%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DY.-C.%26aulast%3DSy%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DY.-S.%26aulast%3DTu%26aufirst%3DH.-Z.%26aulast%3DChen%26aufirst%3DB.-C.%26atitle%3DIn%2520vitro%2520activities%2520of%2520linezolid%2520against%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520isolated%2520in%2520Taiwan%2520over%252010%2520years%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2226%26epage%3D2227%26doi%3D10.1128%2Faac.00414-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+first+approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eaVg092NIpWjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0lj4Gw7nFTVPlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0lj4Gw7nFTVPlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/aac.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2Faac.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0lj4Gw7nFTVPlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2Faac.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/aac.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.-W.+Jeongauthor=S.-J.+Jungauthor=H.-H.+Leeauthor=Y.-Z.+Kimauthor=T.-K.+Parkauthor=Y.-L.+Choauthor=S.-E.+Chaeauthor=S.-Y.+Baekauthor=S.-H.+Wooauthor=H.-S.+Leeauthor=J.-H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01-0371%2C+a+new+oxazolidinone&doi=10.1128%2Faac.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0ljkQozV5ji6Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.-W.%26aulast%3DJung%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DKim%26aufirst%3DY.-Z.%26aulast%3DPark%26aufirst%3DT.-K.%26aulast%3DCho%26aufirst%3DY.-L.%26aulast%3DChae%26aufirst%3DS.-E.%26aulast%3DBaek%26aufirst%3DS.-Y.%26aulast%3DWoo%26aufirst%3DS.-H.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01-0371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2Faac.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00165-18</span> <span class="refDoi"> DOI: 10.1128/aac.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+a.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2Faac.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%2Ba.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2Faac.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed Nov 29, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+Nov+29%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gravestock, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wookey, A.</span></span> <span> </span><span class="NLM_article-title">New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4179</span>– <span class="NLM_lpage">4186</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2003.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=14622997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslOgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4179-4186&author=M.+B.+Gravestockauthor=D.+G.+Actonauthor=M.+J.+Bettsauthor=M.+Dennisauthor=G.+Hatterauthor=A.+McGregorauthor=M.+L.+Swainauthor=R.+G.+Wilsonauthor=L.+Woodsauthor=A.+Wookey&title=New+classes+of+antibacterial+oxazolidinones+with+C-5%2C+methylene+O-linked+heterocyclic+side+chains&doi=10.1016%2Fj.bmcl.2003.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New classes of antibacterial oxazolidinones with C-5, methylene O-Linked heterocyclic side chains</span></div><div class="casAuthors">Gravestock, Michael B.; Acton, David G.; Betts, Michael J.; Dennis, Michael; Hatter, Glenn; McGregor, Alexandra; Swain, Michael L.; Wilson, R. Geoffrey; Woods, Lisa; Wookey, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4179-4186</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Exploration of the structure-activity relationships of the traditional C-5 acetamidomethyl side chain of the oxazolidonone antibacterials has yielded new, potent series of compds. of which the first examples, the O-linked iosoxazoles are described in detail, leading to the selection of the pre-clin. candidate AZD2563.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJvzUzhey0kLVg90H21EOLACvtfcHk0ljkQozV5ji6Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslOgsrY%253D&md5=c4d0a9cfcb00ab3863cd7c4fc0bd451e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DGravestock%26aufirst%3DM.%2BB.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DBetts%26aufirst%3DM.%2BJ.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DWilson%26aufirst%3DR.%2BG.%26aulast%3DWoods%26aufirst%3DL.%26aulast%3DWookey%26aufirst%3DA.%26atitle%3DNew%2520classes%2520of%2520antibacterial%2520oxazolidinones%2520with%2520C-5%252C%2520methylene%2520O-linked%2520heterocyclic%2520side%2520chains%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4179%26epage%3D4186%26doi%3D10.1016%2Fj.bmcl.2003.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1128/aac.01903-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01903-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=24189255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=495-502&author=V.+Balasubramanianauthor=S.+Solapureauthor=H.+Iyerauthor=A.+Ghoshauthor=S.+Sharmaauthor=P.+Kaurauthor=R.+Deepthiauthor=V.+Subbulakshmiauthor=V.+Ramyaauthor=V.+Ramachandranauthor=M.+Balganeshauthor=L.+Wrightauthor=D.+Melnickauthor=S.+L.+Butlerauthor=V.+K.+Sambandamurthy&title=Bactericidal+activity+and+mechanism+of+action+of+AZD5847%2C+a+novel+oxazolidinone+for+treatment+of+tuberculosis&doi=10.1128%2Faac.01903-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span></div><div class="casAuthors">Balasubramanian, V.; Solapure, S.; Iyer, H.; Ghosh, A.; Sharma, S.; Kaur, P.; Deepthi, R.; Subbulakshmi, V.; Ramya, V.; Ramachandran, V.; Balganesh, M.; Wright, L.; Melnick, D.; Butler, S. L.; Sambandamurthy, V. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">495-502, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) is impaired by the long duration and complexity of therapy and the rising incidence of drug resistance.  There is an urgent need for new agents with improved efficacy, safety, and compatibility with combination chemotherapies.  Oxazolidinones offer a potential new class of TB drugs, and linezolid-the only currently approved oxazolidinone-has proven highly effective against extensively drug-resistant (XDR) TB in exptl. trials.  However, widespread use of linezolid is prohibited by its significant toxicities.  AZD5847, a novel oxazolidinone, demonstrates improved in vitro bactericidal activity against both extracellular and intracellular M. tuberculosis compared to that of linezolid.  Killing kinetics in broth media and in macrophages indicate that the rate and extent of kill obtained with AZD5847 are superior to those obtained with linezolid.  Moreover, the efficacy of AZD5847 was additive when tested along with a variety of conventional TB agents, indicating that AZD5847 may function well in combination therapies.  AZD5847 appears to function similarly to linezolid through impairment of the mycobacterial 50S ribosomal subunit.  Future studies should be undertaken to further characterize the pharmacodynamics and pharmacokinetics of AZD5847 in both in vitro and animal models as well is in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnhn96nzN0bVg90H21EOLACvtfcHk0ljkQozV5ji6Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D&md5=9a55e83a915b1677ccb1189192d850f8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.01903-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01903-13%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DH.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDeepthi%26aufirst%3DR.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DRamya%26aufirst%3DV.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DBactericidal%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520AZD5847%252C%2520a%2520novel%2520oxazolidinone%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D495%26epage%3D502%26doi%3D10.1128%2Faac.01903-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinones</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1007%2F7355_2017_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=97-122&author=M.+R.+Barbachyn&title=The+oxazolidinones&doi=10.1007%2F7355_2017_15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_15%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DThe%2520oxazolidinones%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D97%26epage%3D122%26doi%3D10.1007%2F7355_2017_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2042</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/aac.01411-05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01411-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=16723564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2042-2049&author=E.+E.+McKeeauthor=M.+Fergusonauthor=A.+T.+Bentleyauthor=T.+A.+Marks&title=Inhibition+of+mammalian+mitochondrial+protein+synthesis+by+oxazolidinones&doi=10.1128%2Faac.01411-05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span></div><div class="casAuthors">McKee, E. E.; Ferguson, M.; Bentley, A. T.; Marks, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2042-2049</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were detd. in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow.  The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis.  Inhibition was similar in mitochondria from all tissues studied.  Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis.  These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis.  Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not.  Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWXrB0u0817Vg90H21EOLACvtfcHk0lh3dxyJTYC8xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D&md5=4dce4c12ad8fddadae1fd90953a596d1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.01411-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01411-05%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DE.%2BE.%26aulast%3DFerguson%26aufirst%3DM.%26aulast%3DBentley%26aufirst%3DA.%2BT.%26aulast%3DMarks%26aufirst%3DT.%2BA.%26atitle%3DInhibition%2520of%2520mammalian%2520mitochondrial%2520protein%2520synthesis%2520by%2520oxazolidinones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2042%26epage%3D2049%26doi%3D10.1128%2Faac.01411-05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meintjes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1080/14787210.2016.1225498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1080%2F14787210.2016.1225498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=27532292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=901-915&author=S.+Wassermanauthor=G.+Meintjesauthor=G.+Maartens&title=Linezolid+in+the+treatment+of+drug-resistant+tuberculosis%3A+the+challenge+of+its+narrow+therapeutic+index&doi=10.1080%2F14787210.2016.1225498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span></div><div class="casAuthors">Wasserman, Sean; Meintjes, Graeme; Maartens, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">901-915</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Linezolid is an oxazolidinone with potent activity against M tuberculosis, and improves culture conversion and cure rates when added to treatment regimens for drug resistant tuberculosis.  However, linezolid has a narrow therapeutic window, and the optimal dosing strategy that minimizes the substantial toxicity assocd. with linezolid's prolonged use in tuberculosis treatment has not been detd., limiting the potential impact of this anti-mycobacterial agent.  Areas covered: This paper aims to review and summarize the current knowledge on linezolid for the treatment of drug-resistant tuberculosis.  The focus is on the pharmacokinetic-pharmacodynamic determinants of linezolid's efficacy and toxicity in tuberculosis, and how this relates to defining an optimal dose.  Mechanisms of linezolid toxicity and resistance, and the potential role of therapeutic drug monitoring are also covered.  Expert commentary: Prospective pharmacokinetic-pharmacodynamic studies are required to define optimal therapeutic targets and to inform improved linezolid dosing strategies for drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRY5QIBD8h57Vg90H21EOLACvtfcHk0lh3dxyJTYC8xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL&md5=4e1bc3ec740ecd73d1e5f70144254214</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F14787210.2016.1225498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2016.1225498%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DMeintjes%26aufirst%3DG.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%253A%2520the%2520challenge%2520of%2520its%2520narrow%2520therapeutic%2520index%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2016%26volume%3D14%26spage%3D901%26epage%3D915%26doi%3D10.1080%2F14787210.2016.1225498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhasmana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid induced adverse drug reactions-an update</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.2174/1389200216666151001121004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.2174%2F1389200216666151001121004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26424176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVGnsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=553-559&author=K.+Kishorauthor=N.+Dhasmanaauthor=S.+Kambleauthor=R.+Sahu&title=Linezolid+induced+adverse+drug+reactions-an+update&doi=10.2174%2F1389200216666151001121004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid Induced Adverse Drug Reactions - An Update</span></div><div class="casAuthors">Kishor, Kamal; Dhasmana, Neha; Kamble, Shashank Shivaji; Sahu, Roshan Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">553-559</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Treatment regimen recommended for resistant tuberculosis consists of various drugs and these drugs are prescribed for at least 12-15 mo.  Such a long duration therapy and high dose of antibiotics result in adverse drug reactions (ADRs).  ADRs may lead to various complications in disease management like replacement of drugs, dose increment, therapy withdrawal, etc.  Linezolid is one of those drugs, practiced as an anti-mycobacterial agent and it is an important member of drug regimen for MDR and XDR tuberculosis.  Linezolid is a broad spectrum antibiotic known for its unique mechanism of inhibition of resistant pathogenic strains.  However, it causes serious adverse effects like thrombocytopenia, optic neuropathy, peripheral neuropathy, lactic acidosis, etc.  Literature suggests that Linezolid can cause severe ADRs which affect patient compliance and hinder in therapy to a larger extent.  Recent studies confirm the possibility of ADRs to be predicted with genetic make-up of individuals.  To effectively deliver the available treatment regimen and ensure patient compliance, it is important to manage ADRs more efficiently.  The role of pharmacogenomics in reducing adverse drug effects has been recently explored.  In the present review, we discussed about Linezolid induced adverse drug reactions, mechanisms and genetic assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2wVMXb4fSNLVg90H21EOLACvtfcHk0lh3dxyJTYC8xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVGnsbbJ&md5=4136597a46a864743d6de332c73fb736</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200216666151001121004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200216666151001121004%26sid%3Dliteratum%253Aachs%26aulast%3DKishor%26aufirst%3DK.%26aulast%3DDhasmana%26aufirst%3DN.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DSahu%26aufirst%3DR.%26atitle%3DLinezolid%2520induced%2520adverse%2520drug%2520reactions-an%2520update%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2015%26volume%3D16%26spage%3D553%26epage%3D559%26doi%3D10.2174%2F1389200216666151001121004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, L. H.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone antimicrobials: a patent review (2012-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1168807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1517%2F13543776.2016.1168807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26998627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=591-605&author=O.+A.+Phillipsauthor=L.+H.+Sharaf&title=Oxazolidinone+antimicrobials%3A+a+patent+review+%282012-2015%29&doi=10.1517%2F13543776.2016.1168807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antimicrobials: a patent review (2012-2015)</span></div><div class="casAuthors">Phillips, Oludotun A.; Sharaf, Leyla H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Gram-pos. bacteria is a major health care issue.  This review summarizes patent publications from 2012 to 2015 that divulged novel oxazolidinones as antibacterial agents.: A total of 25 patents obtained from Espacenet, WIPO Patentscope and FreePatentsOnline, and AcclaimIP search engines were reviewed.  The patents were scrutinized based on the novelty of the compds., their antibacterial activity (MIC, μg/mL), and the process of prepn.  The oxazolidinones with promising antibacterial activity were classified according to the following structural diversities, as biaryl heterocyclic, fused heteroaryl rings contg. oxazolidinones, and others.  The biaryl heterocyclic, fused heteroaryl, benzoxazine, and the 1H-pyrazol-1-yl contg. oxazolidinone derivs. demonstrated potent antibacterial activities superior to linezolid against Gram-pos. bacteria.  Some derivs. were effective against std. strains of Gram-neg. bacteria, namely Moraxella catarrhalis ATCC A894, and Escherichia coli ATCC 25922.  In addn., a patent disclosed a structural isomer of linezolid with marginal activity against the aerobic Gram-neg. bacteria MDR Stenotrophomonas (Xanthomonas) maltophilia, while linezolid and vancomycin did not inhibit growth.  Finally, some derivs. showed activity against respiratory infectious diseases' causative agents, such as B. anthracis, B. mallei, Y. pestis, and M. pneumoniae.  Overall, there is limited in vivo data to support the potential clin. advancement of the currently reported novel derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLzO8rJvUsrVg90H21EOLACvtfcHk0lj8nFQk7F5vSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D&md5=c5582e97a91b14e1ae65b19b2f4e0343</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1168807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1168807%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DSharaf%26aufirst%3DL.%2BH.%26atitle%3DOxazolidinone%2520antimicrobials%253A%2520a%2520patent%2520review%2520%25282012-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D591%26epage%3D605%26doi%3D10.1517%2F13543776.2016.1168807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0lj8nFQk7F5vSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0lj8nFQk7F5vSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant Tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+Tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0ljdLeh7Ezv9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520Tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisóstomo, F. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new benzocyclotrimer analogues: new receptors for tetramethylammonium ion recognition</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2912</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.5b01058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b01058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFakt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=2912-2915&author=R.+Carrilloauthor=M.+J.+Hynesauthor=V.+S.+Mart%C3%ADnauthor=T.+Mart%C3%ADnauthor=F.+P.+Cris%C3%B3stomo&title=Synthesis+of+new+benzocyclotrimer+analogues%3A+new+receptors+for+tetramethylammonium+ion+recognition&doi=10.1021%2Facs.orglett.5b01058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of New Benzocyclotrimer Analogues: New Receptors for Tetramethylammonium Ion Recognition</span></div><div class="casAuthors">Carrillo, Romen; Hynes, Michael J.; Martin, Victor S.; Martin, Tomas; Crisostomo, Fernando Pinacho</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2912-2915</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a [2+2+2] cycloaddn./Mitsunobu reaction sequence, a convenient synthesis to access new benzocyclotrimer analogs has been developed.  The new receptors have the geometry and functionality capable of recognizing the tetramethylammonium ion in the gas phase and in soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1BqelNg22TrVg90H21EOLACvtfcHk0ljdLeh7Ezv9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFakt74%253D&md5=ce458e0861c43aafee24c35b2b18a678</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b01058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b01058%26sid%3Dliteratum%253Aachs%26aulast%3DCarrillo%26aufirst%3DR.%26aulast%3DHynes%26aufirst%3DM.%2BJ.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%2BS.%26aulast%3DMart%25C3%25ADn%26aufirst%3DT.%26aulast%3DCris%25C3%25B3stomo%26aufirst%3DF.%2BP.%26atitle%3DSynthesis%2520of%2520new%2520benzocyclotrimer%2520analogues%253A%2520new%2520receptors%2520for%2520tetramethylammonium%2520ion%2520recognition%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D2912%26epage%3D2915%26doi%3D10.1021%2Facs.orglett.5b01058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7770</span>– <span class="NLM_lpage">7791</span>, <span class="refDoi"> DOI: 10.1021/jm501045e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501045e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7770-7791&author=T.+Xueauthor=S.+Dingauthor=B.+Guoauthor=Y.+Zhouauthor=P.+Sunauthor=H.+Wangauthor=W.+Chuauthor=G.+Gongauthor=Y.+Wangauthor=X.+Chenauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+and+structure-pharmacokinetic+relationship+studies+of+novel+%5B6%2C6%2C5%5D+tricyclic+fused+oxazolidinones+leading+to+the+discovery+of+a+potent%2C+selective%2C+and+orally+bioavailable+FXa+inhibitor&doi=10.1021%2Fjm501045e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity and Structure-Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor</span></div><div class="casAuthors">Xue, Tao; Ding, Shi; Guo, Bin; Zhou, Yuren; Sun, Peng; Wang, Heyao; Chu, Wenjing; Gong, Guoqing; Wang, Yinye; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7770-7791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood coagulation enzyme factor Xa (FXa) is a particularly promising target for anticoagulant therapy, and identification of oral small-mol. inhibitors of FXa remains a research focus.  On the basis of the X-ray crystal structure of FXa and its inhibitor rivaroxaban, we designed and synthesized a series of conformationally restricted mimics contg. a novel [6,6,5] tricyclic fused oxazolidinone scaffold.  Intensive structure-activity relationship (SAR) and structure-pharmacokinetic relationship (SPR) studies on this new series led to the discovery of compd. I (11a): a highly potent, selective, direct, and orally bioavailable FXa inhibitor with excellent in vivo antithrombotic efficacy and preferable pharmacokinetic profiles.  Druggability evaluation of compd. 11a was undertaken and elicited pos. outcomes.  All results indicate that compd. 11a is a promising drug candidate for the prevention and treatment of thromboembolic diseases in venous and arterial systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKRZp1NluvTLVg90H21EOLACvtfcHk0ljdLeh7Ezv9Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7fL&md5=9a75218d558748ddcf5f451649bb5520</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501045e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501045e%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520and%2520structure-pharmacokinetic%2520relationship%2520studies%2520of%2520novel%2520%255B6%252C6%252C5%255D%2520tricyclic%2520fused%2520oxazolidinones%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520FXa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7770%26epage%3D7791%26doi%3D10.1021%2Fjm501045e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajarao, A. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of novel oxazolidinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6424</span>– <span class="NLM_lpage">6428</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2009.09.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=19811911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWls7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6424-6428&author=B.+Dasauthor=A.+V.+S.+Rajaraoauthor=S.+Rudraauthor=A.+Yadavauthor=A.+Rayauthor=M.+Pandyaauthor=A.+Rattanauthor=A.+Mehta&title=Synthesis+and+biological+activity+of+novel+oxazolidinones&doi=10.1016%2Fj.bmcl.2009.09.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of novel oxazolidinones</span></div><div class="casAuthors">Das, Biswajit; Rajarao, A. V. S.; Rudra, Sonali; Yadav, Ajay; Ray, Abhijit; Pandya, Manisha; Rattan, Ashok; Mehta, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6424-6428</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of 5-substituted derivs. of Ranbezolid, a novel oxazolidinone were synthesized.  Antibacterial activity of the compds. against a no. of sensitive and resistant bacteria showed promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocgk-ZW-CRo7Vg90H21EOLACvtfcHk0liy7mak2_kstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWls7%252FI&md5=d23b5b1d37e93359dc4879a1b23a62a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DRajarao%26aufirst%3DA.%2BV.%2BS.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DA.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DPandya%26aufirst%3DM.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520novel%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6424%26epage%3D6428%26doi%3D10.1016%2Fj.bmcl.2009.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3697</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=23721807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3697-3699&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+biological+evaluation+of+novel+benzoxazinyl-oxazolidinones+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3697-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of benzoxazinyl-oxazolidinones bearing 3-triazolylmethyl or 3-carboxamide side chain were designed and synthesized with the aim to develop antibacterial agents with improved properties.  In vitro antibacterial activities of these novel compds. were evaluated against a panel of resistant and susceptible Gram-pos. bacteria.  Most analogs bearing 3-triazolylmethyl showed good to moderate antibacterial activities.  Compd. I exhibited a fourfold increase in activity compared with linezolid against all the tested strains, which was identified to be a promising antibacterial agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGOMF4mbAZWbVg90H21EOLACvtfcHk0liy7mak2_kstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D&md5=6b94ab65a6988a6456e66f526f871ef4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzoxazinyl-oxazolidinones%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3697%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">A concise synthesis of a bridged thiomorpholine: (1R, 5S)-3-thia-8-azabicyclo[3.2.1]octane</span>. <i>Chin. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=373-377&author=D.+Zhangauthor=S.+Chenauthor=L.+Fanauthor=Z.+Linauthor=H.+Huang&title=A+concise+synthesis+of+a+bridged+thiomorpholine%3A+%281R%2C+5S%29-3-thia-8-azabicyclo%5B3.2.1%5Doctane"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DA%2520concise%2520synthesis%2520of%2520a%2520bridged%2520thiomorpholine%253A%2520%25281R%252C%25205S%2529-3-thia-8-azabicyclo%255B3.2.1%255Doctane%26jtitle%3DChin.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D25%26spage%3D373%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. E.</span></span> <span> </span><span class="NLM_article-title">Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.pharmthera.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=15922018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1SltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=357-387&author=S.+K.+Kruegerauthor=D.+E.+Williams&title=Mammalian+flavin-containing+monooxygenases%3A+structure%2Ffunction%2C+genetic+polymorphisms+and+role+in+drug+metabolism&doi=10.1016%2Fj.pharmthera.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism</span></div><div class="casAuthors">Krueger, Sharon K.; Williams, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-387</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Flavin-contg. monooxygenase (FMO) oxygenates drugs and xenobiotics contg. a "soft nucleophile", usually N or S.  FMO, like cytochrome P 450 (CYP), is a monooxygenase, utilizing the reducing equiv. of NADPH to reduce 1 atom of O2 to H2O, while the other atom is used to oxidize the substrate.  FMO and CYP also exhibit similar tissue and cellular location, mol. wt., substrate specificity, and exist as multiple enzymes under developmental control.  The human FMO functional gene family is much smaller (5 families each with a single member) than CYP.  FMO does not require a reductase to transfer electrons from NADPH and the catalytic cycle of the 2 monooxygenases is strikingly different.  Another distinction is the lack of induction of FMOs by xenobiotics.  In general, CYP is the major contributor to oxidative xenobiotic metab.  However, FMO activity may be of significance in a no. of cases and should not be overlooked.  FMO and CYP have overlapping substrate specificities, but often yield distinct metabolites with potentially significant toxicol./pharmacol. consequences.  The physiol. function(s) of FMOs are poorly understood.  Three of the 5 expressed human FMO genes, FMO1, FMO2, and FMO3, exhibit genetic polymorphisms.  The most studied of these is FMO3 (adult human liver) in which mutant alleles contribute to the disease known as trimethylaminuria.  The consequences of these FMO genetic polymorphisms in drug metab. and human health are areas of research requiring further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwDBzxhgaYbVg90H21EOLACvtfcHk0liy7mak2_kstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1SltLc%253D&md5=2f0b76495aa8a53069bacc9b4ae8de43</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DS.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BE.%26atitle%3DMammalian%2520flavin-containing%2520monooxygenases%253A%2520structure%252Ffunction%252C%2520genetic%2520polymorphisms%2520and%2520role%2520in%2520drug%2520metabolism%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D106%26spage%3D357%26epage%3D387%26doi%3D10.1016%2Fj.pharmthera.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0liy7mak2_kstA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span> <span> </span><span class="NLM_article-title">Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5185</span>– <span class="NLM_lpage">5193</span>, <span class="refDoi"> DOI: 10.1128/aac.00699-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00699-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=21844321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSru7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=5185-5193&author=Y.+Luauthor=M.+Zhengauthor=B.+Wangauthor=L.+Fuauthor=W.+Zhaoauthor=P.+Liauthor=J.+Xuauthor=H.+Zhuauthor=H.+Jinauthor=D.+Yinauthor=H.+Huangauthor=A.+M.+Uptonauthor=Z.+Ma&title=Clofazimine+analogs+with+efficacy+against+experimental+tuberculosis+and+reduced+potential+for+accumulation&doi=10.1128%2Faac.00699-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation</span></div><div class="casAuthors">Lu, Yu; Zheng, Meiqin; Wang, Bin; Fu, Lei; Zhao, Weijie; Li, Peng; Xu, Jian; Zhu, Hui; Jin, Haixia; Yin, Dali; Huang, Haihong; Upton, Anna M.; Ma, Zhenkun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5185-5193</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global tuberculosis crisis urgently demands new, efficacious, orally available drugs with the potential to shorten and simplify the long and complex treatments for drug-sensitive and drug-resistant disease.  Clofazimine, a riminophenazine used for many years to treat leprosy, demonstrates efficacy in animal models of tuberculosis via a novel mode of action.  However, clofazimine's physicochem. and pharmacokinetic properties contribute to side effects that limit its use; in particular, an extremely long half-life and propensity for tissue accumulation together with clofazimine's dye properties leads to unwelcome skin discoloration.  We recently conducted a systematic structure-activity study of more than 500 riminophenazine analogs for anti-Mycobacterium tuberculosis activity.  We describe here the characteristics of 12 prioritized compds. in more detail.  The new riminophenazine analogs demonstrated enhanced in vitro activity compared to clofazimine against replicating M. tuberculosis H37Rv, as well as panels of drug-sensitive and drug-resistant clin. isolates.  The new compds. demonstrate at least equiv. activity compared to clofazimine against intracellular M. tuberculosis and, in addn., most of them were active against nonreplicating M. tuberculosis.  Eleven of these more water-sol. riminophenazine analogs possess shorter half-lives than clofazimine when dosed orally to mice, suggesting that they may accumulate less.  Most importantly, the nine compds. that progressed to efficacy testing demonstrated inhibition of bacterial growth in the lungs that is superior to the activity of an equiv. dose of clofazimine when administered orally for 20 days in a murine model of acute tuberculosis.  The efficacy of these compds., along with their decreased potential for accumulation and therefore perhaps also for tissue discoloration, warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZWSDoWqS4I7Vg90H21EOLACvtfcHk0ljDO_ltmD3D4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSru7nF&md5=07beec6fbd38eb9b3a3df87bcd2fbed6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.00699-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00699-11%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DClofazimine%2520analogs%2520with%2520efficacy%2520against%2520experimental%2520tuberculosis%2520and%2520reduced%2520potential%2520for%2520accumulation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D5185%26epage%3D5193%26doi%3D10.1128%2Faac.00699-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Pengxu Wang, Sarah M. Batt, Bin Wang, Lei Fu, Rongfei Qin, Yu Lu, Gang Li, Gurdyal S. Besra, <span class="NLM_string-name hlFld-ContribAuthor">Haihong Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 6241-6261. <a href="https://doi.org/10.1021/acs.jmedchem.1c00263" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00263%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BThiophene-arylamide%252BDerivatives%252Bas%252BDprE1%252BInhibitors%252Bwith%252BPotent%252BAntimycobacterial%252BActivities%26aulast%3DWang%26aufirst%3DPengxu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10022021%26date%3D14042021%26volume%3D64%26issue%3D9%26spage%3D6241%26epage%3D6261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Akanksha Sharma, Maria De Rosa, Neha Singla, Gurpal Singh, Ravi P. Barnwal, <span class="NLM_string-name hlFld-ContribAuthor">Ankur Pandey</span>. </span><span class="cited-content_cbyCitation_article-title">Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4359-4395. <a href="https://doi.org/10.1021/acs.jmedchem.0c01833" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01833%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTuberculosis%25253A%252BAn%252BOverview%252Bof%252Bthe%252BImmunogenic%252BResponse%25252C%252BDisease%252BProgression%25252C%252Band%252BMedicinal%252BChemistry%252BEfforts%252Bin%252Bthe%252BLast%252BDecade%252Btoward%252Bthe%252BDevelopment%252Bof%252BPotential%252BDrugs%252Bfor%252BExtensively%252BDrug-Resistant%252BTuberculosis%252BStrains%26aulast%3DSharma%26aufirst%3DAkanksha%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D20102020%26date%3D07042021%26volume%3D64%26issue%3D8%26spage%3D4359%26epage%3D4395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongqi Wu, Bin Wang, Haijia Lu, Hongyi Zhao, Beibei Yang, Li Li, Yu Lu, Dongfeng Zhang, Ning Sun, <span class="NLM_string-name hlFld-ContribAuthor">Haihong Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3234-3248. <a href="https://doi.org/10.1021/acs.jmedchem.0c02153" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02153%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BNovel%252BTricyclic%252BBenzo%25255B1%25252C3%25255Doxazinyloxazolidinones%252Bas%252BPotent%252BAntibacterial%252BAgents%252Bwith%252BExcellent%252BPharmacokinetic%252BProfiles%252Bagainst%252BDrug-Resistant%252BPathogens%26aulast%3DWu%26aufirst%3DYongqi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14122020%26date%3D11032021%26volume%3D64%26issue%3D6%26spage%3D3234%26epage%3D3248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Foti</span>, <span class="hlFld-ContribAuthor ">Anna  Piperno</span>, <span class="hlFld-ContribAuthor ">Angela  Scala</span>, <span class="hlFld-ContribAuthor ">Ottavia  Giuffrè</span>. </span><span class="cited-content_cbyCitation_article-title">Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (14)
                                     , 4280. <a href="https://doi.org/10.3390/molecules26144280" title="DOI URL">https://doi.org/10.3390/molecules26144280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26144280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26144280%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOxazolidinone%252BAntibiotics%25253A%252BChemical%25252C%252BBiological%252Band%252BAnalytical%252BAspects%26aulast%3DFoti%26aufirst%3DClaudia%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D14%26spage%3D4280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianwei  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuke  Liu</span>, <span class="hlFld-ContribAuthor ">Xiao  Liu</span>, <span class="hlFld-ContribAuthor ">Dongfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Haihong  Huang</span>, <span class="hlFld-ContribAuthor ">Baolian  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Sheng</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Simultaneous determination of a novel oxazolidinone anti-tuberculosis OTB-658 and its metabolites in monkey blood by LC-MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography B</span><span> <strong>2021,</strong> <em>1167 </em>, 122552. <a href="https://doi.org/10.1016/j.jchromb.2021.122552" title="DOI URL">https://doi.org/10.1016/j.jchromb.2021.122552</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jchromb.2021.122552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jchromb.2021.122552%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520B%26atitle%3DSimultaneous%252Bdetermination%252Bof%252Ba%252Bnovel%252Boxazolidinone%252Banti-tuberculosis%252BOTB-658%252Band%252Bits%252Bmetabolites%252Bin%252Bmonkey%252Bblood%252Bby%252BLC-MS%25252FMS%26aulast%3DJiang%26aufirst%3DJianwei%26date%3D2021%26volume%3D1167%26spage%3D122552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of oxazolidinones as anti-TB agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Lead optimization strategy of 3<i>a</i>,4-dihydro-1<i>H</i>,3<i>H</i>-benzo[<i>b</i>]oxazolo[3,4-<i>d</i>][1,4]oxazin-1-one.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>9a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TrCl, Et<sub>3</sub>N, DMAP, DCM, 0 °C-rt for <b>8a</b>; TrCl, 2,4,6-collidine, TBAI, DCM, 0 °C-rt, for <b>8b</b>; (ii) <i>m</i>-CPBA, DCM, 30 °C; and (iii) TBHP, Ti(OiPr)<sub>4</sub>, 4 Å MS, DCM, −40 to −20 °C, <span class="smallcaps smallerCapital"><i>d</i></span>-(−)-DET for <b>9c</b>, <span class="smallcaps smallerCapital"><i>l</i></span>-(+)-DET for <b>9d</b>.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>12a–f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) amine, <i>N</i>-methylmorpholine (NMM), MeCN, 80 °C; (ii) H<sub>2</sub>, Raney Ni, THF, 20–50 psi, rt for <b>12a</b>, <b>12c–e</b>; Zn, AcOH, THF, 30–40 °C for <b>12b</b> and <b>12f</b>; and (iii) CbzCl, NaHCO<sub>3</sub>, THF/H<sub>2</sub>O, 0 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>15a–i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) ADDP, PPh<sub>3</sub>, THF or DCM, 0 °C-rt; (ii) <i>t</i>-BuOLi, THF, rt for <b>14a</b>, <b>14b</b> and <b>14d</b>; <i>n</i>-BuLi, THF, −78 °C-rt for <b>14c</b> and <b>14e–i</b>; and (iii) TFA, DCM, rt for <b>15a–f</b> and <b>15h</b>; TsOH·H<sub>2</sub>O, DCM, MeOH, rt for <b>15g</b> and <b>15i</b>.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>19a–l</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, Et<sub>3</sub>N, DMAP, DCM, 0 °C-rt; (ii) potassium phthalimide, DMF, 80 °C; (iii) MeNH<sub>2</sub>, MeOH, reflux; (iv) acetic anhydride, pyridine, DCM, 0 °C-rt; (v) acetyl chloride, Et<sub>3</sub>N, DCM, 0 °C-rt; and (vi) methylsulfonyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>19f</b>; acyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>19g–i</b>; isonicotinic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>19j</b>; pyrazine-2-carboxylic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>19k</b>; CDI, THF, rt, then MeOH, THF, rt for <b>19l</b>.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>19m–o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) MeNH<sub>2</sub>, MeOH, THF, sealed tube, 100 °C; (ii) <i>N</i>-Boc-3-aminoisoxazole, NaH, DMF, 0–70 °C; (iii) HCl, EtOAc rt then H<sub>2</sub>O, NaHCO<sub>3</sub>, rt; (iv) NaN<sub>3</sub>, DMF, 80 °C; and (v) bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>19p–s</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) acetic anhydride, DMAP, 100 °C; (ii) MeI, NaH, THF, reflux; (iii) NaIO<sub>4</sub>, MeOH, H<sub>2</sub>O, rt; and (iv) NaIO<sub>4</sub>, MeOH, H<sub>2</sub>O, 60 °C.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>19t</b>, <b>20a–g</b>, <b>21</b>, <b>22</b>, and <b>23a–d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) TsCl, Et<sub>3</sub>N, DMAP, DCM, rt; (ii) ammonium hydroxide, THF, sealed tube, 100 °C; (iii) acetic anhydride, pyridine, DCM, 0 °C-rt for <b>19t</b>, <b>20a</b>, <b>21</b> and <b>22</b>; CDI, THF, rt, then MeOH, THF, rt for <b>20b</b>; acyl chloride, Et<sub>3</sub>N, DCM, 0 °C for <b>20c–e</b>; isonicotinic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>20f</b>; pyrazine-2-carboxylic acid, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt for <b>20g</b>; (iv) MsCl, NMM, DCM, rt; (v) NaN<sub>3</sub>, DMF, 70 °C; (vi) H<sub>2</sub>, Pd/C, THF; (vii) acetic anhydride, pyridine, THF, 0 °C-rt for <b>23a</b>; acyl chloride, Et<sub>3</sub>N, THF, 0 °C for <b>23b–c</b>; and (viii) bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>20h</b> and <b>20i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>N</i>-boc-3-aminoisoxazole, NaH, DMF, 0–70 °C then HCl, EtOAc rt then H<sub>2</sub>O, NaHCO<sub>3</sub>, rt and (ii) NaN<sub>3</sub>, DMF, 80 °C then bicyclo[2.2.1]hepta-2,5-diene, dioxane, reflux.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystallographic structure of compound <b>19c</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/medium/jm0c00500_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy in the mouse model of acute <i>M. tuberculosis</i> infection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c00500/20200903/images/large/jm0c00500_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00500&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i158">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 31 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Global Tuberculosis Report
2019</i>; <span class="NLM_publisher-name">World Health
Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global+Tuberculosis+Report%0A2019%3B+World+Health%0AOrganization%3A+Geneva%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DGlobal%2520Tuberculosis%2520Report%250A2019%26pub%3DWorld%2520Health%250AOrganization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0lgVpHF1pX3mag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ippolito, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanyo, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franceschi, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steitz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, E. M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3356</span>, <span class="refDoi"> DOI: 10.1021/jm800379d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800379d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3353-3356&author=J.+A.+Ippolitoauthor=Z.+F.+Kanyoauthor=D.+Wangauthor=F.+J.+Franceschiauthor=P.+B.+Mooreauthor=T.+A.+Steitzauthor=E.+M.+Duffy&title=Crystal+structure+of+the+oxazolidinone+antibiotic+linezolid+bound+to+the+50S+ribosomal+subunit&doi=10.1021%2Fjm800379d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit</span></div><div class="casAuthors">Ippolito, Joseph A.; Kanyo, Zoltan F.; Wang, Deping; Franceschi, Francois J.; Moore, Peter B.; Steitz, Thomas A.; Duffy, Erin M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3353-3356</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxazolidinone antibacterials target the 50S subunit of prokaryotic ribosomes.  To gain insight into their mechanism of action, the crystal structure of the canonical oxazolidinone, linezolid, has been detd. bound to the Haloarcula marismortui 50S subunit.  Linezolid binds the 50S A-site, near the catalytic center, which suggests that inhibition involves competition with incoming A-site substrates.  These results provide a structural basis for the discovery of improved oxazolidinones active against emerging drug-resistant clin. strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2a6yG28gBjbVg90H21EOLACvtfcHk0ljUnMD6nrh-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtF2ku7g%253D&md5=bdf67198829f16561cf447257ac21f8e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm800379d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800379d%26sid%3Dliteratum%253Aachs%26aulast%3DIppolito%26aufirst%3DJ.%2BA.%26aulast%3DKanyo%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DFranceschi%26aufirst%3DF.%2BJ.%26aulast%3DMoore%26aufirst%3DP.%2BB.%26aulast%3DSteitz%26aufirst%3DT.%2BA.%26aulast%3DDuffy%26aufirst%3DE.%2BM.%26atitle%3DCrystal%2520structure%2520of%2520the%2520oxazolidinone%2520antibiotic%2520linezolid%2520bound%2520to%2520the%252050S%2520ribosomal%2520subunit%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3353%26epage%3D3356%26doi%3D10.1021%2Fjm800379d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jadhavar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaja, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhameliya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborti, A.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4379</span>– <span class="NLM_lpage">4397</span>, <span class="refDoi"> DOI: 10.2174/0929867323666151106125759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.2174%2F0929867323666151106125759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26549430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=4379-4397&author=P.+Jadhavarauthor=M.+Vajaauthor=T.+Dhameliyaauthor=A.+Chakraborti&title=Oxazolidinones+as+anti-tubercular+agents%3A+discovery%2C+development+and+future+perspectives&doi=10.2174%2F0929867323666151106125759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives</span></div><div class="casAuthors">Jadhavar, Pradeep S.; Vaja, Maulikkumar D.; Dhameliya, Tejas M.; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">4379-4397</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">TB drug development pipeline represents varied structural classes of mols.  Oxazolidinones represent synthetic anti-bacterial agents with unique mechanism of action having wide spectrum of activity, oral bioavailability and well established SAR.  They act by inhibiting translation at the initiation phase of protein synthesis.  Linezolid was the first oxazolidinone to reach the market in the year 2000 for the treatment of methicillin-resistant staphylococcal and vancomycin-resistant enterococcal infections.  Oxazolidinones have shown very good anti-mycobacterial activities.  Several oxazolidinones are currently in development for their possible use in TB therapy.  Oxazolidinones are classified on the basis of C-ring modifications.  DuP-721 was the first oxazolidinone having good anti-TB activity.  Linezolid, sutezolid and AZD5847 are in clin. development.  Several other C-ring modifications have shown promising results.  The usefulness of these oxazolidinones in the drug resistant TB is already established.  Toxicity, esp. myelosuppression, has been an important limiting factor for their development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe0zxDblkvjLVg90H21EOLACvtfcHk0ljUnMD6nrh-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOmtw%253D%253D&md5=82f05591b2efaa98e30416bcecfc5749</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151106125759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151106125759%26sid%3Dliteratum%253Aachs%26aulast%3DJadhavar%26aufirst%3DP.%26aulast%3DVaja%26aufirst%3DM.%26aulast%3DDhameliya%26aufirst%3DT.%26aulast%3DChakraborti%26aufirst%3DA.%26atitle%3DOxazolidinones%2520as%2520anti-tubercular%2520agents%253A%2520discovery%252C%2520development%2520and%2520future%2520perspectives%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2015%26volume%3D22%26spage%3D4379%26epage%3D4397%26doi%3D10.2174%2F0929867323666151106125759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone structure-activity relationships leading to linezolid</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2023</span>, <span class="refDoi"> DOI: 10.1002/anie.200200528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1002%2Fanie.200200528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=2010-2023&author=M.+R.+Barbachynauthor=C.+W.+Ford&title=Oxazolidinone+structure-activity+relationships+leading+to+linezolid&doi=10.1002%2Fanie.200200528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone structure-activity relationships leading to linezolid</span></div><div class="casAuthors">Barbachyn, Michael R.; Ford, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2010-2023</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of bacterial resistance to currently available antibacterial agents is a growing global health problem.  Of particular concern are infections caused by multidrug-resistant Gram-pos. pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings.  A no. of solns. to the problem of bacterial resistance are possible.  The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogs with improved attributes.  Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity.  Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise.  Such agents would exhibit a lack of cross-resistance with existing antimicrobial drugs.  This review describes the work leading to the discovery of linezolid, the first clin. useful oxazolidinone antibacterial agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGritv1CBogyHbVg90H21EOLACvtfcHk0ljUnMD6nrh-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkt1Snu7k%253D&md5=681744cbb331d9256cc32d8b60987284</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.200200528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200200528%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DFord%26aufirst%3DC.%2BW.%26atitle%3DOxazolidinone%2520structure-activity%2520relationships%2520leading%2520to%2520linezolid%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2003%26volume%3D42%26spage%3D2010%26epage%3D2023%26doi%3D10.1002%2Fanie.200200528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sy, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.-C.</span></span> <span> </span><span class="NLM_article-title">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2226</span>– <span class="NLM_lpage">2227</span>, <span class="refDoi"> DOI: 10.1128/aac.00414-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00414-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=18391030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2226-2227&author=T.-S.+Huangauthor=Y.-C.+Liuauthor=C.-L.+Syauthor=Y.-S.+Chenauthor=H.-Z.+Tuauthor=B.-C.+Chen&title=In+vitro+activities+of+linezolid+against+clinical+isolates+of+Mycobacterium+tuberculosis+complex+isolated+in+Taiwan+over+10+years&doi=10.1128%2Faac.00414-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years</span></div><div class="casAuthors">Huang, Tsi-Shu; Liu, Yung-Ching; Sy, Cheng-Len; Chen, Yao-Shen; Tu, Hui-Zin; Chen, Bao-Chen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2226-2227</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Significant increases in the MIC90s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 μg/mL) and 2004 (2 μg/mL).  The MICs were 4 μg/mL in three strains.  Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoueJqnCpdKkrVg90H21EOLACvtfcHk0ljIrJi5XT1l-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVait7g%253D&md5=444b842f9b0931bc13cb0f6d231e3a5e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1128%2FAAC.00414-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00414-07%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.-S.%26aulast%3DLiu%26aufirst%3DY.-C.%26aulast%3DSy%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DY.-S.%26aulast%3DTu%26aufirst%3DH.-Z.%26aulast%3DChen%26aufirst%3DB.-C.%26atitle%3DIn%2520vitro%2520activities%2520of%2520linezolid%2520against%2520clinical%2520isolates%2520of%2520Mycobacterium%2520tuberculosis%2520complex%2520isolated%2520in%2520Taiwan%2520over%252010%2520years%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2226%26epage%3D2227%26doi%3D10.1128%2Faac.00414-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: first approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+first+approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eZYn2qiAs_sf7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520first%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brickner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cynamon, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilburn, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klemens, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glickman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grega, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendges, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toops, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">680</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1021/jm950956y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950956y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=680-685&author=M.+R.+Barbachynauthor=D.+K.+Hutchinsonauthor=S.+J.+Bricknerauthor=M.+H.+Cynamonauthor=J.+O.+Kilburnauthor=S.+P.+Klemensauthor=S.+E.+Glickmanauthor=K.+C.+Gregaauthor=S.+K.+Hendgesauthor=D.+S.+Toopsauthor=C.+W.+Fordauthor=G.+E.+Zurenko&title=Identification+of+a+novel+oxazolidinone+%28U-100480%29+with+potent+antimycobacterial+activity&doi=10.1021%2Fjm950956y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity</span></div><div class="casAuthors">Barbachyn, Michael R.; Hutchinson, Douglas K.; Brickner, Steven J.; Cynamon, Michael H.; Kilburn, James O.; Klemens, Sally P.; Glickman, Suzanne E.; Grega, Kevin C.; Hendges, Susan K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">680-5</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A subclass of oxazolidinone antibacterial agents with esp. potent in vitro activity against mycobacteria was discovered.  The salient structural feature of these oxazolidinone analogs, U-100480 [i.e., (S)-N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide], U-101603, and U-101244 is their appended thiomorpholine moiety.  The rational design, synthesis, and evaluation of the in vitro antimycobacterial activity of these analogs was described.  Potent activity against a screening strain of Mycobacterium tuberculosis was demonstrated by U-100480 and U-101603 (min. inhibitory concns. or MIC's ≤0.125 μg/mL).  Oxazolidinones U-100480 and U-101244 exhibit MIC90 values of 0.50 μg/mL or less against a panel of organisms consisting of five drug-sensitive and five multidrug-resistant strains of M. tuberculosis, with U-100480 being the most active congener.  Potent in vitro activity against other mycobacterial species was also demonstrated by U-100480.  For example, U-100480 exhibited excellent in vitro activity against multiple clin. isolates of Mycobacterium avium complex (MIC's = 0.5-4 μg/mL).  Orally administered U-100480 displays in vivo efficacy against M. tuberculosis and M. avium similar to that of clin. comparators isoniazid and azithromycin, resp.  Consideration of these factors, along with a favorable pharmacokinetic and chronic toxicity profile in rats, suggests that U-100480 is a promising antimycobacterial agent (tuberculostatic).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAvvlFTIROHbVg90H21EOLACvtfcHk0ljIrJi5XT1l-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVCisQ%253D%253D&md5=8636d20221390257b48f2d3dd6884b78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm950956y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950956y%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DHutchinson%26aufirst%3DD.%2BK.%26aulast%3DBrickner%26aufirst%3DS.%2BJ.%26aulast%3DCynamon%26aufirst%3DM.%2BH.%26aulast%3DKilburn%26aufirst%3DJ.%2BO.%26aulast%3DKlemens%26aufirst%3DS.%2BP.%26aulast%3DGlickman%26aufirst%3DS.%2BE.%26aulast%3DGrega%26aufirst%3DK.%2BC.%26aulast%3DHendges%26aufirst%3DS.%2BK.%26aulast%3DToops%26aufirst%3DD.%2BS.%26aulast%3DFord%26aufirst%3DC.%2BW.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26atitle%3DIdentification%2520of%2520a%2520novel%2520oxazolidinone%2520%2528U-100480%2529%2520with%2520potent%2520antimycobacterial%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D680%26epage%3D685%26doi%3D10.1021%2Fjm950956y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1086/655471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1086%2F655471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=20629533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2010&pages=745-751&author=R.+S.+Wallisauthor=W.+M.+Jakubiecauthor=V.+Kumarauthor=A.+M.+Silviaauthor=D.+Paigeauthor=D.+Dimitrovaauthor=X.+Liauthor=L.+Ladutkoauthor=S.+Campbellauthor=G.+Friedlandauthor=M.+Mitton-Fryauthor=P.+F.+Miller&title=Pharmacokinetics+and+whole-blood+bactericidal+activity+against+Mycobacterium+tuberculosis+of+single+doses+of+PNU-100480+in+healthy+volunteers&doi=10.1086%2F655471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley M.; Kumar, Vikas; Silvia, Annette M.; Paige, Darcy; Dimitrova, Dessislava; Li, Xiaoxi; Ladutko, Lynn; Campbell, Sheldon; Friedland, Gerald; Mitton-Fry, Mark; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">745-751</span>CODEN:
                <span class="NLM_cas:coden">JIDIAQ</span>;
        ISSN:<span class="NLM_cas:issn">0022-1899</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Background: The oxazolidinone PNU-100480 is superior to linezolid against exptl. murine tuberculosis.  Two metabolites contribute to but do not fully account for its superiority.  This study examd. the safety, tolerability, pharmacokinetics, and mycobactericidal activity of single ascending doses of PNU-100480.  Methods: Nineteen healthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.  Eight subjects received 4 daily doses of 300 mg of linezolid.  Drug concns. and bactericidal activity against Mycobacterium tuberculosis in whole-blood bactericidal culture were measured.  Results: All doses were safe and well tolerated.  PNU-100480 doses to 1000 mg were well absorbed and showed approx. proportional increases in exposures of parent and metabolites.  The geometric mean maximal concns. of PNU-100480, PNU-101603, and PNU-101244 (sulfoxide and sulfone metabolites) at 1000 mg were 839, 3558, and 54 ng/mL, resp.  The maximal whole-blood bactericidal activity (-037 ± .06 log/day) occurred at combined PNU levels ≥2 times the min. inhibitory concn.  The obsd. geometric mean maximal concn. for linezolid was 6425 ng/mL.  Its maximal whole-blood bactericidal activity also occurred at ≥2 times the min. inhibitory concn., but it was only -0.16 ± .05 log/day (P < .001).  Neither drug showed enhanced activity at higher concns.  Conclusions: Single doses of PNU-100480 to 1000 mg were well tolerated and exhibited antimycobacterial activity superior to 300 mg of linezolid at steady state.  Addnl. studies are warranted to define its role in drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgr7U7caSPNbVg90H21EOLACvtfcHk0ljYveF-lv5Cag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKjsrzM&md5=bd6fb9cd1190593681d167471f09a06d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1086%2F655471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F655471%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%2BM.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DSilvia%26aufirst%3DA.%2BM.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DDimitrova%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DFriedland%26aufirst%3DG.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DPharmacokinetics%2520and%2520whole-blood%2520bactericidal%2520activity%2520against%2520Mycobacterium%2520tuberculosis%2520of%2520single%2520doses%2520of%2520PNU-100480%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2010%26volume%3D202%26spage%3D745%26epage%3D751%26doi%3D10.1086%2F655471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubiec, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedarida, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paige, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladutko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P. F.</span></span> <span> </span><span class="NLM_article-title">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1128/aac.01179-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01179-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=21078950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=567-574&author=R.+S.+Wallisauthor=W.+Jakubiecauthor=V.+Kumarauthor=G.+Bedaridaauthor=A.+Silviaauthor=D.+Paigeauthor=T.+Zhuauthor=M.+Mitton-Fryauthor=L.+Ladutkoauthor=S.+Campbellauthor=P.+F.+Miller&title=Biomarker-assisted+dose+selection+for+safety+and+efficacy+in+early+development+of+PNU-100480+for+tuberculosis&doi=10.1128%2Faac.01179-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis</span></div><div class="casAuthors">Wallis, Robert S.; Jakubiec, Wesley; Kumar, Vikas; Bedarida, Gabriella; Silvia, Annette; Paige, Darcy; Zhu, Tong; Mitton-Fry, Mark; Ladutko, Lynn; Campbell, Sheldon; Miller, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">567-574</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tuberculosis is a serious global health threat for which new treatments are urgently needed.  This study examd. the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy.  Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28.  A sixth cohort was given linezolid at 300 mg daily for 4 days.  Signs, symptoms, and routine safety tests were monitored.  Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture.  Plasma drug and metabolite concns. were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis.  All doses were safe and well tolerated.  There were no hematol. or other safety signals during 28 days of dosing at 600 mg twice daily.  Plasma concns. of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis.  Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (-0.316 ± 0.04 log) were superior to the activities of all other doses tested (P < 0.001) and was significantly augmented by pyrazinamide (-0.420 ± 0.06 log) (P = 0.002).  In conclusion, PNU-100480 was safe and well tolerated at all tested doses.  Further studies in patients with tuberculosis are warranted.  Biomarkers can accelerate early development of new tuberculosis treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCYDkvTtgkiLVg90H21EOLACvtfcHk0ljYveF-lv5Cag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVyjsLs%253D&md5=332e0a4d1903c4f9408b6e5e412eabb0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.01179-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01179-10%26sid%3Dliteratum%253Aachs%26aulast%3DWallis%26aufirst%3DR.%2BS.%26aulast%3DJakubiec%26aufirst%3DW.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DBedarida%26aufirst%3DG.%26aulast%3DSilvia%26aufirst%3DA.%26aulast%3DPaige%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DMitton-Fry%26aufirst%3DM.%26aulast%3DLadutko%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DP.%2BF.%26atitle%3DBiomarker-assisted%2520dose%2520selection%2520for%2520safety%2520and%2520efficacy%2520in%2520early%2520development%2520of%2520PNU-100480%2520for%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D567%26epage%3D574%26doi%3D10.1128%2Faac.01179-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, T.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwak, J.-H.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5359</span>– <span class="NLM_lpage">5362</span>, <span class="refDoi"> DOI: 10.1128/aac.00723-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00723-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=20855730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5359-5362&author=J.-W.+Jeongauthor=S.-J.+Jungauthor=H.-H.+Leeauthor=Y.-Z.+Kimauthor=T.-K.+Parkauthor=Y.-L.+Choauthor=S.-E.+Chaeauthor=S.-Y.+Baekauthor=S.-H.+Wooauthor=H.-S.+Leeauthor=J.-H.+Kwak&title=In+vitro+and+in+vivo+activities+of+LCB01-0371%2C+a+new+oxazolidinone&doi=10.1128%2Faac.00723-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo activities of LCB01-0371, a new oxazolidinone</span></div><div class="casAuthors">Jeong, Ji-Woong; Jung, Sung-Ji; Lee, Hyun-Hee; Kim, Yong-Zu; Park, Tae-Kyo; Cho, Young-Lag; Chae, Sang-Eun; Baek, Sung-Yoon; Woo, Sung-Ho; Lee, Hyang-Sook; Kwak, Jin-Hwan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5359-5362</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">LCB01-0371 is a new oxazolidinone with cyclic amidrazone.  In vitro activity of LCB01-0371 against 624 clin. isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics.  LCB01-0371 showed good activity against Gram-pos. pathogens.  In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated.  LCB01-0371 was more active than linezolid against these systemic infections.  LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobg2lKKc8bzbVg90H21EOLACvtfcHk0ljYveF-lv5Cag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msr%252FJ&md5=27471d63f1195f29f869689c125f643e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.00723-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00723-10%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DJ.-W.%26aulast%3DJung%26aufirst%3DS.-J.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DKim%26aufirst%3DY.-Z.%26aulast%3DPark%26aufirst%3DT.-K.%26aulast%3DCho%26aufirst%3DY.-L.%26aulast%3DChae%26aufirst%3DS.-E.%26aulast%3DBaek%26aufirst%3DS.-Y.%26aulast%3DWoo%26aufirst%3DS.-H.%26aulast%3DLee%26aufirst%3DH.-S.%26aulast%3DKwak%26aufirst%3DJ.-H.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activities%2520of%2520LCB01-0371%252C%2520a%2520new%2520oxazolidinone%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5359%26epage%3D5362%26doi%3D10.1128%2Faac.00723-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span> <span> </span><span class="NLM_article-title">Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>, <span class="NLM_elocation-id">e00165-18</span> <span class="refDoi"> DOI: 10.1128/aac.00165-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00165-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=29844043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&author=Z.+Zongauthor=W.+Jingauthor=J.+Shiauthor=S.+a.+Wenauthor=T.+Zhangauthor=F.+Huoauthor=Y.+Shangauthor=Q.+Liangauthor=H.+Huangauthor=Y.+Pang&title=Comparison+of+in+vitro+activity+and+MIC+distributions+between+the+novel+oxazolidinone+delpazolid+and+linezolid+against+multidrug-resistant+and+extensively+drug-resistant+Mycobacterium+tuberculosis+in+China&doi=10.1128%2Faac.00165-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.00165-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00165-18%26sid%3Dliteratum%253Aachs%26aulast%3DZong%26aufirst%3DZ.%26aulast%3DJing%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DS.%2Ba.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHuo%26aufirst%3DF.%26aulast%3DShang%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DPang%26aufirst%3DY.%26atitle%3DComparison%2520of%2520in%2520vitro%2520activity%2520and%2520MIC%2520distributions%2520between%2520the%2520novel%2520oxazolidinone%2520delpazolid%2520and%2520linezolid%2520against%2520multidrug-resistant%2520and%2520extensively%2520drug-resistant%2520Mycobacterium%2520tuberculosis%2520in%2520China%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26doi%3D10.1128%2Faac.00165-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">U.S. National Library of Medicine</span>. <span> </span><span class="NLM_article-title">ClinicalTrials.gov</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT03758612" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03758612</a> (accessed Nov 29, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+National+Library+of+Medicine.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03758612+%28accessed+Nov+29%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DClinicalTrials.gov" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gravestock, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swain, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wookey, A.</span></span> <span> </span><span class="NLM_article-title">New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chains</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4179</span>– <span class="NLM_lpage">4186</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2003.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=14622997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslOgsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=4179-4186&author=M.+B.+Gravestockauthor=D.+G.+Actonauthor=M.+J.+Bettsauthor=M.+Dennisauthor=G.+Hatterauthor=A.+McGregorauthor=M.+L.+Swainauthor=R.+G.+Wilsonauthor=L.+Woodsauthor=A.+Wookey&title=New+classes+of+antibacterial+oxazolidinones+with+C-5%2C+methylene+O-linked+heterocyclic+side+chains&doi=10.1016%2Fj.bmcl.2003.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">New classes of antibacterial oxazolidinones with C-5, methylene O-Linked heterocyclic side chains</span></div><div class="casAuthors">Gravestock, Michael B.; Acton, David G.; Betts, Michael J.; Dennis, Michael; Hatter, Glenn; McGregor, Alexandra; Swain, Michael L.; Wilson, R. Geoffrey; Woods, Lisa; Wookey, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4179-4186</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Exploration of the structure-activity relationships of the traditional C-5 acetamidomethyl side chain of the oxazolidonone antibacterials has yielded new, potent series of compds. of which the first examples, the O-linked iosoxazoles are described in detail, leading to the selection of the pre-clin. candidate AZD2563.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJvzUzhey0kLVg90H21EOLACvtfcHk0lh_IWe7yBT03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslOgsrY%253D&md5=c4d0a9cfcb00ab3863cd7c4fc0bd451e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DGravestock%26aufirst%3DM.%2BB.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DBetts%26aufirst%3DM.%2BJ.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DHatter%26aufirst%3DG.%26aulast%3DMcGregor%26aufirst%3DA.%26aulast%3DSwain%26aufirst%3DM.%2BL.%26aulast%3DWilson%26aufirst%3DR.%2BG.%26aulast%3DWoods%26aufirst%3DL.%26aulast%3DWookey%26aufirst%3DA.%26atitle%3DNew%2520classes%2520of%2520antibacterial%2520oxazolidinones%2520with%2520C-5%252C%2520methylene%2520O-linked%2520heterocyclic%2520side%2520chains%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D4179%26epage%3D4186%26doi%3D10.1016%2Fj.bmcl.2003.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solapure, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deepthi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subbulakshmi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balganesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambandamurthy, V. K.</span></span> <span> </span><span class="NLM_article-title">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">502</span>, <span class="refDoi"> DOI: 10.1128/aac.01903-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01903-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=24189255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=495-502&author=V.+Balasubramanianauthor=S.+Solapureauthor=H.+Iyerauthor=A.+Ghoshauthor=S.+Sharmaauthor=P.+Kaurauthor=R.+Deepthiauthor=V.+Subbulakshmiauthor=V.+Ramyaauthor=V.+Ramachandranauthor=M.+Balganeshauthor=L.+Wrightauthor=D.+Melnickauthor=S.+L.+Butlerauthor=V.+K.+Sambandamurthy&title=Bactericidal+activity+and+mechanism+of+action+of+AZD5847%2C+a+novel+oxazolidinone+for+treatment+of+tuberculosis&doi=10.1128%2Faac.01903-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis</span></div><div class="casAuthors">Balasubramanian, V.; Solapure, S.; Iyer, H.; Ghosh, A.; Sharma, S.; Kaur, P.; Deepthi, R.; Subbulakshmi, V.; Ramya, V.; Ramachandran, V.; Balganesh, M.; Wright, L.; Melnick, D.; Butler, S. L.; Sambandamurthy, V. K.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">495-502, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Treatment of tuberculosis (TB) is impaired by the long duration and complexity of therapy and the rising incidence of drug resistance.  There is an urgent need for new agents with improved efficacy, safety, and compatibility with combination chemotherapies.  Oxazolidinones offer a potential new class of TB drugs, and linezolid-the only currently approved oxazolidinone-has proven highly effective against extensively drug-resistant (XDR) TB in exptl. trials.  However, widespread use of linezolid is prohibited by its significant toxicities.  AZD5847, a novel oxazolidinone, demonstrates improved in vitro bactericidal activity against both extracellular and intracellular M. tuberculosis compared to that of linezolid.  Killing kinetics in broth media and in macrophages indicate that the rate and extent of kill obtained with AZD5847 are superior to those obtained with linezolid.  Moreover, the efficacy of AZD5847 was additive when tested along with a variety of conventional TB agents, indicating that AZD5847 may function well in combination therapies.  AZD5847 appears to function similarly to linezolid through impairment of the mycobacterial 50S ribosomal subunit.  Future studies should be undertaken to further characterize the pharmacodynamics and pharmacokinetics of AZD5847 in both in vitro and animal models as well is in human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcnhn96nzN0bVg90H21EOLACvtfcHk0lh_IWe7yBT03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFChsr8%253D&md5=9a55e83a915b1677ccb1189192d850f8</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FAAC.01903-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01903-13%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramanian%26aufirst%3DV.%26aulast%3DSolapure%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DH.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DDeepthi%26aufirst%3DR.%26aulast%3DSubbulakshmi%26aufirst%3DV.%26aulast%3DRamya%26aufirst%3DV.%26aulast%3DRamachandran%26aufirst%3DV.%26aulast%3DBalganesh%26aufirst%3DM.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DMelnick%26aufirst%3DD.%26aulast%3DButler%26aufirst%3DS.%2BL.%26aulast%3DSambandamurthy%26aufirst%3DV.%2BK.%26atitle%3DBactericidal%2520activity%2520and%2520mechanism%2520of%2520action%2520of%2520AZD5847%252C%2520a%2520novel%2520oxazolidinone%2520for%2520treatment%2520of%2520tuberculosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D495%26epage%3D502%26doi%3D10.1128%2Faac.01903-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span> <span> </span><span class="NLM_article-title">The oxazolidinones</span>. <i>Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1007/7355_2017_15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1007%2F7355_2017_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=97-122&author=M.+R.+Barbachyn&title=The+oxazolidinones&doi=10.1007%2F7355_2017_15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F7355_2017_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2017_15%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DThe%2520oxazolidinones%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D97%26epage%3D122%26doi%3D10.1007%2F7355_2017_15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKee, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2042</span>– <span class="NLM_lpage">2049</span>, <span class="refDoi"> DOI: 10.1128/aac.01411-05</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.01411-05" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=16723564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=2042-2049&author=E.+E.+McKeeauthor=M.+Fergusonauthor=A.+T.+Bentleyauthor=T.+A.+Marks&title=Inhibition+of+mammalian+mitochondrial+protein+synthesis+by+oxazolidinones&doi=10.1128%2Faac.01411-05"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones</span></div><div class="casAuthors">McKee, E. E.; Ferguson, M.; Bentley, A. T.; Marks, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2042-2049</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The effects of a variety of oxazolidinones, with different antibacterial potencies, including linezolid, on mitochondrial protein synthesis were detd. in intact mitochondria isolated from rat heart and liver and rabbit heart and bone marrow.  The results demonstrate that a general feature of the oxazolidinone class of antibiotics is the inhibition of mammalian mitochondrial protein synthesis.  Inhibition was similar in mitochondria from all tissues studied.  Further, oxazolidinones that were very potent as antibiotics were uniformly potent in inhibiting mitochondrial protein synthesis.  These results were compared to the inhibitory profiles of other antibiotics that function by inhibiting bacterial protein synthesis.  Of these, chloramphenicol and tetracycline were significant inhibitors of mammalian mitochondrial protein synthesis while the macrolides, lincosamides, and aminoglycosides were not.  Development of future antibiotics from the oxazolidinone class will have to evaluate potential mitochondrial toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYWXrB0u0817Vg90H21EOLACvtfcHk0lhYjd46Q_nEkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsVOitbo%253D&md5=4dce4c12ad8fddadae1fd90953a596d1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FAAC.01411-05&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01411-05%26sid%3Dliteratum%253Aachs%26aulast%3DMcKee%26aufirst%3DE.%2BE.%26aulast%3DFerguson%26aufirst%3DM.%26aulast%3DBentley%26aufirst%3DA.%2BT.%26aulast%3DMarks%26aufirst%3DT.%2BA.%26atitle%3DInhibition%2520of%2520mammalian%2520mitochondrial%2520protein%2520synthesis%2520by%2520oxazolidinones%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2006%26volume%3D50%26spage%3D2042%26epage%3D2049%26doi%3D10.1128%2Faac.01411-05" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meintjes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maartens, G.</span></span> <span> </span><span class="NLM_article-title">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1080/14787210.2016.1225498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1080%2F14787210.2016.1225498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=27532292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=901-915&author=S.+Wassermanauthor=G.+Meintjesauthor=G.+Maartens&title=Linezolid+in+the+treatment+of+drug-resistant+tuberculosis%3A+the+challenge+of+its+narrow+therapeutic+index&doi=10.1080%2F14787210.2016.1225498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index</span></div><div class="casAuthors">Wasserman, Sean; Meintjes, Graeme; Maartens, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">901-915</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Linezolid is an oxazolidinone with potent activity against M tuberculosis, and improves culture conversion and cure rates when added to treatment regimens for drug resistant tuberculosis.  However, linezolid has a narrow therapeutic window, and the optimal dosing strategy that minimizes the substantial toxicity assocd. with linezolid's prolonged use in tuberculosis treatment has not been detd., limiting the potential impact of this anti-mycobacterial agent.  Areas covered: This paper aims to review and summarize the current knowledge on linezolid for the treatment of drug-resistant tuberculosis.  The focus is on the pharmacokinetic-pharmacodynamic determinants of linezolid's efficacy and toxicity in tuberculosis, and how this relates to defining an optimal dose.  Mechanisms of linezolid toxicity and resistance, and the potential role of therapeutic drug monitoring are also covered.  Expert commentary: Prospective pharmacokinetic-pharmacodynamic studies are required to define optimal therapeutic targets and to inform improved linezolid dosing strategies for drug-resistant tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRY5QIBD8h57Vg90H21EOLACvtfcHk0lhYjd46Q_nEkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVehu7vL&md5=4e1bc3ec740ecd73d1e5f70144254214</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1080%2F14787210.2016.1225498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2016.1225498%26sid%3Dliteratum%253Aachs%26aulast%3DWasserman%26aufirst%3DS.%26aulast%3DMeintjes%26aufirst%3DG.%26aulast%3DMaartens%26aufirst%3DG.%26atitle%3DLinezolid%2520in%2520the%2520treatment%2520of%2520drug-resistant%2520tuberculosis%253A%2520the%2520challenge%2520of%2520its%2520narrow%2520therapeutic%2520index%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2016%26volume%3D14%26spage%3D901%26epage%3D915%26doi%3D10.1080%2F14787210.2016.1225498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhasmana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, R.</span></span> <span> </span><span class="NLM_article-title">Linezolid induced adverse drug reactions-an update</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.2174/1389200216666151001121004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.2174%2F1389200216666151001121004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26424176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVGnsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=553-559&author=K.+Kishorauthor=N.+Dhasmanaauthor=S.+Kambleauthor=R.+Sahu&title=Linezolid+induced+adverse+drug+reactions-an+update&doi=10.2174%2F1389200216666151001121004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Linezolid Induced Adverse Drug Reactions - An Update</span></div><div class="casAuthors">Kishor, Kamal; Dhasmana, Neha; Kamble, Shashank Shivaji; Sahu, Roshan Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">553-559</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Treatment regimen recommended for resistant tuberculosis consists of various drugs and these drugs are prescribed for at least 12-15 mo.  Such a long duration therapy and high dose of antibiotics result in adverse drug reactions (ADRs).  ADRs may lead to various complications in disease management like replacement of drugs, dose increment, therapy withdrawal, etc.  Linezolid is one of those drugs, practiced as an anti-mycobacterial agent and it is an important member of drug regimen for MDR and XDR tuberculosis.  Linezolid is a broad spectrum antibiotic known for its unique mechanism of inhibition of resistant pathogenic strains.  However, it causes serious adverse effects like thrombocytopenia, optic neuropathy, peripheral neuropathy, lactic acidosis, etc.  Literature suggests that Linezolid can cause severe ADRs which affect patient compliance and hinder in therapy to a larger extent.  Recent studies confirm the possibility of ADRs to be predicted with genetic make-up of individuals.  To effectively deliver the available treatment regimen and ensure patient compliance, it is important to manage ADRs more efficiently.  The role of pharmacogenomics in reducing adverse drug effects has been recently explored.  In the present review, we discussed about Linezolid induced adverse drug reactions, mechanisms and genetic assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2wVMXb4fSNLVg90H21EOLACvtfcHk0lg3v7Vfk3d4wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVGnsbbJ&md5=4136597a46a864743d6de332c73fb736</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200216666151001121004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200216666151001121004%26sid%3Dliteratum%253Aachs%26aulast%3DKishor%26aufirst%3DK.%26aulast%3DDhasmana%26aufirst%3DN.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DSahu%26aufirst%3DR.%26atitle%3DLinezolid%2520induced%2520adverse%2520drug%2520reactions-an%2520update%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2015%26volume%3D16%26spage%3D553%26epage%3D559%26doi%3D10.2174%2F1389200216666151001121004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharaf, L. H.</span></span> <span> </span><span class="NLM_article-title">Oxazolidinone antimicrobials: a patent review (2012-2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.1517/13543776.2016.1168807</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1517%2F13543776.2016.1168807" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=26998627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=591-605&author=O.+A.+Phillipsauthor=L.+H.+Sharaf&title=Oxazolidinone+antimicrobials%3A+a+patent+review+%282012-2015%29&doi=10.1517%2F13543776.2016.1168807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Oxazolidinone antimicrobials: a patent review (2012-2015)</span></div><div class="casAuthors">Phillips, Oludotun A.; Sharaf, Leyla H.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">591-605</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Antimicrobial resistance in Gram-pos. bacteria is a major health care issue.  This review summarizes patent publications from 2012 to 2015 that divulged novel oxazolidinones as antibacterial agents.: A total of 25 patents obtained from Espacenet, WIPO Patentscope and FreePatentsOnline, and AcclaimIP search engines were reviewed.  The patents were scrutinized based on the novelty of the compds., their antibacterial activity (MIC, μg/mL), and the process of prepn.  The oxazolidinones with promising antibacterial activity were classified according to the following structural diversities, as biaryl heterocyclic, fused heteroaryl rings contg. oxazolidinones, and others.  The biaryl heterocyclic, fused heteroaryl, benzoxazine, and the 1H-pyrazol-1-yl contg. oxazolidinone derivs. demonstrated potent antibacterial activities superior to linezolid against Gram-pos. bacteria.  Some derivs. were effective against std. strains of Gram-neg. bacteria, namely Moraxella catarrhalis ATCC A894, and Escherichia coli ATCC 25922.  In addn., a patent disclosed a structural isomer of linezolid with marginal activity against the aerobic Gram-neg. bacteria MDR Stenotrophomonas (Xanthomonas) maltophilia, while linezolid and vancomycin did not inhibit growth.  Finally, some derivs. showed activity against respiratory infectious diseases' causative agents, such as B. anthracis, B. mallei, Y. pestis, and M. pneumoniae.  Overall, there is limited in vivo data to support the potential clin. advancement of the currently reported novel derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLzO8rJvUsrVg90H21EOLACvtfcHk0lg3v7Vfk3d4wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xltlyhs7s%253D&md5=c5582e97a91b14e1ae65b19b2f4e0343</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F13543776.2016.1168807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2016.1168807%26sid%3Dliteratum%253Aachs%26aulast%3DPhillips%26aufirst%3DO.%2BA.%26aulast%3DSharaf%26aufirst%3DL.%2BH.%26atitle%3DOxazolidinone%2520antimicrobials%253A%2520a%2520patent%2520review%2520%25282012-2015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D591%26epage%3D605%26doi%3D10.1517%2F13543776.2016.1168807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of highly potent novel benzoxazinyl-oxazolidinone antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7493</span>– <span class="NLM_lpage">7502</span>, <span class="refDoi"> DOI: 10.1021/jm200614t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200614t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7493-7502&author=Q.+Xinauthor=H.+Fanauthor=B.+Guoauthor=H.+Heauthor=S.+Gaoauthor=H.+Wangauthor=Y.+Huangauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+highly+potent+novel+benzoxazinyl-oxazolidinone+antibacterial+agents&doi=10.1021%2Fjm200614t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents</span></div><div class="casAuthors">Xin, Qi-Sheng; Fan, Hou-Xing; Guo, Bin; He, Hui-Li; Gao, Suo; Wang, Hui; Huang, Yan-Qin; Yang, Yu-She</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7493-7502</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel benzoxazinyl-oxazolidinones bearing nonarom. heterocycle or aryl groups were designed and synthesized.  Their in vitro and in vivo antibacterial activities were investigated.  Most of the (3S, 3aS) biaryl benzoxazinyl-oxazolidinones exhibited potent activity against Gram-pos. pathogens.  SAR trends were obsd.; a pyridyl C ring was preferable to other 5- or 6-member aryl C rings, while fluorine substitution on the B ring generated derivs. with reduced activity.  Various substituent group positions on the pyridyl ring were also evaluated.  The resulting compds. displayed excellent activity against linezolid-resistant strains.  Compd. I exhibited excellent in vitro activity, with a MIC value of 0.25-0.5 μg/mL against MRSA and an activity against linezolid-resistant strains of 8-16-fold higher potency than linezolid.  In a MRSA systemic infection model, compd. 45 displayed an ED50 < 5.0 mg/kg, a potency that is nearly 3-fold better than that of linezolid.  This compd. also showed excellent pharmacokinetic profiles, with a half-life of more than 5 h as well as an oral bioavailability of 81% in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWmvFSwZGAmrVg90H21EOLACvtfcHk0lg3v7Vfk3d4wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht12ktrrE&md5=c3535d090f53b2f4de9582567ab7b3e7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm200614t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200614t%26sid%3Dliteratum%253Aachs%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520highly%2520potent%2520novel%2520benzoxazinyl-oxazolidinone%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7493%26epage%3D7502%26doi%3D10.1021%2Fjm200614t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2642</span>– <span class="NLM_lpage">2650</span>, <span class="refDoi"> DOI: 10.1021/jm4000598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2642-2650&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Solubility-driven+optimization+of+%28pyridin-3-yl%29+benzoxazinyl-oxazolidinones+leading+to+a+promising+antibacterial+agent&doi=10.1021%2Fjm4000598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Huang, Yanqin; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2642-2650</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The soly.-driven structural modification of substituted (pyridin-3-yl)-contg. hydrobenzo[b]oxazolo[3,4-d][1,4]oxazinones is described, which resulted in the development of a new series of benzo[b]oxazolo[3,4-d][1,4]oxazinone analogs with high antibacterial activity against Gram-pos. pathogens, including that against linezolid-resistant strains, and low hERG inhibition.  With regard to structure-activity relationship (SAR) trends among the various substituents on the pyridyl ring, relatively small and nonbasic substituents were preferable to sterically demanding or basic substituents.  Oxazolidinone ring substitution on the pyridyl ring generated analogs with antibacterial activity superior to imidazolidinone ring.  Soly. was enhanced by the incorporation of polar groups, esp. when compds. were converted to their prodrugs.  Among the prodrugs, compd. I exhibited excellent soly. and a good pharmacokinetic profile.  In a MRSA systemic infection model, compd. I displayed an ED50 = 5.00 mg/kg, a potency that is 2-fold better than that of linezolid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6VdLd2a4z0LVg90H21EOLACvtfcHk0lgXvQU2Ch6m5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivVyju7g%253D&md5=531c0bab630f3625674880d9dd1f5166</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm4000598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000598%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSolubility-driven%2520optimization%2520of%2520%2528pyridin-3-yl%2529%2520benzoxazinyl-oxazolidinones%2520leading%2520to%2520a%2520promising%2520antibacterial%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2642%26epage%3D2650%26doi%3D10.1021%2Fjm4000598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of fluorine-containing benzoxazinyl-oxazolidinones for the treatment of multidrug resistant Tuberculosis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">537</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=533-537&author=H.+Zhaoauthor=Y.+Luauthor=L.+Shengauthor=Z.+Yuanauthor=B.+Wangauthor=W.+Wangauthor=Y.+Liauthor=C.+Maauthor=X.+Wangauthor=D.+Zhangauthor=H.+Huang&title=Discovery+of+fluorine-containing+benzoxazinyl-oxazolidinones+for+the+treatment+of+multidrug+resistant+Tuberculosis&doi=10.1021%2Facsmedchemlett.7b00068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis</span></div><div class="casAuthors">Zhao, Hongyi; Lu, Yu; Sheng, Li; Yuan, Zishuo; Wang, Bin; Wang, Weiping; Li, Yan; Ma, Chen; Wang, Xiaoliang; Zhang, Dongfeng; Huang, Haihong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">533-537</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of fluorine-contg. benzoxazinyl-oxazolidinones were designed and synthesized as antidrug-resistant tuberculosis agents possessing good activity and improved pharmacokinetic profiles.  Compd. I exhibited not only outstanding in vitro activity with a MIC value of 0.25-0.50 μg/mL against drug-susceptible H37Rv strain and two clin. isolated drug-resistant Mycobacterium tuberculosis strains, but also acceptable in vitro ADME/T properties.  Moreover, this compd. displayed excellent mouse pharmacokinetic profiles with an oral bioavailability of 102% and a longer elimination half-life of 4.22 h, thereby supporting further optimization and development of this promising lead series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogwgObIiYn5rVg90H21EOLACvtfcHk0lgXvQU2Ch6m5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtVWltL8%253D&md5=288fd039d5f0eb32cd751e6390733dc7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00068%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DSheng%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520fluorine-containing%2520benzoxazinyl-oxazolidinones%2520for%2520the%2520treatment%2520of%2520multidrug%2520resistant%2520Tuberculosis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D533%26epage%3D537%26doi%3D10.1021%2Facsmedchemlett.7b00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynes, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisóstomo, F. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of new benzocyclotrimer analogues: new receptors for tetramethylammonium ion recognition</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2912</span>– <span class="NLM_lpage">2915</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.5b01058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.5b01058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFakt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=2912-2915&author=R.+Carrilloauthor=M.+J.+Hynesauthor=V.+S.+Mart%C3%ADnauthor=T.+Mart%C3%ADnauthor=F.+P.+Cris%C3%B3stomo&title=Synthesis+of+new+benzocyclotrimer+analogues%3A+new+receptors+for+tetramethylammonium+ion+recognition&doi=10.1021%2Facs.orglett.5b01058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of New Benzocyclotrimer Analogues: New Receptors for Tetramethylammonium Ion Recognition</span></div><div class="casAuthors">Carrillo, Romen; Hynes, Michael J.; Martin, Victor S.; Martin, Tomas; Crisostomo, Fernando Pinacho</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2912-2915</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a [2+2+2] cycloaddn./Mitsunobu reaction sequence, a convenient synthesis to access new benzocyclotrimer analogs has been developed.  The new receptors have the geometry and functionality capable of recognizing the tetramethylammonium ion in the gas phase and in soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1BqelNg22TrVg90H21EOLACvtfcHk0ljgOO-5Ph5toQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFakt74%253D&md5=ce458e0861c43aafee24c35b2b18a678</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.5b01058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.5b01058%26sid%3Dliteratum%253Aachs%26aulast%3DCarrillo%26aufirst%3DR.%26aulast%3DHynes%26aufirst%3DM.%2BJ.%26aulast%3DMart%25C3%25ADn%26aufirst%3DV.%2BS.%26aulast%3DMart%25C3%25ADn%26aufirst%3DT.%26aulast%3DCris%25C3%25B3stomo%26aufirst%3DF.%2BP.%26atitle%3DSynthesis%2520of%2520new%2520benzocyclotrimer%2520analogues%253A%2520new%2520receptors%2520for%2520tetramethylammonium%2520ion%2520recognition%26jtitle%3DOrg.%2520Lett.%26date%3D2015%26volume%3D17%26spage%3D2912%26epage%3D2915%26doi%3D10.1021%2Facs.orglett.5b01058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7770</span>– <span class="NLM_lpage">7791</span>, <span class="refDoi"> DOI: 10.1021/jm501045e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501045e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7770-7791&author=T.+Xueauthor=S.+Dingauthor=B.+Guoauthor=Y.+Zhouauthor=P.+Sunauthor=H.+Wangauthor=W.+Chuauthor=G.+Gongauthor=Y.+Wangauthor=X.+Chenauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+and+structure-pharmacokinetic+relationship+studies+of+novel+%5B6%2C6%2C5%5D+tricyclic+fused+oxazolidinones+leading+to+the+discovery+of+a+potent%2C+selective%2C+and+orally+bioavailable+FXa+inhibitor&doi=10.1021%2Fjm501045e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity and Structure-Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor</span></div><div class="casAuthors">Xue, Tao; Ding, Shi; Guo, Bin; Zhou, Yuren; Sun, Peng; Wang, Heyao; Chu, Wenjing; Gong, Guoqing; Wang, Yinye; Chen, Xiaoyan; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7770-7791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The blood coagulation enzyme factor Xa (FXa) is a particularly promising target for anticoagulant therapy, and identification of oral small-mol. inhibitors of FXa remains a research focus.  On the basis of the X-ray crystal structure of FXa and its inhibitor rivaroxaban, we designed and synthesized a series of conformationally restricted mimics contg. a novel [6,6,5] tricyclic fused oxazolidinone scaffold.  Intensive structure-activity relationship (SAR) and structure-pharmacokinetic relationship (SPR) studies on this new series led to the discovery of compd. I (11a): a highly potent, selective, direct, and orally bioavailable FXa inhibitor with excellent in vivo antithrombotic efficacy and preferable pharmacokinetic profiles.  Druggability evaluation of compd. 11a was undertaken and elicited pos. outcomes.  All results indicate that compd. 11a is a promising drug candidate for the prevention and treatment of thromboembolic diseases in venous and arterial systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKRZp1NluvTLVg90H21EOLACvtfcHk0ljgOO-5Ph5toQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGht7fL&md5=9a75218d558748ddcf5f451649bb5520</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm501045e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501045e%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520and%2520structure-pharmacokinetic%2520relationship%2520studies%2520of%2520novel%2520%255B6%252C6%252C5%255D%2520tricyclic%2520fused%2520oxazolidinones%2520leading%2520to%2520the%2520discovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520FXa%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7770%26epage%3D7791%26doi%3D10.1021%2Fjm501045e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajarao, A. V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological activity of novel oxazolidinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6424</span>– <span class="NLM_lpage">6428</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.09.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2009.09.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=19811911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWls7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6424-6428&author=B.+Dasauthor=A.+V.+S.+Rajaraoauthor=S.+Rudraauthor=A.+Yadavauthor=A.+Rayauthor=M.+Pandyaauthor=A.+Rattanauthor=A.+Mehta&title=Synthesis+and+biological+activity+of+novel+oxazolidinones&doi=10.1016%2Fj.bmcl.2009.09.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of novel oxazolidinones</span></div><div class="casAuthors">Das, Biswajit; Rajarao, A. V. S.; Rudra, Sonali; Yadav, Ajay; Ray, Abhijit; Pandya, Manisha; Rattan, Ashok; Mehta, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6424-6428</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of 5-substituted derivs. of Ranbezolid, a novel oxazolidinone were synthesized.  Antibacterial activity of the compds. against a no. of sensitive and resistant bacteria showed promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocgk-ZW-CRo7Vg90H21EOLACvtfcHk0ljgOO-5Ph5toQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWls7%252FI&md5=d23b5b1d37e93359dc4879a1b23a62a3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.09.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.09.054%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DB.%26aulast%3DRajarao%26aufirst%3DA.%2BV.%2BS.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DA.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DPandya%26aufirst%3DM.%26aulast%3DRattan%26aufirst%3DA.%26aulast%3DMehta%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520novel%2520oxazolidinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6424%26epage%3D6428%26doi%3D10.1016%2Fj.bmcl.2009.09.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3697</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.bmcl.2013.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=23721807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3697-3699&author=B.+Guoauthor=H.+Fanauthor=Q.+Xinauthor=W.+Chuauthor=H.+Wangauthor=Y.+Yang&title=Synthesis+and+biological+evaluation+of+novel+benzoxazinyl-oxazolidinones+as+potential+antibacterial+agents&doi=10.1016%2Fj.bmcl.2013.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents</span></div><div class="casAuthors">Guo, Bin; Fan, Houxing; Xin, Qisheng; Chu, Wenjing; Wang, Hui; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3697-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A no. of benzoxazinyl-oxazolidinones bearing 3-triazolylmethyl or 3-carboxamide side chain were designed and synthesized with the aim to develop antibacterial agents with improved properties.  In vitro antibacterial activities of these novel compds. were evaluated against a panel of resistant and susceptible Gram-pos. bacteria.  Most analogs bearing 3-triazolylmethyl showed good to moderate antibacterial activities.  Compd. I exhibited a fourfold increase in activity compared with linezolid against all the tested strains, which was identified to be a promising antibacterial agent for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGOMF4mbAZWbVg90H21EOLACvtfcHk0ljLGA0sMLoX2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1GjsLk%253D&md5=6b94ab65a6988a6456e66f526f871ef4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzoxazinyl-oxazolidinones%2520as%2520potential%2520antibacterial%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3697%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2013.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span> <span> </span><span class="NLM_article-title">A concise synthesis of a bridged thiomorpholine: (1R, 5S)-3-thia-8-azabicyclo[3.2.1]octane</span>. <i>Chin. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">377</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=373-377&author=D.+Zhangauthor=S.+Chenauthor=L.+Fanauthor=Z.+Linauthor=H.+Huang&title=A+concise+synthesis+of+a+bridged+thiomorpholine%3A+%281R%2C+5S%29-3-thia-8-azabicyclo%5B3.2.1%5Doctane"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DH.%26atitle%3DA%2520concise%2520synthesis%2520of%2520a%2520bridged%2520thiomorpholine%253A%2520%25281R%252C%25205S%2529-3-thia-8-azabicyclo%255B3.2.1%255Doctane%26jtitle%3DChin.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D25%26spage%3D373%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. E.</span></span> <span> </span><span class="NLM_article-title">Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1016%2Fj.pharmthera.2005.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=15922018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1SltLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=357-387&author=S.+K.+Kruegerauthor=D.+E.+Williams&title=Mammalian+flavin-containing+monooxygenases%3A+structure%2Ffunction%2C+genetic+polymorphisms+and+role+in+drug+metabolism&doi=10.1016%2Fj.pharmthera.2005.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism</span></div><div class="casAuthors">Krueger, Sharon K.; Williams, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">357-387</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Flavin-contg. monooxygenase (FMO) oxygenates drugs and xenobiotics contg. a "soft nucleophile", usually N or S.  FMO, like cytochrome P 450 (CYP), is a monooxygenase, utilizing the reducing equiv. of NADPH to reduce 1 atom of O2 to H2O, while the other atom is used to oxidize the substrate.  FMO and CYP also exhibit similar tissue and cellular location, mol. wt., substrate specificity, and exist as multiple enzymes under developmental control.  The human FMO functional gene family is much smaller (5 families each with a single member) than CYP.  FMO does not require a reductase to transfer electrons from NADPH and the catalytic cycle of the 2 monooxygenases is strikingly different.  Another distinction is the lack of induction of FMOs by xenobiotics.  In general, CYP is the major contributor to oxidative xenobiotic metab.  However, FMO activity may be of significance in a no. of cases and should not be overlooked.  FMO and CYP have overlapping substrate specificities, but often yield distinct metabolites with potentially significant toxicol./pharmacol. consequences.  The physiol. function(s) of FMOs are poorly understood.  Three of the 5 expressed human FMO genes, FMO1, FMO2, and FMO3, exhibit genetic polymorphisms.  The most studied of these is FMO3 (adult human liver) in which mutant alleles contribute to the disease known as trimethylaminuria.  The consequences of these FMO genetic polymorphisms in drug metab. and human health are areas of research requiring further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwDBzxhgaYbVg90H21EOLACvtfcHk0ljLGA0sMLoX2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1SltLc%253D&md5=2f0b76495aa8a53069bacc9b4ae8de43</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DS.%2BK.%26aulast%3DWilliams%26aufirst%3DD.%2BE.%26atitle%3DMammalian%2520flavin-containing%2520monooxygenases%253A%2520structure%252Ffunction%252C%2520genetic%2520polymorphisms%2520and%2520role%2520in%2520drug%2520metabolism%26jtitle%3DPharmacol.%2520Ther.%26date%3D2005%26volume%3D106%26spage%3D357%26epage%3D387%26doi%3D10.1016%2Fj.pharmthera.2005.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordeev, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. Y.</span></span> <span> </span><span class="NLM_article-title">New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4487</span>– <span class="NLM_lpage">4497</span>, <span class="refDoi"> DOI: 10.1021/jm401931e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401931e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4487-4497&author=M.+F.+Gordeevauthor=Z.+Y.+Yuan&title=New+potent+antibacterial+oxazolidinone+%28MRX-I%29+with+an+improved+class+safety+profile&doi=10.1021%2Fjm401931e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile</span></div><div class="casAuthors">Gordeev, Mikhail F.; Yuan, Zhengyu Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4487-4497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors.  Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid.  This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), I, distinguished by its high activity against Gram-pos. pathogens coupled with markedly reduced potential for myelosuppression and MAOI.  The medical need, medicinal chem. rationale, preclin. data, and phase I clin. trial summary for this new agent are reviewed herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNWIpQP5Wgg7Vg90H21EOLACvtfcHk0ljLGA0sMLoX2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsbw%253D&md5=70b6b32e113b86ab6344cb266687f64f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401931e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401931e%26sid%3Dliteratum%253Aachs%26aulast%3DGordeev%26aufirst%3DM.%2BF.%26aulast%3DYuan%26aufirst%3DZ.%2BY.%26atitle%3DNew%2520potent%2520antibacterial%2520oxazolidinone%2520%2528MRX-I%2529%2520with%2520an%2520improved%2520class%2520safety%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4487%26epage%3D4497%26doi%3D10.1021%2Fjm401931e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upton, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span> <span> </span><span class="NLM_article-title">Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5185</span>– <span class="NLM_lpage">5193</span>, <span class="refDoi"> DOI: 10.1128/aac.00699-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=10.1128%2FAAC.00699-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=21844321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSru7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=5185-5193&author=Y.+Luauthor=M.+Zhengauthor=B.+Wangauthor=L.+Fuauthor=W.+Zhaoauthor=P.+Liauthor=J.+Xuauthor=H.+Zhuauthor=H.+Jinauthor=D.+Yinauthor=H.+Huangauthor=A.+M.+Uptonauthor=Z.+Ma&title=Clofazimine+analogs+with+efficacy+against+experimental+tuberculosis+and+reduced+potential+for+accumulation&doi=10.1128%2Faac.00699-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation</span></div><div class="casAuthors">Lu, Yu; Zheng, Meiqin; Wang, Bin; Fu, Lei; Zhao, Weijie; Li, Peng; Xu, Jian; Zhu, Hui; Jin, Haixia; Yin, Dali; Huang, Haihong; Upton, Anna M.; Ma, Zhenkun</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5185-5193</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The global tuberculosis crisis urgently demands new, efficacious, orally available drugs with the potential to shorten and simplify the long and complex treatments for drug-sensitive and drug-resistant disease.  Clofazimine, a riminophenazine used for many years to treat leprosy, demonstrates efficacy in animal models of tuberculosis via a novel mode of action.  However, clofazimine's physicochem. and pharmacokinetic properties contribute to side effects that limit its use; in particular, an extremely long half-life and propensity for tissue accumulation together with clofazimine's dye properties leads to unwelcome skin discoloration.  We recently conducted a systematic structure-activity study of more than 500 riminophenazine analogs for anti-Mycobacterium tuberculosis activity.  We describe here the characteristics of 12 prioritized compds. in more detail.  The new riminophenazine analogs demonstrated enhanced in vitro activity compared to clofazimine against replicating M. tuberculosis H37Rv, as well as panels of drug-sensitive and drug-resistant clin. isolates.  The new compds. demonstrate at least equiv. activity compared to clofazimine against intracellular M. tuberculosis and, in addn., most of them were active against nonreplicating M. tuberculosis.  Eleven of these more water-sol. riminophenazine analogs possess shorter half-lives than clofazimine when dosed orally to mice, suggesting that they may accumulate less.  Most importantly, the nine compds. that progressed to efficacy testing demonstrated inhibition of bacterial growth in the lungs that is superior to the activity of an equiv. dose of clofazimine when administered orally for 20 days in a murine model of acute tuberculosis.  The efficacy of these compds., along with their decreased potential for accumulation and therefore perhaps also for tissue discoloration, warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZWSDoWqS4I7Vg90H21EOLACvtfcHk0lhhs740dtl1Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSru7nF&md5=07beec6fbd38eb9b3a3df87bcd2fbed6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.00699-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00699-11%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DUpton%26aufirst%3DA.%2BM.%26aulast%3DMa%26aufirst%3DZ.%26atitle%3DClofazimine%2520analogs%2520with%2520efficacy%2520against%2520experimental%2520tuberculosis%2520and%2520reduced%2520potential%2520for%2520accumulation%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D5185%26epage%3D5193%26doi%3D10.1128%2Faac.00699-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i155"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00500">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28828"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00500?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00500</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra of all compounds and chiral HPLC of compounds <b>9a</b>, <b>9c–d</b>, <b>14a</b>, <b>14c–d</b>, <b>19a</b>, and <b>19c–d</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_001.pdf">PDF</a>)</p></li><li><p class="inline">X-ray crystal structure data of compound <b>19c</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_002.cif">CIF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_001.pdf">jm0c00500_si_001.pdf (7.55 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_002.cif">jm0c00500_si_002.cif (3.96 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00500/suppl_file/jm0c00500_si_003.csv">jm0c00500_si_003.csv (7.7 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00500&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-17%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00500" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00500" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994f63da373c88","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
